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While g L-1 quantities of recombinant protein are common in Chinese Hamster 
Ovary (CHO) cell factories, the rise of more complex products presents novel 
upstream manufacturing challenges. Bioactive small molecule enhancers (SMEs) 
present opportunities for targeted CHO culture performance improvements. Here 
we present the development of a high-throughput (HT) screening technology for the 
identification of SMEs and their combinations for improved bioprocess. 
Firstly, we describe the development of the HT screening platform. A miniaturised, 
shaking culture methodology was developed, enabling rapid assessment of 96 
cultures simultaneously. Growth and production performance was similar to shake 
flask cultures, demonstrating scalability. HT growth, viability and titer measurement 
technologies were established. 
Secondly, a large suite of SMEs was evaluated for the purposes of CHO cell 
biopharmaceutical production. 43 SMEs were assessed rapidly using the HT 
culturing and analytical platforms. Molecules that improved cellular growth or 
production in a stable production format were used to inform combinatorial designs 
to determine interactions for amplifying culture performance. This work would form 
the foundation of a commercial screening tool, wherein a deep well plate product 
pre-coated with selected enhancer concentrations and combinations would be 
available for testing with cell lines and products of choice. The product along with 
statistical modelling tools like Design of Experiments methodologies would advise 
chemical supplementation strategies to create bespoke media for enhanced 
bioprocess. 
Finally, we demonstrate another use of the HT screening tool for the discovery of 
novel molecules for biotherapeutic production. Molecules were selected based on 
structural similarity to established titer enhancing SMEs and evaluated using the 
HT platform. A novel molecule and associated parent molecule maintained 
production improvements when scaled-up to shake flasks. Various mechanistic 
analyses revealed that the molecule acted epigenetically, resulting in higher 
transcription of the product. 
Given the age of biosimilars/biobetters, having a competitive edge in terms of 
speed and cost is crucial. The HT screening tool developed utilises the potential of 
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This	 chapter	 reviews	 and	 summarises	 recombinant	 protein	 production	 in	
mammalian	 cell	 factories.	 Emphasis	 is	 given	 to	 host	 cell	 factory	 selection	 and	
upstream	 processing	 leading	 to	 the	 final	 protein	 product	 ready	 for	 downstream	
processing.	The	significance	of	high-throughput	technologies	coupled	with	statistical	
modelling	 for	 process	 development	 is	 discussed.	 The	 potential	 of	 culture	 media	








Biopharmaceuticals refer to pharmaceuticals that are produced using 
biotechnological techniques. They (also referred to as biologics) mostly 
encompass recombinant proteins that are mainly used as therapeutic drugs to 
treat cancer and autoimmune diseases; with a small number being employed in 
diagnostics (Carter, 2011). Biologics are generally derived from “host” cells that 
are engineered genetically to produce these therapeutics as part of their protein 
production machinery. Protein-based biopharmaceuticals dominate the 
biopharmaceutical industry. Monoclonal antibodies (mAbs) (a protein 
therapeutic) form the largest selling sub group of biopharmaceuticals (Aggarwal, 
2014; Zhang, 2010) and also dominate approval rates (Walsh, 2014). Other 
biologic types include recombinant hormones, blood factors, growth factors, 
coagulation factors, interferons, vaccines, fusion proteins and enzymes (Walsh, 
2014; Zhang, 2010).  
Biopharmaceutical sales have always witnessed steady increases over the 
years with global sales reaching $163 billion in 2016 (Kesik-Brodacka, 2018). 
mAb product sales usually account for a large percentage of this figure ($107 
billion; 2016) (Kesik-Brodacka, 2018). In 2016, 6 of the top 10 selling drugs 
were antibody based products (Strohl, 2018). The market is growing at a rapid 
rate, with 12 biologics being approved in 2017 and 2 being approved in the first 
quarter of 2018 alone (Defrancesco, 2018; De La Torre and Albericio, 2018).  
The advent and steady increase in approvals of biosimilars and biobetters, 
indicates stiff competition amongst biologics manufacturers. The expiry of 
patent protection for several large revenue yielding biologics is imminent 
(Deloitte, 2016; Kesik-Brodacka, 2018), presenting opportunities for biosimilar 
and biobetter development to further expand. 
Walsh (2014) indicates that there is a large degree of innovation in the mAb 
sector. Fc fusions, antibody fragment, antibody drug conjugates and bispecifics 
are just some of the antibody derived products (Kesik-Brodacka, 2018; Walsh, 
2014). The development and engineering of these next generation biologics can 
sometimes prove to be more difficult-to-express (DTE) than natural protein 




formats along with stiff industrial competition, translates to an ever-increasing 
need for quick and cost-effective optimisation and innovation in recombinant 
protein production processes. 
 
1.2. Expression Systems 
 
The first step to creating a biotherapeutic involves selecting a host cell system, 
a cell type that can be genetically engineered to produce the product  (usually a 
protein) as part of their gene expression machinery. Proteins requiring specific 
attachment of sugar residues for efficacious biological activity (commonly 
termed glycosylated proteins or glycoproteins) form 70% of all protein 
therapeutics (Jaffe et al., 2014). Correct protein glycosylation is essential for 
desired pharmokinetics and product safety (Jaffe et al., 2014). Production cell 
factories have a profound effect on determining product quality and thus remain 
at the heart of the biomanufacturing process (Le et al., 2015).  
A plethora of host cell systems are available for recombinant protein production. 
The first approved recombinant product, recombinant insulin was manufactured 
using an Escherichia coli (E. coli) cell factory (Huang et al., 2012). E. coli is an 
easy organism to work with due to its economical nature and quick culturing 
times. However, they struggle with complex post-translational modifications, 
particularly glycosylation (Huang et al., 2012). Innovative efforts have focused 
on engineering the periplasmic secretory pathway along with adding 
glycosylation machinery in E. coli (Berlec and Štrukelj, 2013; Huang et al., 
2012; Jaffe et al., 2014). E. coli expression systems  are the second most 
employed cell production factory (only behind mammalian cell systems) 
accounting for nearly 20% of approvals since 1982 (Brown et al., 2017; Walsh, 
2014). Other host cell systems employed include yeast and insect expression 
systems. Both these systems are mainly utilised for protein vaccine production 
(Walsh, 2014). A summary of the frequency of use of different host cell factories 
is displayed in Figure 1.1. 
The major limitation of the host cell systems mentioned above is the inability to 




production systems, as already mentioned, inherently lack efficient 
glycosylation machinery. Yeast systems are known to produce proteins with 
high mannosylation epitopes and these glycoforms can elicit human immune 
responses (Celik and Calık, 2012). Insect systems, on the other hand struggle 
with correct protein folding, resulting in intracellular aggregates and low 
production titer outputs. (Demain and Vaishnav, 2009; Drugmand et al., 2012). 
 
Figure 1.1 A summary of the host cells employed for approved 
biopharmaceuticals marketed in USA and Europe as of July 2014. Information 
gathered from: (Walsh, 2014). Host cell information for 191 approved products is 
displayed. Percentage of total for each host cell type is shown. Actual product numbers 




1.3. Chinese Hamster Ovary (CHO) Cells 
 
The appeal and utilisation of mammalian cell hosts was significantly boosted by 
the approval of tissue plasminogen activator as the first biologic produced in 
Chinese Hamster Ovary (CHO) systems in 1986 (Collen et al., 1984; Collen and 
Lijnen, 2004; Wurm, 2004). Since then, mammalian cell systems, specifically 
CHO cells have remained the predominant vehicle for biopharmaceutical 
production (Jayapal et al., 2007; Zhang, 2010; Zhu, 2012). Mammalian host 
           Host Cell Systems for Approved Biologics
Total=191
Mammalian:51.31% (98)
Chinese hamster ovary (69)
Baby hamster kidney (3)
Mouse (21)





E. coli: 31.41% (60)




utilisation allows for the manufacture of complex proteins like mAbs with more 
“human like” glycosylation (Zhang, 2010), making them attractive for use in 
comparison to the non-mammalian hosts discussed above. CHO cells have a 
remarkable proven safety and approval records making them frontrunners for 
biopharmaceutical production (Jayapal et al., 2007). 5 of the top 10 selling 
biopharmaceuticals in 2014 were manufactured in CHO cells, providing 
evidence of their proven track record (Sanchez-Garcia et al., 2016). 
CHO cells were first isolated in 1957 from Cricetulus griseus (Chinese hamster) 
(Tjio and Puck, 1958). These cells were then subjected to multiple genetic 
engineering and adaptation processes resulting in the creation of distinct CHO 
lineages (Wurm, 2013). CHO-DG44, CHO-K1, CHO-S, DUKX-B11 and CHO-
K1SV are just some of the different CHO cell types available currently (Brown et 
al., 2017; Derouazi et al., 2006; Estes and Melville, 2014; Wurm, 2013).  
The ability to easily manipulate CHO cell function caused by their inherent 
genetic instability is a crucial factor in its meteoric rise as a model recombinant 
production host (Brown et al., 2017; Davies et al., 2013). CHO cells have been 
readily adapted for suspension culture and efforts have been made to push 
cellular biomass accumulation and production capabilities (Kim et al., 2012). 
Adaption to serum free and chemical defined media is another factor is the 
adoption of CHO cells as common protein product production hosts (Lai et al., 
2013). Serum containing media is non-ideal due to its animal source and 
undefined nature (Butler, 2005). CHO cells have been readily adapted to large 
bioreactor cultures, wherein g L-1 quantities of product are commonplace (Lai et 
al., 2013). CHO cells are non-human in source and thus any human pathogen 
proliferation (including herpes, measles and human immunodeficiency virus) is 
kept at bay (Bandaranayake and Almo, 2014; Jayapal et al., 2007; Lai et al., 
2013; Rita Costa et al., 2010; Zhang, 2010).  This parameter alone 
distinguishes CHO cells from other able human cell hosts.  
Glycosylation, a post-translational modification, is often a crucial parameter for 
determining efficacy and safety of the protein product. Galα1,3-Gal and N-
glycolylneuraminic acid (Neu5Gc) residues are often considered immunogenic 
(Butler and Spearman, 2014). CHO cells tend to express lower levels of these 




(Butler and Spearman, 2014). Thus, CHO cells are often favourable to employ 
based on this aspect. 
CHO cell host systems are not without their flaws. The same genetic instability 
that contributes towards ease of genetic manipulation, can exacerbate 
phenomena like genetic drift. This creates heterogeneity in cell populations 
which can result in unpredictable production performance and loss in 
productivity (Davies et al., 2013). Generally, CHO cells have lower proliferation 
rates in comparison to bacterial and yeast counterparts (Fischer et al., 2015). 
Additional, it has been brought to attention that CHO host cell proteins can 
present downstream processing challenges and have the potential to be 
immunogenic (Yuk et al., 2015a).  
Nevertheless, the sheer volume of research that has gone into CHO cell 
bioprocess, cements their position as the leading biologics production chassis. 
High titers have been recorded using both transient and stable production 
formats (Daramola et al., 2014; Fischer et al., 2015). CHO cell dominance 
remains set to continue in light of the multiple engineering strategies that have 
been implemented to improve the CHO bioprocess (Fischer et al., 2015).  
 
1.4. Alternative Mammalian Cell Factories 
 
Other mammalian cellular hosts can also be employed for biotherapeutic 
production. These include mouse myeloma cells (NS0, Sp2/0-Ag14) and baby 
hamster kidney (BHK) cells. Alternatively, human cells can also be employed. 
Human cell lines include human embryonic kidney cells (HEK293) and Per.C6, 
a human retina derived cell line (Berlec and Štrukelj, 2013; Kim et al., 2012). 
BHK cells are employed mainly for anti-coagulant production (Butler and 
Spearman, 2014). 10 products that are produced in mouse myeloma cells have 
been approved for therapeutic use (Walsh, 2014). This cell type has been 
shown to produce higher levels of two potentially immunogenic epitopes 
Galα1,3-Gal and Neu5Gc (Butler and Spearman, 2014). Human cell types are 
logically capable of producing proteins with most suited human-like 




from HEK293) are comparatively in the nascent stage for biopharmaceutical 
production purposes. HEK293, perhaps the most rigorously tested of human 
cell types, has been shown to have an advantage over CHO cells for the 
manufacture of a particular protein, producing the required carboxylation 
modifications (Swiech et al., 2012). Additionally, PER.C6, CAP and HKB-11 are 
attractive to employ from a human-like glycosylation perspective (Brown et al., 
2017; Swiech et al., 2012). 
 
1.5. Upstream Production Process For Biopharmaceuticals 
 
The section below details and discusses the iterative approach undertaken in 
industry and academic circles to produce a protein product through recombinant 
protein expression in CHO cells. Upstream technologies are described 
beginning from cell factory, expression plasmid selection and optimisation 
through to process optimisation and bioreactor scale up. 
Biologics manufacturing processes originate with cell factory selection. The 
previous section described the different cell types available for production 
purposes. Within CHO bioprocessing, there are a number of options of cell lines 
stemming from different CHO lineages (Wurm, 2013). Even with the established 
cell lines, multiple engineering strategies, such as anti-apoptosis engineering 
(Templeton et al., 2014) and glyco-engineering (Hossler et al., 2009) are 
sometimes necessary for creating a cell line most suited for the required 
production process. Engineering of the glycosylation pathway is particular 
rewarding in terms of enhancing pharmacokinetics and product safety (Rita 
Costa et al., 2014). Monoclonal antibodies lacking a core fucose epitope have 
higher resultant antibody-dependent cellular cytotoxicity (Fischer et al., 2015). A 
complete knockdown of the fut8 gene in CHO cells, an enzyme involved in core 
fucosylation, results in the product lacking core fucosylation (Yamane-Ohnuki et 
al., 2004). Similarly, more human-like terminal sialic acid content can be 
produced by the upregulation of α-2,6-sialyltransferase (ST6GAL) gene (Fischer 




To surmise, there are a multitude of options available for CHO cell line factory 
selection. Industrial companies spend a lot of time and resources towards 
optimising their parental cell lines towards the ‘ideal’ host cell candidate. 
 
 Expression Plasmid  1.5.1.
 
Recombinant protein expression in CHO cells is usually driven by plasmid 
vector expression. Expression vectors act as carriers of the product gene of 
interest into the CHO cell host. There are various elements of an effective 
plasmid vector. A strong promoter that guides transcription along with regulatory 
elements such as polyA tails is essential (Rita Costa et al., 2010). Selectable 
marker sequences are also routinely included for stable production modes.  
Stable integration into the host genome is a random event, integration into a 
transcriptionally inactive region can result in little or no product gene expression 
(Wurm, 2004). Selection markers are included to allow for the isolation of cells 
that been successfully transfected (Wurm, 2004) . Selection marker genes are 
co-transfected along with the gene of interest and selective environments are 
created that only allows cells that have successfully integrated the plasmid 
(product gene and selectable marker gene) to survive. The two most common 
selection marker genes employed are dihydrofolate reductase (DHFR) and 
glutamine synthetase (GS) (Rita Costa et al., 2010). Selection occurs by 
culturing cells in specific nutrient deficient media. Only cells with the DHFR 
enzyme would be able to proliferate in hypoxanthine and thymidine deficient 
media. Likewise, only cells with the GS enzyme would be able to proliferate in 
glutamine deficient media (Rita Costa et al., 2010). A second stage is employed 
for the isolation of hosts overexpressing the selection maker (and thus the 
protein product gene) by subjecting the cells to increasing concentrations of 
specific enzyme inhibitors; methotrexate for DHFR and methionine sulfoximine 
for GS. Herein, cell survival is determined by the overexpression of the 
selection marker gene, leading to co-amplification of the product gene. 
Sophisticated strategies such as targeted integration into transcriptionally active 




2006) and epigenetic regulatory elements such ubiquitously acting chromatin 
opening elements (UCOEs) are increasingly employed for improving protein 




The choices available for the mode of insertion of the expression plasmid into 
CHO cells are diverse. Transfection technologies can vary from being chemical 
based (lipofection, calcium-phosphate precipitation, polyethylenimine) to 
physical based (electroporation) (Rita Costa et al., 2010). Extensive efforts 
have been made to optimise the methods mentioned above with the cell line of 
choice to achieve high transfection efficiency and titers in both stable and 
transient modes (Baldi et al., 2007; Thompson et al., 2012). Transient 
transfection presents a quick approach to generating cell populations 
expressing the recombinant protein product. Herein, the cells do not stably 
integrate the gene of interest and thus the expression window is short. No 
selection and amplification steps are necessary resulting in a shortened 
development process. Transient expression can prove invaluable to assess 
general productivity trends, assess gene overexpression strategies, and 
evaluate protein product characteristics (Baldi et al., 2007; Hansen et al., 2015; 
Rita Costa et al., 2010). Stably transfected cells provide for a more production 
relevant setup where large quantities of protein can be manufactured and 
production capabilities are maintained for a longer period. Development of 
stable lines is a time consuming and laborious process, however with their 
ability to achieve production demands, it is the industrial standard for large-
scale therapeutic protein production (Rita Costa et al., 2010). 
 
 Cloning, Screening and Selection 1.5.3.
 
The initial selection and amplification strategies (through the use of selection 
markers detailed in Section 1.5.1) still result in a largely heterogeneous 




production performance. Thus, isolating a single cell clone that exhibits the 
desired characteristic is crucial (Li et al., 2010). Traditional methods like limiting 
dilution cloning are time consuming, laborious and relatively low-throughput and 
can take up to 8 months to complete (Noh et al., 2013; Priola et al., 2016). It is 
thus unsurprising that there is an active shift toward high-throughput (HT) and 
more sophisticated clone selection technologies in industrial cell line 
development. 
Flow cytometry based fluorescence-activated cell sorting (FACS) and the 
ClonePix™system (Kim et al., 2012) present some of the more HT screening 
options. FACS sorting is based on linking cell productivity with fluorescence and 
thus allows for isolation based on productivity. In ClonePix™, fluorescently 
tagged antibodies specific to the protein product are employed. Single cell 
colonies are formed in semi solid media, wherein the cells secrete the protein 
product into the matrix. The fluorescent antibody detects the secreted product, 
which assists in cell sorting based on productivity (Lai et al., 2013).  
A further push in industry has instigated the development of a second 
generation of HT, automated methodologies for single cell cloning. The single-
cell printer™ based on microfluidics to ensure monoclonality has been 
developed (Cytena GmbH, (Gross et al., 2015)). The Beacon platform based on 
nanofluidics and optoelectro positioning also demonstrates successful 
automated single cell cloning (Le et al., 2018). 
Key attributes such as growth rate and productivity are constantly evaluated 
during selection stages to narrow the number of clones. When selected clones 
are brought down to around 10 to 25 in number, mini-bioreactor studies can be 
used to further evaluate growth, production and product quality characteristics 
and determine growth media and feeding regimes. The top 4 to 6 clones are 
further evaluated wherein the final production clone and backup clone decisions 








 Process Development 1.5.4.
 
The cell line development process culminates in a final production clone that 
would be scaled up for therapeutic protein production in stirred tank bioreactors. 
Not every cell clone is created equal and will react differently to media/feed 
addition and bioreactor conditions. Thus, the process development arm of the 
upstream production process involves creating the most suitable environmental 
conditions for biotherapeutic manufacture in CHO production clones.  Process 
development is based on the optimisation of two main factors: (i) culture media 
and feeds (ii) bioreactor operating conditions. The biopharmaceutical production 
process involves reviving the banked cell clone, setting up seed and inoculum 
trains to gather enough biomass to seed production bioreactors ranging from 
5,000 to 25,000 L (Kelley, 2009). 
Production titers using CHO cells have risen over 20 fold (and well into the g L-1 
quantities) since their inception as a biopharmaceutical production host (De 
Jesus and Wurm, 2011). This major improvement is mainly attributed to culture 
media development (Huang et al., 2010; De Jesus and Wurm, 2011; Kim et al., 
2012; Zhu, 2012). Culture media is a vital component of the production process, 
since it caters to the cell’s nutritional requirements and thus impacts cell 
proliferation, productivity and even product quality (Rouiller et al., 2013). The 
1950s and 1960s witnessed the use of serum containing culture media 
(Landauer, 2014; Yamamoto and Niwa, 1993) for culturing cells in vitro. While 
serum provides cells with the nutrients and proteins essential for cell 
proliferation, the undefined composition renders itself to lot-to-lot inconsistency 
(Butler, 2005). Additionally, the animal sourcing of serum increases potential for 
pathogenic agent proliferation (Li et al., 2010; Zhang, 2010). Thus, serum-free 
and chemically defined media development was prioritised to abolish these 
issues. 
Animal component free, chemically defined media is a complex entity. 
Chemically defined media contains a carbon source, amino acids, inorganic 
salts, vitamins and lipids as a minimum (Landauer, 2014; Sandadi et al., 2006), 
with individual companies performing optimisation and supplementation studies 




only impact cell growth but also affect cellular productivity (Reinhart et al., 2015; 
Rodrigues et al., 2012), gene expression (Yuk et al., 2014), product quality 
(Hong et al., 2010) and toxic metabolic by-product accumulation (Ha and Lee, 
2014; Luo et al., 2012).   
There are a plethora of options at a user’s disposal for optimising media for a 
bioproduction process. The simplest “one factor at a time” (OFAT) screening 
allows for testing a singular factor effectively but discounts any interactions 
between components (Parampalli et al., 2007; Rouiller et al., 2013). Thus, 
multivariate statistical analytical methodologies such as Design of Experiments 
(DOE) are often employed (Parampalli et al., 2007; Sandadi et al., 2006). 
Additionally, media blending techniques wherein a number of media component 
blends (at different ratios) are created and analysed in a HT manner to 
determine optimal concentrations of components (Rouiller et al., 2013).  Spent 
medium analysis and metabolomics often play a role in media development as 
well (Li et al., 2010; Liu et al., 2015b). Rational supplementation of production 
and growth enhancers to the basal medium also returns improvements in 
protein production (Allen et al., 2008; Kim and Park, 2016; Yuk et al., 2015b). 
Overall, there are multiple techniques available to create media environments 
most suited to a user’s production process. 
Bioreactor conditions also have been shown to have a profound impact on 
culture performance. Bioreactor culture operating parameters such as operating 
temperature, gas flow rate, impeller speed, pH and dissolved oxygen can 
impact production processes and require constant maintenance and 
optimisation (Li et al., 2010; Shukla and Thömmes, 2010).. Bench top and 
small-scale bioreactors often assist in the optimisation studies to develop 
bioreactor operating protocols for a fed-batch production run for a particular cell 
line and product.  
 
1.6. High-Throughput Technologies for Upstream Process Development 
 
Briefly touched upon in the previous sections, HT technologies form a vital part 




present scenario, given the surge of biosimilars and biobetters stimulated by 
parent proteins losing patent protection. The rise in demand for more complex 
proteins like fusion proteins and bispecifics also plays a role in the increasing 
demand for HT techniques. Simply put, companies need to make large amounts 
of complex protein products, rapidly and cost-effectively. This section mainly 
focuses on HT culturing technologies for process development. HT techniques 
are based on three principles: (i) miniaturisation (ii) parallelisation and (iii) 
automation (Bhambure et al., 2011).  
HT culturing techniques mainly accelerate process development however also 
aid in clone selection. Miniaturised bioreactors can come in two variants: 
shaken cultures or stirred impeller cultures (Hemmerich et al., 2018). Stirred 
impeller mini-bioreactors have the obvious benefit of having the same mixing 
technique as scaled-up stirred tank bioreactors. The most notable product in the 
stirred variant is the ambr 15 system (TAP Biosystems (part of Sartorius 
Stedium Biotech, Hertfordshire, UK). Here, 24 to 48 cultures with 10 to 15 mL 
culture volumes can proceed in parallel (Hsu et al., 2012). Dissolved oxygen 
and pH can be monitored in each mini-bioreactor, allowing for sophisticated 
control (Hemmerich et al., 2018; Rameez et al., 2014). The bioreactors can be 
linked up to automated liquid handling systems for automated feed addition and 
sampling (Hemmerich et al., 2018). Similar growth and production profiles were 
observed with 7L bioreactors demonstrating good scalability (Lewis et al., 
2010). However, non-invasive optic based parameter measurements are not 
possible (Hemmerich et al., 2018) and the instrument is relatively costly and 
requires high maintenance. Another HT stirred culture system alternative is the 
bioREACTOR (2mag AG, München, Germany). Similar to the ambr 15, it is 
mainly employed for microbial cultivation (Hemmerich et al., 2018). 
On the other hand, shaken technologies present multiple options for HT 
culturing. Herein, multi-well plate variants are the most common culture vessel. 
The level of control and monitoring varies with the different options available. 
The BioLector (m2p-labs GmbH, Baesweiler, Germany) allows for 48 parallel 
fermentations, wherein pH, dissolved oxygen can be monitored along with 




(Hemmerich et al., 2018). A similar 24 multi-well plate technology is the micro-
Matrix (Applicon Biotechnology, Delft, The Netherlands). 
Perhaps, the simplest and cheapest culturing technique is the use of general 
commercial multi-well plates. Containing from 6 to 384 wells, the amount of 
throughput offered can be decided by the user. Shallow well plates are limited 
to lower culture volumes (around 150 µL for a 96 well plate) and are more 
suited for static setup, though shaking is possible (Hermann et al., 2003). 
Suspension cell lines (like CHO cell lines used in industry today) would logically 
be better suited to shaking cultures. Thus, many multi-well plate shaking 
technologies have been developed (Duetz, 2007). These generally employ 
deep well plates (DWPs), which allow for higher culture volume resulting in 
multiple invasive culture attribute sampling from the same well (Chaturvedi et 
al., 2014). Clamps developed by Enzyscreen BV (Heemstede, Netherlands) 
(Duetz, 2007) are most commonly employed for 24 and 96 DWP culturing 
(detailed in Chapter 4). Herein, the plates are secured in place using a clamp 
system (“System Duetz”). 16 clamps (1 clamp per plate) fit inside a standard 
sized incubator, thus 1,536 cultures can be evaluated in parallel (for a 96 well 
plate) (Enzyscreen BV,). Thus, this system can provide higher throughput than 
other technologies such as the ambr 15. Culture aeration and mass transfer is 
dependent upon shaking speed, orbital diameter, well geometry and cultivation 
volume (Hemmerich et al., 2018). Thus, optimisations are necessary to obtain 
similar growth and production profiles of a larger scale (such as shake flasks). 
Due to the simplicity of the system, non-invasive monitoring of pH, dissolved 
oxygen and biomass content is generally not available (Long et al., 2014). Plate 
closure systems provided by Enzyscreen BV also help in minimising 
evaporation while maintaining adequate gas transfer (Chaturvedi et al., 2014) 
through plate closure systems. This is usually a sandwich cover comprising a 
stainless steel lid (with holes) with layers of filter and silicone; the cover seals 
the plate and prevents contamination as well (Chaturvedi et al., 2014; Duetz, 
2007). Other closure systems like self-adhesive plate seals were rendered 
inadequate in providing optimum gas transfer and minimising evaporation rates 




These HT cultivation systems are invaluable in accelerating process 
development and optimisation. The addition of multivariate statistical analysis in 
tandem with these systems, allows for testing multiple parameters and 
components in conjunction. The most common methodology employed is DOE 
methodology. This statistical modelling method is based on multiple linear 
regression (Mandenius and Brundin, 2008). The technique allows for 
maximising information of factor impact while minimising the number of 
experimentations required (Franceschini and Macchietto, 2008). This in turn 
reduces cost, time and resources involved. There are many different types of 
DOE approaches available, however the most common approaches taken are 
factorial designs and response surface methodologies (RSM). Factorial designs 
are extremely useful when the design space is large, allowing for quick screens 
to identify significant factors and interactions and eliminate non-significant ones. 
RSM is more suited as a second approach to adopt after factorial designs.  The 
design space is comparatively smaller and is intended to optimise the process 
and return best factor settings based on the predictive model (Anderson and 
Whitcomb, 2016; Mandenius and Brundin, 2008). 
One of the most common uses of DOE is for media development (Brühlmann et 
al., 2017b; González-Leal et al., 2011; Grainger and James, 2013; Parampalli 
et al., 2007; Sandadi et al., 2006). DOE can also be used for other processes in 
the biopharmaceutical industry such as optimisation of bioreactor operation 
parameters (Legmann et al., 2009). Despite the power of DOE as a prediction 
and optimisation tool, many biologists are wary of adopting it in their 
optimisation experiments. This hesitation stems for a poor understanding of the 
tool and notion of it being illogical for biological recommendations (Comley, 
2009). Nevertheless, there is a real push to employ these strategies for 


















This	 chapter	 presents	 a	 focused	 discussion	 and	 review	 on	 the	 potential	 of	 small	




will	 be	 discussed	 that	would	 emphasise	 the	 opportunities	 of	 this	 research	 study	 to	
facilitate	 the	 design	 of	 a	 commercial	 screening	 tool	 to	 inform	 a	 user	 of	 a	 bespoke	





2.1. Introduction: Engineering Culture Media 
 
Every step of the biopharmaceutical upstream process pathway presents 
opportunities for improvement. There are 3 main strategies to overcome 
production constraints in CHO cell based manufacturing: engineering the (i) cell, 
(ii) media and (iii) process conditions. Cellular engineering strategies are often 
comparatively longer and more tedious to employ (Brühlmann et al., 2017b). 
Additionally, alternative cell engineering approaches such as the use of a 
directed evolutionary pressure have extremely long timelines to yield results. 
Process conditions such as hypothermic temperature shift to create biphasic 
culture conditions, could be relatively low-throughput, i.e. sequestering a whole 
incubator for culturing at a different temperature. Media development has been 
shown to be the major contributor towards improving biotherapeutic production 
rates in the past 25 to 30 years (Huang et al., 2010; De Jesus and Wurm, 
2011). Culture media is always in a state of optimisation, and improvement 
using strategic supplementation of different chemical additives is an attractive 
opportunity. These small molecule enhancers (SMEs) could already form part of 
the growth media (for example: copper (Yuk et al., 2015b) and zinc (Kim and 
Park, 2016)) as cell line and base media specific optimisations are often 
required. Such small molecules could also inform feed design. Additionally, 
media component substitutes could be beneficial: for example, substituting 
glutamine with other molecules such as glutamate (Hong et al., 2010) or α 
ketoglutarate (Ha and Lee, 2014) can lower ammonia levels in culture and 
improve production. Alternatively, some bioactive small molecules that would 
normally not form part of growth media could be used to strategically enhance 
the culture process. A notable example is sodium butyrate (Backliwal et al., 
2008; Palermo et al., 1991) that has been employed in multiple studies to 
improve cellular production levels by promoting an actively transcribing 
chromatin structure. Cell cycle inhibitors (for example lithium (Ha et al., 2014)) 
can be employed strategically to allow for repression of growth while enhancing 
cellular productivity (qP).  Chemical chaperones can be utilised to promote 
production, correct protein folding and diminish aggregation in DTE proteins 
(Johari et al., 2015). Hence, it is visible that chemical supplementation 




manipulating cell culture performance to reach its desired potential. Chemical 
supplementation guided media engineering strategies are comparatively cheap, 
facile and quick to execute than their cell engineering counterparts (Brühlmann 
et al., 2017b; Ha et al., 2014; Park et al., 2016), making it an attractive option to 
employ for rapid results. Supplementation strategies can be easily varied: 
concentration, timing of addition, combinatorial supplementation can all impact 
level of efficacy. This strategy is further discussed in this chapter wherein 
examples of successful small molecule supplementation approaches are 
discussed from an enhancement of cell and process function viewpoint. 
Followed after, the need of a HT screening platform for media additives is 
discussed through the use of potential utility scenarios. A thesis layout is 
presented to conclude this chapter. 
 
2.2. SMEs for Bioprocess Improvement and Optimisation 
 
 Efficient Metabolic Processing and Control 2.2.1.
 
Inefficient cell metabolic cycling can put strains on production culture 
performance. Accumulation of toxic by-products such as lactate and ammonia 
is a common occurrence in CHO cell culture (Dean and Reddy, 2013). This is 
especially true for fed-batch bioreactor production culture where pH needs to be 
controlled due to excessive acidification (Luo et al., 2012). Base addition 
increases osmolarity, which can arrest cell proliferation (Templeton et al., 2013). 
The major metabolic determinant of the toxic product build-up is the Warburg 
effect (Warburg, 1956). CHO cells exhibit similar phenotype to cancer cells, 
wherein they employ aerobic glycolysis for their short-term energy needs 
(Buchsteiner et al., 2018). This pathway ends in lactate formation and its 
subsequent build-up in the culture media. To combat this, various metabolic 
angles within the cells have been investigated. Copper sulphate 
supplementation has proven effective in modulating lactate metabolism (Luo et 
al., 2012; Qian et al., 2011; Yuk et al., 2014; Yuk et al., 2015b). Copper plays a 
role in the electron transport chain and maintaining a specific level of copper 




aerobic glycolysis decreases lactate output. The studies mentioned above all 
reported an increased in cell proliferation that translated into higher production 
yields.  
Sodium dichloroacetate, a pyruvate dehydrogenase kinase inhibitor, indirectly 
increases pyruvate dehydrogenase activity and promotes tricarboxylic acid 
(TCA) cycle entry (Buchsteiner et al., 2018). Similar to copper, Warburg effect 
and the resulting lactate production are downregulated. Studies have reported 
on the ability of dichloroacetate to elongate culture durations due to mitigating 
frequent base additions to maintain pH (Buchsteiner et al., 2018; Skelton et al., 
2010). Another detrimental by-product of cellular metabolism is ammonia (Yang 
and Butler, 2000). Substitution of the carbon source by other agents such as 
glutamate (Hong et al., 2010) and α ketoglutaric acid (Ha and Lee, 2014) have 
provided moderate success in improving culture performance by dampening 
ammonia formation. 
De novo lipid synthesis has been shown to play a role in cancer cell 
proliferation and tumorigenesis (Mukherjee et al., 2012). For instance, fatty acid 
synthase (FAS) expression (a marker for lipid synthesis) is heightened in cancer 
cells (Santos and Schulze, 2012). This is understandable since tumour cells 
depend on lipid biosynthesis to meet their proliferation and energy needs 
(Mukherjee et al., 2012). 17β-estradiol, a FAS upregulator has been shown to 
increase cell proliferation in MCF-7 cells (Lu and Archer, 2010). Other 
molecules have been discovered that have been shown to activate FAS 
expression (Kim et al., 2004; Mukherjee et al., 2012). Applying the same 
rationale, these lipid synthesis enhancers can be applied to CHO cell factories 
to assist in their growth and proliferation. 
Basal media itself is another major determinant of cell culture performance. The 
shift in industry towards chemically defined medium (due to the infection risk 
and poor reproducibility of serum media) (Jerums and Yang, 2005; Kishishita et 
al., 2015) has led to the creation of a vast media design space. The ability to 
plug and play different components is vital to improving CHO production 
performance. It is obvious that one basal media will not produce optimal culture 
performance across all cell lines and products. Different commercially available 




metabolic responses when applied to the same cell line (Reinhart et al., 2015; 
Velugula-Yellela et al., 2017). Thus, it is important to find the right balance for 
the production system at hand. Metal ions form a vital part of base media and 
modulations of their levels have proven to improve production performance. For 
instance, zinc supplementation in CHO cultures cultivated in different culture 
media yielded various degrees of improvement (Kim and Park, 2016). Zinc has 
insulin mimetic properties that render it a good component in chemically defined 
media (as a replacement for insulin) (Wong et al., 2004; Zhang et al., 2006). 
Various iron sources and carriers to replace bovine transferrin have also 
produced positive impacts on growth and titer upon supplementation (see: 
selenium, ferric citrate and ferric ammonium citrate in Table 2.1). Overall 
studies investigating singular supplementation of metal ion compounds have 
shown improvements to the CHO production process, supporting the notion that 
base media formulations need to be optimised for maximising performance.  
Another component that forms part of cell culture media is amino acids. 
Strategic feeding of a combination of certain amino acids demonstrated 
production yield enhancements in a study by Kishishita et al. (2015).  
 
Other Strategies for Metabolic Control:    
    
While singular chemical supplementation or optimisation of media components 
can yield reward, industries and research also employ metabolic flux analysis to 
fully understand their production system, and use it to inform them of rational 
media design (Xing et al., 2011).  Alternatively, genetic engineering strategies 
can also be employed for sophisticated metabolic control. To reduce ammonia 
build-up, urea cycle genes can be overexpressed that promote conversion of 
ammonia to citrulline; leading to increased cell proliferation (Park et al., 2000). 
Other overexpression strategies also exist for the improvement of CHO 
metabolism for enhanced culture longevity and product yields (Chong et al., 
2010; Fischer et al., 2015; Gupta et al., 2017; Tabuchi and Sugiyama, 2013).  
Gene knockdown can also modulate processes that are detrimental towards 
sustained cell proliferation. Most knockdowns (usually interfering RNA 




acidification (Fischer et al., 2015; Jeong et al., 2001; Kim and Lee, 2007; Zhou 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 Transcriptional Enhancement 2.2.2.
 
Transgene transcriptional activity and expression stability can be influenced by 
a multitude of epigenetic and environmental factors. Firstly, the site of 
integration can impact expression of the product gene (Kwaks and Otte, 2006; 
Yang et al., 2010). For instance, random integration into the functionally 
repressive and structurally condense heterochromatin region can lead to 
transgene silencing. Secondly, changes around the site of integration such as 
epigenetic modifications on the histone tail (i.e. acetylation, methylation, 
phosphorylation and ubiquitination of mainly residues on the N-terminus) 
influence gene activation or repression (Dahodwala and Sharfstein, 2014; 
Kwaks and Otte, 2006; Nishihara et al., 2017; Zhang and Reinberg, 2001). 
Thirdly, hypermethylation of the DNA molecule itself, especially at the promoter 
region can lead to gene silencing (Yang et al., 2010).  
In general, two histone modifications play a major role in transgene expression 
stability: acetylation and methylation along with methylation of DNA molecule 
itself (Kwaks and Otte, 2006). Several bioactive small molecules can target the 
aforementioned epigenetic regulatory pathways to restore gene transcription. 
The most widely employed epigenetic modifiers for biopharmaceutical 
production are histone deacetylase (HDAC) inhibitors. Histone deacetylases 
remove acetyl groups on lysine residues on the histone tail, promoting 
interactions between histone and DNA (Ropero and Esteller, 2007). This results 
in a more compact chromatin structure obstructing transcription machinery 
access to DNA (Bora-Tatar et al., 2009; Ropero and Esteller, 2007). HDAC 
inhibitors regulate global acetylation and promote transcription and gene 
activation. The most widely employed HDAC inhibitor sodium butyrate has been 
used extensively to augment product yields in both transient and stable 
production formats (Jiang and Sharfstein, 2008). While volumetric yield gains 
from employing this molecule are large, off-target effects such as induction of 
apoptosis and reactive oxygen species (Backliwal et al., 2008; Lee and Lee, 
2012; Malhotra et al., 2008) hamper its appeal.  
Interestingly, sodium butyrate has been shown to reduce levels of a potentially 




butyrate does alter glycosylation profiles undesirably by having a negative 
impact on galactosylation (Hong et al., 2014) and sialic acid content (Sung et 
al., 2004). Other HDAC inhibitors such as valproic acid have been applied in 
biopharmaceutical research with a great degree of success (Backliwal et al., 
2008; Wulhfard et al., 2010; Yang et al., 2014). Molecules like trichostatin A and 
MS 275 have also been employed to with some success in biotherapeutic 
production setup (Backliwal et al., 2008; Nan et al., 2004) (see Table 2.2 for 
summary on other HDAC inhibitors). 
Multiple other HDAC inhibitors are been approved for clinical use as cancer 
therapeutics (Biswas and Rao, 2017). These molecules present opportunities 
for employment in the bioprocess arena as boosters for recombinant protein 
transcription. However, since they are used as apoptosis inducers for 
chemotherapeutic treatments, it is feared that they would impart the same 
functionality in the bioprocess arena. Thus, a degree of caution needs to be 
undertaken while employing these molecules. Other avenues such as 
computational modelling and docking studies have been able to isolate novel 
HDAC inhibitors based on structural analysis (Bora-Tatar et al., 2009). Most 
HDAC inhibitors fall under broad structural classes: hydroxamates, carboxylic 
acids, cyclic tetrapeptides, benzamides and electrophilic ketones (Bora-Tatar et 
al., 2009). Computational structural modelling could potentiate the identification 
of novel bioactive small molecules that are more suited to bioprocess 
production scenarios. Obviously, this would require rigorous testing to validate, 
especially evaluating apoptosis induction upon addition of the chemical. 
Another histone modification that can impact gene activation and repression is 
histone methylation. Histone methylation occurs on lysine and arginine residues 
(Zhang and Reinberg, 2001). Methyltransferases confer methyl groups on the 
histone tail, resulting in gene repression or activation (Curry et al., 2015). 
Applying the same rationale as with HDAC inhibitors, histone methyltransferase 
inhibitors are applied in cancer research to target tumours that have 
characteristic high levels of methyltransferase activity (Curry et al., 2015). Their 
application as inducers of recombinant protein production is rare, with it being 
necessary to determine specific inhibitors for transcription repressive marks. A 




of histone methyltransferase inhibitors for CHO cell recombinant protein 
production. The study identified various histone methyltransferase inhibitors that 
enhanced transient gene expression in CHO cells expressing a luciferase 
reporter. The exact mechanism of action of the successful molecules remains 
unknown. While gaining prominence in chemotherapy circles, these molecules 
are under researched for the purposes of recombinant protein expression and 
more studies are required to critically assess their efficacy. 
Methylation can also occur on the DNA molecule itself. Promoter methylation is 
a major cause for loss in productivity in mammalian recombinant DNA 
expression (Yang et al., 2010). This study demonstrated that heavy methylation 
on the cytomegalovirus (CMV) promoter contributed towards loss in production 
stability over time. Addition of a DNA methyltransferase inhibitor, 5-aza-2′-
deoxycytidine (decitabine), helped recover some of the production capability in 
their CHO clones (Yang et al., 2010). Similarly, 5-azacytidine has proven useful 
in rescuing recombinant gene expression in other studies (Backliwal et al., 
2008; Escher et al., 2005; Tanigawa et al., 1993). However, 5-azacytidine, 
decitabine and other nucleoside analogs can cause DNA breaks and apoptosis 
since they are incorporated into the DNA molecule (Lyko and Brown, 2005; 
Yang et al., 2010). Thus, different non-nucleoside analogs that do not act in a 
cytotoxic manner need to be discovered for the purposes of biologics 
production. A summary on DNA methyltransferase inhibitors that have been 
previously employed to improve recombinant product yields is displayed in 
Table 2.3. 
In conclusion, these molecules are powerful tools for transgene expression 
enhancements due to their ability to promote transcription. The major drawback 
of these molecules is that they can present cytotoxicity risks. Thus, it is 
imperative to titrate the molecules effectively i.e. effective dose is selected 








Other Strategies for Transcriptional Control and Enhancement: 
 
Engineering vector elements to maintain and enhance recombinant gene 
transcription are increasingly being utilised. Scaffold/matric attachment regions 
present the ability to create favourable conditions for transcription, i.e. opening 
and maintaining an open chromatin structure (Dahodwala and Sharfstein, 
2014). They are also known to recruit histone acetyltransferases and generally 
promote transcription (Girod et al., 2007). Other vector elements that can 
promote transgene expression include UCOE and insulator elements (Kwaks 
and Otte, 2006). Another strategy is hot-spot targeting that aims to guide 
transgene integration at a transcriptionally active site (Dahodwala and 
Sharfstein, 2014; Kwaks and Otte, 2006). Synthetic promoters also present 
opportunities for sophisticated transcriptional control, based on rationally driven 
promoter designs (for example assemblies based on transcription factor 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 Proliferation Control to Enhance Cell Production Resources 2.2.3.
 
Maintaining a high growth rate is considered vital for good production 
performance using mammalian cell factories. However, uncontrolled 
proliferation can sometimes yield the opposite of the performance expected. 
Nutrient depletion and accumulation of toxic by-products can shorten culture 
duration, deteriorate the product and complicate downstream processing (Du et 
al., 2015; Mazur et al., 1998).  
Additionally, there is an emphasis on focusing resources completely towards 
protein production and improving specific cellular productivity. It has been 
reported that a cell cycle arrest at the G1 phase bolsters qP (Du et al., 2015; 
Dutton et al., 2006; Ha et al., 2014; Kumar et al., 2007; Mazur et al., 1998; 
Sunley and Butler, 2010). The definite mechanism that causes this boost in qP 
is unknown, however many theories have been put forward to partially explain 
this gain. The cells are generally more metabolically active and bigger in size 
(Carvalhal et al., 2003). There is also evidence that ribosome synthesis is 
heightened at the G1 phase (Dez and Tollervey, 2004). Many small molecule 
inhibitors of the G1 phase of the cell cycle are proven boosters of cellular qP. 
The most notable ones are sodium butyrate, sodium phenylbutyrate and 
valproic acid (Ha et al., 2014; Kumar et al., 2007; Park et al., 2016). These 
molecules mostly act as histone deacetylase inhibitors inhibiting HDAC1, which 
indirectly restrains entry into S phase. It can be considered that their epigenetic 
regulation plays a larger role in their ability to boost qP and titer. However, a 
specific CDK4/6 inhibitor arresting cell cycle in the G1 phase (Du et al., 2015) 
has also been shown to improve cellular productivity, indicating cell cycle block 
at G1 has the ability to improve cellular production capabilities. Also, reducing 
culture temperature has served as a popular technique to improve cell specific 
yield (discussed briefly in Other Approaches for Controlled Proliferation and 
Cell Cycle Arrest). This also relies on a cell cycle block at G1, adding to the 
evidence of G1 arrest being an effective strategy to improve productivity.  
There has also been interest surrounding inducing a cell cycle block at the 
G2/M phase. A study by Yokota and Tanji (2008), reported that maximum 




phase in CHO cells. Lithium chloride, a G2/M inhibitor was easily titrated into 
both stable and transient producing cultures and was able to bolster cell qP (Ha 
et al., 2014; Kim et al., 2016a). Already employed in clinical setting as an anti-
depressant, regulatory concerns for using this molecule in cell culture are 
comparatively low (Ha et al., 2014). Other bioprocess G2/M phase arrest 
strategies through chemical deployment are highlighted in Table 2.4. G2/M 
arresting small molecules (mostly kinase inhibitors) find use in cancer research 
due to their ability to stop malignant cells from proliferating, followed by the 
onset of apoptosis. In the bioprocess arena this is not ideal, since cells need to 
remain viable to continue with protein production. There were some candidates 
highlighted in literature that sustained cell viability. D,L sulforaphane, a naturally 
occurring molecule, when trialled in human ovarian cancer cells did not induce 
apoptotic pathways (Chang et al., 2013). Some G2/M inhibitors in bioprocessing 
circles have proved effective in increasing transient gene expression (Galbraith 
et al.,; Kim et al., 2016a; Tait et al., 2004). It is suggested that these molecules 
aid in gene delivery by (a) increasing nuclear membrane permeability and (b) 
increasing available cell surface area due to bigger cell size (Christensen, 2016; 
Kim et al., 2016a). Additionally, obstruction of cell proliferation prevents the 
transfected DNA from getting diluted too quickly, retaining enough copies in 
each cell, thus increasing qP (Kim et al., 2016a). With regards to stable 
production modes, due to the growth arrested cells being considerably larger 
and containing double recombinant DNA content, an increase in cellular 
productivity is not entirely unexpected (Tait et al., 2004). Lloyd et al. (2000) also 
noted that recombinant protein productivity was highest when CHO cells were in 
the G2/M phase. However, they concluded that cell size was the predominant 
determinant of qP (Lloyd et al., 2000; Tait et al., 2004). 
 
Other Approaches for Controlled Proliferation and Cell Cycle Arrest: 
 
While the use of bioactive small molecule inhibitors of cell cycle is extremely 
easy to implement and cost-effective, off-target effects such as apoptosis can 
yield undesired effects. Perhaps, the most common alternative for cell cycle 




are bigger in size and have a higher qP (Coronel et al., 2016; Kumar et al., 
2007; Sunley and Butler, 2010). Similar to the chemical cell cycle arrest using 
sodium butyrate and valproate, these cells are arrested in G1. Another 
approach is through genetic manipulation. Inducible overexpression of Gadd45, 
a protein involved in the G2/M checkpoint, improved transgene expression in 
CHO cells (Kim et al., 2014). Genes involved in CDK inhibition can be targeted 
for overexpression and upregulation, often arresting cells in G1 phase to 
improve productivity (Kumar et al., 2007; Sunley and Butler, 2010). 
Overexpression of an anti-apoptotic gene, Bcl2 also causes cell cycle arrest but 
viability is maintained, co-expression with other cell cycle arrest inducers can 
improve transgene expression (Du et al., 2015; Fussenegger et al., 1998; 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 Aggregation and Protein Secretion Control 2.2.4.
 
Diseases caused by protein misfolding are a common occurrence: Alzheimer’s, 
Parkinson’s and Prion disease to name a few (Cortez and Sim, 2014). Chemical 
chaperones are effector small molecules that have demonstrated success in 
attenuating protein misfolding and aggregation in the aforementioned disease 
models. The exact mechanism of this set of molecules remains poorly 
understood, however the general consensus remains that they act by promoting 
correct protein folding, mitigating aggregation and generally enhancing protein 
production. Additionally, some chemical chaperones have been shown to be 
effective in assisting molecular chaperone function (De Almeida et al., 2007). 
Applying the same rationale as in misfolding diseases, these molecules have 
been applied in biopharmaceutical production scenarios. With industry focus 
shifting towards the production of more complex and DTE proteins, efficient 
cellular production machinery and correct protein folding becomes critical. Thus, 
chemical chaperones would have a higher sense of utility in these scenarios.  
Most chemical chaperones that are used to improve recombinant protein 
production are osmotically active. These include amino acids and their 
derivatives such as proline, glycine taurine; methylamines like betaine, 
trimethylamine N-oxide and polyols like glycerol, sucrose (Cortez and Sim, 
2014; Welch and Brown, 1996). These molecules are mostly involved in the 
stabilisation of protein structure by sequestering water molecules to promote 
correct protein folding (Cortez and Sim, 2014). The other class of chemical 
chaperones are termed hydrophobic chaperones. These interact with 
hydrophobic regions of the protein that are susceptible to aggregation (Cortez 
and Sim, 2014). The most noteworthy chaperones in this category are 4 
phenylbutyric acid and tauroursodeoxycholic acid. 
A summary of published research on the use of chemical chaperones in the 
biopharmaceutical production design space is shown in Table 2.5. While the 
chaperones that have been tested mainly play a role in upregulating protein 
expression and secretion and/or attenuating aggregation, some chaperones 




indirect impact on the unfolded protein response (UPR) and alleviation of ER 
stress, thus promoting cell survival. This is expanded upon below. 
While chemical chaperones directly modulate protein structure, these molecules 
have been shown to indirectly crosstalk with cellular mechanisms that deal with 
protein secretion and unfolded protein responses. 4 phenylbutyric acid and 
tauroursodeoxycholic acid were shown to affect expression of unfolded protein 
response activators, binding immunoglobulin protein (BiP) and glucose-
regulated protein 94 (GRP94) (De Almeida et al., 2007; Kolb et al., 2015; 
Mimori et al., 2013). 4 phenylbutyric acid is also known to induce transcription of 
other heat shock proteins (De Almeida et al., 2007; Mimori et al., 2012). 
Additionally, tauroursodeoxycholic acid demonstrated cytoprotective effects in 
sepsis models in mice (Doerflinger et al., 2016; Uppala et al., 2017). Betaine 
has been shown to facilitate correct protein transport from the endoplasmic 
reticulum (ER) to the Golgi (Roth et al., 2012). Some chaperones are also 
known to impact the oxidative status of the cell. Glycine betaine (Rabbani and 
Choi, 2018) , trehalose (Patel et al., 2017) and proline (Krishnan et al., 2008) 
are all known to reduce reactive oxygen species in the cell and promote cell 
viability. 
The most comprehensive study on the use of chemical chaperones in CHO 
cells is by Johari et al. (2015). The authors of this study utilised a DTE protein 
product, transient CHO system and attempted to improve production and 
diminish aggregation through chemical chaperone use. There were several 
positive results using singular chemical chaperones (as shown in Table 2.5). It 
was interesting to note that combining 4 phenylbutyric acid and glycerol 
treatment with molecular chaperone cyclophilin B (cypB) overexpression in a 
biphasic culture process, recorded a 5.9 fold improvement in overall titer. While 
this study did not conclusively reveal crosstalk mechanism between chemical 
and molecular chaperones, it did demonstrate the advantages of a combined 
strategy of gene overexpression and chemical treatment. However, if time, 
money and resources are limited, chemical chaperones are an attractive 






Other Approaches for Aggregation and Secretion Control: 
 
In contrast with chemical approaches, genetic engineering approaches can be 
applied to tackle DTE protein secretion and reduce aggregation. Optimising 
expression vectors with signal peptide engineering (Le Fourn et al., 2014; Zhou 
et al., 2018) assist with efficient polypeptide translocation to the ER. 
Overexpression of various ER chaperones such as protein disulphide 
isomerase (PDI), BiP and calnexin (Chung et al., 2004; Johari et al., 2015; Zhou 
et al., 2018) has also shown varying degrees of success. Other strategies 
include UPR engineering (X-box binding protein 1 (XBP1), activating 
transcription factor 6 (ATF6) overexpression) (Pybus et al., 2014; Zhou et al., 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 Glycosylation Processing 2.2.5.
	
Protein product glycosylation is a major factor in determining biotherapeutic 
efficacy, potency and safety (Brühlmann et al., 2015). Control of protein 
glycosylation to prevent any immunogenic epitopes is especially important. 
Additionally, there has been a meteoric rise in the number of biosimilar 
molecules in the bioprocess arena. Maintaining the same glycoprofile as the 
parent biosimilar is imperative. Thus, modulation to achieve the desired 
glycoform is an important requisite in upstream processing. Chemical 
supplementation approaches are simple and effective tools to achieve this 
objective. Nucleotide sugar precursor supplementation can affect final N-linked 
glycosylation through their role in increasing intracellular pools of glycosylation 
substrates, nucleotide sugars (Blondeel et al., 2015) (see Table 2.6). 
Manganese is co-factor for galactosyltransferases (Lee et al., 2017) and has 
been shown to play a unique role in combination with galactose and uridine in 
promoting galactosylation (Grainger and James, 2013; Gramer et al., 2011). 
Conversely, manganese in the absence or limitation of glucose has been shown 
to increase high mannose profiles (Surve and Gadgil, 2015). Other modulators 
such as raffinose and kifunensine (Brühlmann et al., 2017b) can be used to 
tune the glycoprofile towards its optimum, a trait that is especially vital in the 
creation of biosimilars. The major advantage in using small molecules to control 
protein glycosylation is the ease of use: the molecules can be titrated, 
combined and applied at any stage of production to achieve the desired profile. 
This is in contrast to some of the alternative strategies discussed below. 
 
Other Strategies for Glycosylation Control: 
 
Genetic overexpression and/or knockout account for most of the glycosylation 
modulation approaches undertaken in the biotherapeutic industry. For example, 
overexpression of st6gal-I concomitant with a knockout of st3gal resulted in 
increased α-2,6 sialylation levels relative to α‐2,3 sialylation levels (Chung et 
al., 2017). This was beneficial in creating more human-like glycoforms (Fischer 




sialic acid content (Tejwani et al., 2018). Core fucose residues in glycoproteins 
can negatively impact effector function of monoclonal antibodies (Tejwani et al., 
2018). Knock out of the FUT8 gene (a gene that controls α-6-fucosylation) 
resulted in antibodies devoid of core fucose with enhanced antibody dependent 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 High-Throughput Bespoke Media Development could de-2.2.6.
bottleneck Upstream Biomanufacturing Processing 
 
With speed to market being vital, quick process optimisation to maximise benefit 
is crucial. Host cell and process engineering are central to maximising product 
output at the upstream level. Engineering these elements can be achieved 
mainly by optimising genetic elements (vector engineering, host gene 
overexpression/knockdown), evolving cells, media/feeds optimisation and 
bioreactor environment control. Bioactive small molecules present an attractive 
opportunity for the improvement of biologics production in both transient and 
stable formats. There has been a steady rise in use of bioactive small 
molecules in bioprocess. The precision and control can vary greatly depending 
on the process they target, however they are quite effective in increasing 
proliferation, titer or modulating protein quality.  
We envisage that the use of small molecules as media additives can effectively 
fine tune therapeutic protein production processes. Small molecule additives 
have the following advantages: (i) quick and easy to titrate, (ii) cheap and (iii) 
ease of deployment at different stages of culture. We propose a closed box 
testing kit comprising a suite of SME molecules targeting various cell 
processes, coated on a multi well plate. Rational and HT screening of these 
molecules can inform the creation of bespoke media environments tailored to a 
user’s upstream protein production process. There is no universal media 
environment suitable for every cell line and product: media has to be optimised 
for every process, strengthening the need for HT media optimisation 
approaches. 
To expand upon the possible utility and demonstrate the need for such a 
product, various industrial production scenarios are discussed. Depending on 
the situation at hand, informed and educated SME screening can be used to 







 Scenario 1: Undesirable Proliferation Phenotype 2.2.6.1.
 
Most biopharmaceutical companies have a panel of host CHO cell lines that are 
employed for biopharmaceutical production. When a new product is needed for 
production, vector engineering is normally the first route to improve production 
capabilities. Multiple clones are generated and cell proliferation and production 
capabilities are monitored to select the best proliferating and producing CHO 
host. Even after strenuous rounds of cloning and selection, depending on the 
complexity of the product and host system, the user might have a sub-optimal 
production set up, due to slow cell proliferation. Manufacturing process 
development (including media optimisation) plays a huge role in countering this. 
A focused screening plate with growth enhancer molecules (metal ions, 
metabolic modulators) could help speed up media and feed development. A 
proposed deployment of the plate would be after the best performing clone is 
selected. The “best” clone is normally selected based on production 
performance in fed-batch mini bioreactor studies. However, it is probable that 
proliferation performance has not reached full potential. The SME enhancer 
plate profile would prove beneficial in identifying which supplements would be 
useful in improving cell growth and proliferation, in turn helping optimise the 
basal media and feed compositions.  
 
 Scenario 2: DTE Product Molecule 2.2.6.2.
 
Development of novel complex proteins such as bispecifics and fusion proteins 
has been rising steadily (Walsh, 2014). However, expression of these proteins 
and some mAbs in cellular hosts can prove difficult and return low titers (Johari 
et al., 2015). There is an increase in time and cost associated with these DTE 
proteins wherein efforts need to made to meet their production demands (Pybus 
et al., 2014). Some proteins have a tendency to aggregate whereas others have 
folding, assembly and secretion issues. The burden of improper folding can 
result in the initiation of unfolded protein responses, which downregulates 




studies have reported on post-transcriptional bottlenecks causing low protein 
titers (Johari et al., 2015; Ku et al., 2008; Pybus et al., 2014). 
A suite of SMEs specifically known to counter these production issues would 
have a high impact when employed. Specifically, chemical chaperones have a 
variety of mechanisms by which they can target aggregation and/or folding, 
assembly and secretion abnormalities. These have been shown to be highly 
effective in comparison to genetic engineering approaches (Johari et al., 2015). 
The functional pathways targeted and the modulation of the surrounding protein 
structure can be exceptionally versatile. Based on the bottleneck, various 
chemical candidates can be rationally tested and selected to restore correct 
protein production and folding. Simple, easy to deploy and cost-effective, SMEs 
or combinatorial SME deployment could prove attractive to battle production 
incapability in transient and stable production modes. 
 
 Scenario 3: Isolating the Best Performing Clone 2.2.6.3.
 
Clone selection is an important step in the bioproduction process. Clones are 
usually tested in standard conditions (i.e. same media and process conditions) 
and the best producing clone is taken forward for production runs. It has been 
stated that “dynamic” ranking of clones (performed by testing clones in their 
best performing condition) could provide a more accurate representation of the 
true best clone (Legmann et al., 2011). This study showed that clone ranking 
changes significantly in different media and process conditions. Clones can 
respond differently to various media conditions. Applying the same rationale, a 
media supplementation testing plate could be beneficial if incorporated into 
clone selection pathways. The plate would show which supplements elevate 
production performance and give a more educated view on the diversity in 
clone performance. Once a clone is picked based on this new strategy, the 
plate outputs for that particular clone can be used to make informed media 






 Scenario 4: Biosimilar Product Quality 2.2.6.4.
 
The advancement of biosimilars in the biopharmaceutical market has resulted in 
stringent rules being applied to confirm biosimilarity. This is especially crucial for 
glycosylation patterns since they can determine molecule efficacy and safety. 
Cell lines and processes can impose variations in glycoform profiles for the 
same protein molecule. Thus, complete replication of glycoprofiles can require 
some intervention. Bioactive small molecule modulators of glycosylation present 
simple and cost effective strategies. Depending on the glyocoform that needs 
enriching, specific molecules can be used to target glycoprofiles of interest and 
increase molecular fingerprint similarity to the parent molecule (Brühlmann et 
al., 2017a). Since speed-to-market is important to fend off other biosimilar 
competition, a focused HT plate based screening method to identify 
glycosylation modulators that heighten biosimilarity would prove especially 
useful. 
 
 Scenario 5: Biphasic Culture Modality  2.2.6.5.
 
The concept of biphasic cultures is not novel. Biphasic cultures are 
characterised by a cell proliferation phase followed by a protein production 
phase. The most common strategy employed to achieve this is hypothermic 
culture shock. Cells are cultivated at 37°C for a stipulated time period and then 
shifted to 30-32°C. The lower temperatures stagnate growth while maintaining 
cell viability and cellular resources are prioritised for recombinant protein 
production (Sunley and Butler, 2010). Similar rationale applied, chemical 
arrest/solely qP enhancement strategies can be applied to create a biphasic 
culture modality. G1 and G2/M cycle inhibitors and/or epigenetic inhibitors 
can prove useful to this effect. The ease of manipulation and opportunity for 
combination for an enhanced effect make chemical use attractive. The ability to 
screen different chemicals for this purpose in a HT manner is important. Thus, 
having a coated plate with cell cycle inhibitors and qP enhancers allows for 
multiple biphasic culture trialling. The cells can be cultivated on an uncoated 




chemicals from the coated plate to create a HT biphasic culture testing 
modality. 
 
2.3. Thesis Aims and Overview 
 
The previous section highlighted the need and potential utility of HT bioactive 
small molecule testing to accompany bioprocess development. This project 
focuses on the development of simple and quick HT testing technologies to 
harness the potential of bioactive small molecules as enhancers for CHO based 
bioprocessing. This research study has 4 aims. Firstly, to investigate the 
development of a HT screening platform. The envisioned screening platform is 
standardised and easy to use, allowing for the screening of multiple effectors 
concurrently. Secondly, to assess the efficacy of a suite of SME molecules in a 
model production system. Efficacious molecules are defined as those that 
improve one or more culture attribute (growth, volumetric titer or qP). Thirdly, to 
investigate the potential of chemical combinatorial strategies as tools to further 
amplify cell growth or production. Both singular and combinations of successful 
enhancers will form part of the envisioned media additive screening tool. An 
embedded screening design would allow the user to concurrently assess media 
additives and their selected combinations in their production system. Finally, to 
use the developed HT screening tool to investigate potential novel enhancers 
for CHO bioprocess. These could be enhancers that have never been tested in 
CHO production systems specifically or enhancers that have never been 
employed in bioproduction scenarios at all previously.  
The research findings of this project are presented across 3 results chapters. 
Each chapter contains a brief introduction and experimental approach taken to 
tackle the research aim. Investigation of the development of a HT screening 
platform is displayed in Chapter 4. HT, miniaturised culturing methodologies 
were investigated and optimised. Additionally, analytical technologies to assess 
cellular growth and titer were and optimised for HT use. Timing of chemical 




Chapter 5 depicts the chemical screens undertaken using the HT platform to 
inform the media supplement screening tool design. The envisioned product 
design is based on SME coated multi-well plate technologies for easy screening 
of culture performance enhancers. Potential SMEs were selected based on 
literature surveys and past experience. 43 SME (across 8 functional categories) 
screens were performed in a stable producer CHO cell line, wherein singular 
chemical addition was assessed at different concentrations. Chemicals were 
mostly added at the start of culture with additional screens performed for a 
small subset of molecules deployed at mid-exponential phase. Growth and 
production assessments were performed at a single time point in culture. 
Rational combinations of efficacious chemicals were investigated to identify any 
positive interactions between SMEs that elevated growth and/or production 
performance. This was performed using factorial design based DOEs. Finally, 
the chapter depicts the scale-up performance (in shake flasks) of a 
recommended chemical deployment strategy for a model CHO stable producer 
line.  
Chapter 6 demonstrates the use of the HT culturing methodology to test for 
novel SME molecules. A parent molecule was selected based on initial 
screening. Structural similarity testing tools were employed to identify novel 
structural analogues of the parent molecule and test them using the HT 
platform. Multiple analogues were shown to boost qP and/or product titer. While 
the parent molecule has been shown to improve volumetric titer in a previous 
publication, there is no published description of its mechanistic role in cellular 
production pathways. Thus, culture performances of the parent molecule and 
one effective analogue were mechanistically deconstructed using a series of 
functional analyses. It was shown that both molecules acted epigenetically. 
Further, product quality was confirmed to be fairly similar to that of the control 
cultures, demonstrating the potential of these molecules as specific production 


















3.1. Mammalian Cell Culture 
 
 Cell Line and Routine Sub Culture 3.1.1.
 
The cell line employed in all experiments in this thesis was the Cobra 38 
suspension cell line (Cobra Biologics, Södertälje, Sweden). The line is a CHO-S 
transfectant stably producing an anti-human epidermal growth receptor 2 (anti-
HER2) like IgG1 antibody. Cells were cultured in CD CHO medium (Thermo 
Fisher Scientific, Paisley, UK), supplemented with 8 mM L-glutamine, 1% 
hypoxanthine and thymidine supplement and 12.5 µg mL-1 puromycin selection 
marker (all from Thermo Fisher Scientific). The cells were sub-cultured every 3 
to 4 days in vented Erlenmeyer shake flasks (Corning, Amsterdam, The 
Netherlands) maintained at 140 rpm, 37°C and 5% CO2. Cells were typically 
seeded at 0.2×106 cells mL-1. Routine sampling of cell growth and viability 
(Viable Cell Density (VCD)) was performed using a Vi-CELL XR cell viability 
analyser (Beckman Coulter, High Wycombe, UK) based on trypan blue 
exclusion.  
 
 Cell Cryopreservation and Revival 3.1.2.
 
Master and working cell banks for the Cobra 38 clone were prepared and stored 
at −196°C (in liquid nitrogen) for the purposes of this project. Cells were 
harvested in mid-exponential phase and pelleted at 200×g. Cells were 
resuspended in freezing media: CD CHO media containing 10% v/v dimethyl 
sulfoxide (Sigma-Aldrich, Dorset, UK) at a concentration of 1×107 cells mL-1. 
Aliquots of 1.5 mL were transferred to cryovials (Sigma-Aldrich) and frozen 
down in a rate-controlled manner in a Mr. Frosty container (Thermo Fisher 
Scientific) at −80°C. Vials were transferred into liquid nitrogen after 24 hours. 
For experimentation purposes, a vial was thawed out from liquid nitrogen and 
sub-cultured for around 20 passages. Upon removal from −196°C, the vial was 
thawed at 37°C for 2 to 3 minutes. Vial contents were transferred to a tube 
containing 8.5 mL pre-warmed CD CHO. The mixture was centrifuged at 1000 




containing all supplements (as mentioned in Section 3.1.1). Cell density was 
measured and cells were accordingly sub-cultured into a 30 mL culture at 
0.2×106 cells mL-1. 
 
3.2. Fed-Batch Culture 
 
Fed-batch experimentation was performed over a 12 day time period in shaking 
Erlenmeyer flasks (E125). Cells were seeded at 0.2×106 cells mL-1 in a 25 mL 
culture volume and incubated at 140 rpm, 37°C and 5% CO2. CHO CD 
EfficientFeed™B (Thermo Fisher Scientific) was added at 10% of the initial 
culture volume. The culture was fed on days 2, 4, 6 and 8.  
 
3.3. High-Throughput Cell Culture 
 
For HT experimentation, cells were cultivated in 96 deep well plates (square 
well, v-bottomed) (MasterBlock®; Greiner Bio-One, Gloucestershire, United 
Kingdom). Cells grown in these plates were incubated at 320 rpm (25 mm 
throw), 37°C, 5% CO2 and 85% humidity (unless specified otherwise). The 
plates were covered with vented lids and secured using clamps (“System 
Duetz”; Enzyscreen B.V., Heemstede, Netherlands). Cells were seeded at 
0.2×106 cells mL-1 with a seeding volume of 450 µL (unless specified 
otherwise). Cells were cultured for 5 days before culture attributes were 
recorded, unless otherwise stated.  
 
3.4. Alternative Culture Formats 
 
Cultures were generally performed in shake flasks or DWPs. For some 
experimentation (stated where so), culture methodology was varied. Some 
experiments was performed in TubeSpin® Bioreactor 50 (TPP, Trasadingen, 
Switzerland). The working volume was 10 mL and cultures were maintained at 
170 rpm (50 mm throw), 37°C and 5% CO2. Experimentation was also 




(NUNC™; Thermo Fisher Scientific). Cultures were incubated in static, 
humidified conditions at 37°C and 5% CO2. The working volume was 90 µL per 
well. 
 
3.5. High-Throughput Measurement of Cell Growth Performance 
 
 Viable Cell Population: PrestoBlue Assay 3.5.1.
 
The viable cell population in each well in a 96 DWP was measured using the 
PrestoBlue™ Cell Viability Reagent (Thermo Fisher Scientific). PrestoBlue™ is 
a cell permeable, blue, resazurin based solution that is virtually non-fluorescent. 
When added to wells containing viable cells, the solution is converted to a 
highly fluorescent, red coloured compound (known as resorufin), due to the 
reducing environment of a living cell. The fluorescence intensity is a direct 
indication of the viable cell population in the well.   
45 µL of culture sample was taken from each well of a DWP and transferred to 
a 96 well clear flat-bottomed microplate (Nunc™, Thermo Fisher Scientific) 
containing 45 µL of cell culture media (1:1) dilution (unless otherwise stated). 
Typically, 3 media-only samples (blanks) were included on each assay plate to 
account for background fluorescence. PrestoBlue™ was diluted 1:1 in cell 
culture media to make a fresh stock of PrestoBlue mix. 20 µL of the PrestoBlue 
mix was added to each sample containing well. Plate mixing was performed 
using orbital shaking at 700 rpm for 20 seconds before being incubated in the 
dark at 37°C for 30 minutes. Post incubation, the fluorescence intensity of each 
well was measured using the PHERAstar Plus (BMG Labtech, Ortenberg, 
Germany) (excitation: 540 nm; emission: 590 nm). Raw values were converted 
to final normalised readings (expressed in relative fluorescence units (RFU)) 
using the equation below: 








 Viable Cell Population and Culture Viability: Iprasense Norma 3.5.2.
 
In instances where absolute viable cell numbers and a measure of cell viability 
were required, the Iprasense Norma (HT version) (Iprasense, Clapiers, France) 
was employed. The instrument is based on lens-free microscopy (Allier et al., 
2017; Allier et al., 2018). Samples are loaded onto slides (each containing 48 
fluidic chambers) and a point source illuminates each sample. The cells diffract 
light to create distinct holograms and a sensor captures the hologram intensity 
of the sample from the selected field of view (usually set at 29.4 mm2). A 
holographic reconstruction algorithm is then employed for phase and module 
retrieval of each cell. Dead and live cells have distinct holographic signatures 
(derived from the longitudinal and Z profiles) allowing for calculation of culture 
viability.  
For total cell densities between 0.2 and 7×106 cells mL-1, a slide thickness of 
100 µm was employed with a loading volume of 10 µL. For total cell densities 
between 1.8 and 40×106 cells mL-1, a slide thickness of 20 µm was employed 
with a loading volume of 3 µL. Hologram reconstruction for cell number and 
viability determination was performed using the HORUS software (Iprasense). 
 
3.6. Recombinant Protein Quantification 
 
IgG titer was measured using the Valita™TITER assay (Valitacell, Dublin, 
Ireland). The assay can quantify any Fc-containing recombinant protein 
molecule in solution. Sample containing the IgG of interest is loaded onto a well 
(containing a fluorescently labelled peptide) in the 96 well Valita™TITER plate. 
The interaction of the IgG molecule with the fluorescent probe alters the 
polarisation state of the well. The amount of IgG present in the sample is 
directly proportional to the polarisation of the well.  
Supernatant containing the recombinant protein was diluted accordingly in cell 
culture medium (Valita™TITER assay range: 2.5-80 mg L-1). 60 µL of 
Valita™MAb Buffer (Valitacell) was added to black, pre-coated antibody binding 




multichannel pipette, the plate was incubated in the dark for 30 minutes. Post 
incubation, the fluorescence polarisation of the plate was recorded using the 
PHERAstar Plus (BMG Labtech) (excitation: 485 nm; emission (parallel and 
perpendicular): 520 nm). The polarisation value (in mP) was calculated using 
the MARS data analysis software (BMG Labtech). Sample polarisation values 
were normalised against the media-only blank controls by subtraction. Standard 
curves (using IgG1 kappa standard (Sigma-Aldrich)) spanning the assay range 
were generated to interpolate recombinant protein concentration. 
 
3.7. Equations to Quantify Cell Culture Parameters 
 
 Integral of Viable Cell Density 3.7.1.
 
The integral of viable cell density (IVCD; 106 cell day mL-1 or RFU day) between 
2 time points was calculated as follows: 
!"#$ =  !!  + !!2  × ∆!	
Equation 3.2 
where !! and !! are the viable cell densities (106 cells mL-1 or RFU) at the first 
and second time points and ! is the time (days) between the time points. 
 
 Specific Productivity 3.7.2.
 
Specific productivity, also known as qP (pg cell-1 day-1 or mg L-1 RFU-1 day-1) 
was calculated using the following equation: 
!" =  !! − !!!!  + !!
2  × ∆!
	
Equation 3.3 
where !! and !! are the protein titer levels (mg L-1) at the first and second time 
points. !! and !! are the viable cell densities (106 cells mL-1 or RFU) at the two 





3.8. Small Molecule Enhancer Preparation 
 
The SME molecules employed in this study were ordered from commercial 
suppliers in powder or solubilised forms (Suppliers detailed in Table 5.1). 
Powder SMEs were solubilised in the solvent of choice (deionised water, 
dimethyl sulfoxide or ethanol; in accordance with powder manufacturer 
recommendations) to create stock solutions. Each stock in deionised water was 
filter sterilised using 0.2 µm filters (Corning). Stocks were stored at 4°C for 
short-term storage and at −20°C for long-term storage. 
 
3.9. Flow Cytometry 
 
 Cell Cycle Analysis 3.9.1.
 
Cells were fixed for cell cycle analysis using 4% paraformaldehyde (PFA; Alfa 
Aesar, Lancashire,UK).  
1×106 cells were harvested from culture and spun at 200×g for 3 minutes. After 
medium removal, the cells were washed with warm 1×phosphate-buffered 
saline (PBS) (Thermo Fisher Scientific) and centrifuged again. The cells were 
then incubated in cold 4% PFA at a concentration of 1×107 cells mL-1 for 15 
minutes at 4°C. After incubation, the PFA solution was removed. Cells were re-
suspended in cold PBS and stored at 4°C for further analysis.  
Flow cytometric analysis was carried out on the Attune Acoustic Focusing 
Cytometer (Thermo Fisher Scientific). FxCycle™ PI/RNase Staining Solution 
(Thermo Fisher Scientific) was employed for cell cycle analysis. The staining 
solution contains propidium iodide (PI), a nucleic acid binding fluorescent dye 
and RNase to ensure that the dye does not bind to RNA and only DNA content 
is measured. Measuring DNA content allows for differentiation of cells into 
various phases of the cell cycle (Gap 1 (G1), Synthesis (S) and Gap 2(G2)). 
The cells were centrifuged to remove the PBS storage solution. The cell pellet 
was re-suspended in 0.5 mL of FxCycle™ PI/RNase Staining Solution. The 




the flow cytometer using a 488 nm excitation laser and the emitted fluorescence 
captured using a 574/26 bandpass filter (BL2). At least 10,000 cell events were 
recorded. Data was analysed using the Attune Cytometric Software (version 2) 
(Thermo Fisher Scientific). 
 
 Apoptosis Analysis 3.9.2.
 
The apoptotic state of the cell (early apoptosis, dead) was assessed using the 
PE Annexin V Apoptosis Detection Kit I (BD Biosciences, Berkshire, UK) 
according to the manufacturer’s instructions. The apoptosis indicator Annexin V 
is supplied as a complex with phycoerythrin (PE), a fluorophore.  
An aliquot of 1×106 total cells was taken from culture and pelleted at 200×g for 3 
minutes.  Cells were washed twice in cold PBS. Cells were then pelleted and re-
suspended in 1×binding buffer (as provided in the kit) to a concentration of 
1×106 cells mL-1. 100 µL of the solution was transferred to a new eppendorf and 
5 µL each of Annexin V (apoptosis indicator) and 7-amino-actinomycin D (7-
AAD) (a dead cell indicator) was added to the solution. The cells were gently 
vortexed and incubated for ~15 minutes in the dark. 400 µL of 1×binding buffer 
was added prior to analysis on the Attune Acoustic Focusing Cytometer 
(Thermo Fisher Scientific). ~10,00 total events were analysed for each sample. 
Unstained samples and samples containing either 7AAD or Annexin V were 
used as controls for compensation. Samples were excited by the 488 nm laser 
and emitted fluorescence captured using a 574/26 bandpass filter (BL2: PE) 
and a 690/50 bandpass filter (BL3: 7-AAD). Data was analysed using the Attune 
Cytometric Software (version 2) (Thermo Fisher Scientific). 
 
3.10.  Measurement of Cellular mRNA 
 
Real-time quantitative PCR (qPCR) was employed to quantify mRNA levels of 






 RNA Extraction 3.10.1.
 
Total RNA was extracted from cells using the RNeasy® Mini Kit (Qiagen, 
Crawley, UK) according to the manufacturer’s instructions. 1×106 cells were 
harvested from culture. The cells were disrupted using Buffer RLT and 
homogenised using a QIAshredder spin column (Qiagen). Samples were then 
applied to RNeasy spin columns. Total RNA bound to the membrane and 
contaminants were washed away. RNA was eluted in nuclease free water 
(Qiagen). Purity was confirmed using 260:230 nm and 260:280 nm absorbance 
ratio measurements on the NanoDrop spectrophotometer (Thermo Fisher 
Scientific). RNA samples were stored at −20°C until further use. 
 
 Reverse Transcription 3.10.2.
 
800 ng of extracted RNA was reverse transcribed into cDNA using the 
QuantiTect® Reverse Transcription kit (Qiagen) according to the 
manufacturer’s instructions. The procedure comprised 2 main steps: Elimination 
of genomic DNA and cDNA synthesis. Quantiscript Reverse Transcriptase was 
used to convert RNA into cDNA. For each RNA sample, an extra reverse 
transcription reaction was performed in the absence of reverse transcriptase. 
These served as negative controls for qPCR reactions, to establish the 
presence of genomic DNA post the elimination step.  
 
 Real-Time Quantitative PCR (qPCR) 3.10.3.
 
cDNA was diluted 1 in 1000 in nuclease free water (Qiagen) before performing 
qPCR reactions on a 7500 Fast Real-Time PCR system (Applied Biosystems, 
Cheshire, UK). Reaction mixtures (25 µL) contained the following components: 
12.5 µL of 2×QuantiFast SYBR Green PCR Master Mix, 2.5 µL primer mix (final 
concentration of 200 nM per primer), 2 µL cDNA and 8 µL of nuclease free 
water. These mixtures were set up in MicroAmp Fast Optical 96-well plates 




minutes 95°C for 15 minutes, 40 cycles at 94°C for 15 seconds and 60°C for 60 
seconds. Each plate contained negative controls as follows: reactions 
containing no template and reactions containing product in the absence of 
reverse transcriptase (as mentioned in Section 3.10.2). Each sample was run 
in triplicate and mean cycle threshold (Ct) values were recorded. 
Primers for cDNA corresponding to the recombinant antibody heavy and light 
chain mRNA were employed. Internal reference controls used were: Mmadhc 
and Fkbp1a (Brown et al., 2018). All primer sequences are shown in Table 3.1. 
Primer efficiencies were tested by melting curve analysis using a 10-fold serial 
dilution standard curve of sample cDNA (performed from 60°C-95°C post 
amplification steps).  
Table 3.1 Primer sequences for genes employed in the qPCR study. 
Gene Primer sequence 
IgG1 Light chain CAGCAAGGACAGCACCTACA 
GACTTCGCAGGCGTAGACTT 








Efficiency was calculated using: 




All primer efficiencies were between 98 to 101% (see Appendix A). 
Heavy and light chain mRNA levels were quantified using the 2−ΔΔ Ct method 







3.11. Mass Spectrometry: Histone Modification Analysis 
 
10×106 cells were pelleted by centrifugation at 200×g for 5 minutes. Pellets 
were stored at −20°C till further analysis. Histones were extracted from the cells 
as described below and fragmented into peptides that were analysed by mass 
spectrometry, different charge states were analysed and histone modifications 
identified. Acetylation and methylation were the identified modifications and 
relative abundance was calculated for each unique modification in the peptide 
analysed.  
Histone preparation, mass spectrometry and data analysis was performed by 
PhD student Eleanor Hanson at The University of Sheffield. 
Histones were extracted using acid extraction detailed in Shechter et al. (2007). 
The extracted histones were washed twice in ice cold acetone and dissolved in 
100 µL HPLC grade water. Chemical derivatisation of histone proteins was 
performed with propionic anhydride as detailed in Garcia et al. (2007). 
Propionylation was performed twice. Trypsin digestion was performed on the 
derivatised histones. These methods are explained in more detail in Appendix 
A. 
Propionylated histone samples were re-suspended in 30 µL of 0.1% 
trifluoroacetic acid (TFA). HyperSep™ Hypercarb tips (Thermo Fisher Scientific) 
were primed for use with five 20 µL washes using elution buffer (90% 
acetonitrile (ACN), 0.1% TFA) followed by 5×20 µL washes using binding buffer 
(0.1%TFA). Peptides were bound on the tips by ~100 aspirations in volumes of 
20 µL. The tip was washed twice with 20 µL of binding buffer. The peptides 
were eluted into fresh eppendorfs using 200 µL of elution buffer in increments of 
20 µL. 80 µL of binding buffer was added to the tube prior to drying down using 
the SpeedVac (Thermo Fisher Scientific). 
Samples were re-suspended in 0.1% TFA prior to being run on the QE-HF 
Orbitrap mass spectrometer (Thermo Fisher Scientific) coupled to an UltiMate 
3000 HPLC (Dionex; Thermo Fisher Scientific). A PepMap300 c18 trapping 
column was used along with a 50 cm×75 um EASY-Spray PepMap c18 




nL/min and column temperature maintained at 40°C. Buffers employed were as 
follows: 
Buffer A: 0.1% Formic acid, 3% ACN 
Buffer B: 0.1% Formic acid, 80% ACN 
Loading buffer: 0.1% TFA, 3% ACN 
Samples were injected into the trapping column and washed with Buffer A for a 
minute. This was followed by elution onto the analytical column, with Buffer B 
applied at a gradient rising from 3% to 25% over 55 minutes and then from 25% 
to 60% over 26 minutes (see Appendix A). 
Data was collected using Data Independent Acquisation (DIA). MS1 and MS2 
resolution detailed in Appendix A. Sample data was analysed using Skyline 
(MacLean et al., 2010). A spectral library using data dependent analysis of 
CHO histones (created by Eleanor Hanson) was employed. Modifications to the 
N-terminus were set up as separate modifications. Histones H3 and H4 were 
analysed with each modified peptide entered as a separate entity into Skyline. 
MS2 data was employed to manually identify the correct peak. The area under 
the peak was extracted from the MS1 scan using the MStats package. Relative 
abundance was calculated as follows: 
!"#$%&'" !"#$%!$&' = !"#! !"#$% !"#$ !"#$"%!#& !" !"#$%#&#"'!"# !" !"" !"#!"#$#%& !"#$"%!#!$% !"# !ℎ! !"!#$%" 
Equation 3.5 
 
where a proteoform is a unique modified version of the peptide.  
 
3.12. Glycoform Analytics 
 
 Protein A Purification of IgG1 3.12.1.
 
On day 6 of batch culture, all available culture volume (30-50 mL) was 
centrifuged at 200×g, supernatant collected and stored at −80°C till further use. 




Healthcare Life Sciences, Buckinghamshire, UK) were utilised for antibody 
purification. These columns have high specificity for the Fc region of IgG 
molecules and can bind up to 30 mg of human IgG mL-1 of medium (GE 
Healthcare, 2014). Buffers were prepared as follows:  
Binding buffer: 20 mM sodium phosphate, 0.15 M NaCl, pH 7.2 
Elution buffer: 0.1 M sodium citrate, pH 3.5 
Neutralisation buffer: 1 M Tris-HCl, pH 9.0 (~250 µL per 1 mL fraction) 
Cleaning-in-place wash buffer: 0.5 M NaOH 
Supernatant was filtered through a 0.2 µm filter (Corning) before application to 
the column. Sample and buffers were applied to the column using a 50 mL 
syringe (BD Biosciences) driven by a syringe driver at flow rates in accordance 
with manufacturer instructions. Eluted antibody was collected in fractions of 5 
for each condition. Cleaning-in-place was performed immediately after elution to 
prepare the column for the next purification. 
Purity (A260/230: 0.5-0.6) and concentration of each fraction of the eluted 
antibody was determined using the NanoDrop spectrophotometer (Extinction 
coefficient 15.00) (Thermo Fisher Scientific). Fractions were collated 
accordingly. Samples were run on an SDS-PAGE gel to confirm presence of 




SDS-PAGE was run under reducing and non-reducing conditions to confirm 
presence of IgG antibody after purification and to detect any degradation. Pre-
cast NuPAGE™ 4-12% Bis-Tris gels (Thermo Fisher Scientific) were employed. 
2 µg of protein was prepared for each well along 2.5 µL of NuPAGE™ LDS 
Sample Buffer (4×), 1 µL NuPAGE™ Reducing Agent (10×) (both Thermo 
Fisher Scientific), and deionised water to make up a total of 10 µL. The 
reducing agent was omitted for the non-reducing condition. Reducing sample 




Samples were loaded appropriately on the pre-cast gels contained in a XCell 
SureLock™ Mini-Cell gel running tank (Thermo Fisher Scientific). A protein 
standard (Chameleon™ Duo, LI-COR UK, Cambridge, UK) was included on 
each gel. 1×NuPAGE™ MOPS SDS running buffer (Thermo Fisher Scientific) 
was added to the chamber and the gel run for 50 minutes at 200 V. The gel was 
removed from the cassette, washed and stained using Coomassie Blue staining 
(Thermo Fisher Scientific). 
  
 N-Glycan Analytics 3.12.3.
 
Purified protein samples were provided to the NIBRT Glycoscience group in 
Dublin for glycosylation analysis. Analysis was performed by Dr Roisin 
O’Flaherty and Dr Karen P. Coss. 2-aminobenzamide (2-AB) derivatised N-
Glycans were analysed by Ultra-High Performance Liquid Chromatography 
(UPLC).  
Briefly, glycoprotein denaturation and glycan release was performed as follows: 
55 µL of denaturation buffer (100 mM ammonium bicarbonate (ABC), 12 mM 
dithiothreitol (DTT)) was added to each sample containing well (5 µL) in a 96 
well v bottom microplate (Greiner Bio-One). The mix was incubated at 65°C, 
700 rpm for 30 minutes. After cooling, 10 µL of 120 mM iodoacetamide solution 
was added, and the mix was incubated at room temperature, 700 rpm for 30 
minutes. 10 µL of trypsin (40,000 U/mL) solution was added and the mix 
incubated at 37°C, 700 rpm, 120 minutes. Next, temperature was increased to 
105°C for 10 minutes. The plate was then cooled to room temperature and 10 
µL PNGase F (New England Biolabs® (0.13 mU in 1 M ABC, pH 8.0)) added to 
each well and the plate incubated at 40°C, 700 rpm for 120 minutes. Hydrazide-
assisted glycan clean-up and glycan labelling and solid phase extraction was 
performed as previously described (Stöckmann et al., 2015). 2-AB derivatised 
N-glycans were separated by UPLC with fluorescence detection on a Waters 
Acquity UPLC H-Class instrument (Waters, Milford, MA, USA). The hydrophilic 
interaction liquid chromatography (HILIC) separations were performed using a 
Waters Ethylene Bridged Hybrid Glycan column (Waters), with 50 mM 




53% ACN at 0.56 mL/min in 30 min. Samples in 70% v/v ACN were injected (19 
µL) at 40°C. Fluorescence excitation: 330 nm; emission: 420 nm. A dextran 
ladder described previously (Royle et al., 2008) was used to assign glucose unit 
values based on retention times.  
 
3.13. Design of Experiments Methodology 
 
Experiments to test for interactions between SMEs were designed and 
analysed using the Design-Expert®10 modelling software (Stat-Ease, 
Minneapolis, USA). Full factorial designs were employed for all combinatorial 
experimentation. Each chemical enhancer (termed “factor”) was coded at 2 
levels:−1 and +1. The −1 level was set at 0 i.e. no addition of the factor. +1 level 
concentrations were based on previous experimentation. Experimental runs 
were randomised. Each design was replicated thrice to improve model 
precision. 
After experimentation, the culture attribute results (IVCD, Titer and qP) were 
entered back into Design-Expert®10 for model creation. The following steps 
summarise the analytical approach undertaken by Design-Expert®10 to model 
the combinatorial data: 
1. For each factor and combination, an effect was calculated for a culture 






Where Y is the attribute output and ! is the number of runs at a particular 
level. 
2. The effects were plotted on a half normal plot. A line was fit through the 
residual points. Any points that deviated from this line were selected as 
model terms.  
3. An analysis of variance (ANOVA) table was created to provide results on 





4. Normality of residuals was tested to validate statistical assumptions and 
test for outliers. Any outliers were removed and power transforms 
conducted where necessary. 
5. A predictive linear equation model was created based on the effects of 
the significant singular and combinatorial factors. Non-significant singular 
parent factors of significant combinations were included to maintain 
hierarchy. 













ABSTRACT:	 In	 the	 present	 competitive	 biopharmaceutical	 arena,	 high-throughput	
technologies	 have	 gained	 prominence.	 To	 rapidly	 assess	 multiple	 small	 molecule	
enhancers	 for	 CHO	 cell	 bioprocess,	 a	 high-throughput	 culturing	 and	 analytical	
platform	was	crucial.	We	tested	and	optimised	high-throughput	cell	growth,	viability	
and	 product	 titer	 measurement	 technologies.	 To	 accurately	 determine	 viable	 cell	
growth,	 we	 employed	 the	 PrestoBlue	 assay.	 The	 assay,	 based	 on	 the	 metabolic	
activity	of	a	living	cell,	had	a	large	dynamic	counting	range	(0.22	to	7×106	cells	mL-1)	
and	 compared	 favourably	 with	 the	 Vi-CELL	 XR.	 Additionally,	 we	 investigated	 and	




range	 was	 found	 to	 be	 1.25	 to	 80	 mg	 L-1.	 To	 develop	 microscale	 culturing	
methodologies,	 we	 explored	 the	 use	 of	 shaking	 deep	 well	 plates	 using	 the	 Duetz	
platform,	which	 allowed	 plates	 to	 be	 clamped	 in	 place	with	 covers	 that	minimised	





production	 performance	 was	 highly	 similar	 to	 that	 of	 shake	 flasks	 at	 the	
aforementioned	conditions,	with	cultures	lasting	7	days.	Lastly,	we	evaluated	the	best	
timing	of	addition	for	qP	enhancers.	Some	well-known	qP	enhancers	were	utilised	in	
the	 study.	 Day	 3	 addition	 of	 the	 chemical	 generally	 yielded	 higher	 increases	 in	
product	yield	with	titers	reaching	up	to	3	fold	higher	than	the	control	cultures	at	the	








The development of the HT culturing platform was undertaken in collaboration 





Before embarking on the development of a HT media additive screening tool, it 
was imperative to design a standardised testing platform. Shake flask 
experimentation is laborious in nature, wherein large numbers of parallelised 
flask experimentation are tedious (Amanullah et al., 2010). Thus, the shift 
towards HT technologies to accelerate biopharmaceutical manufacturing 
processes is understandable. The biopharmaceutical industry has a large 
repertoire of HT screening technologies, most of which are employed in cell line 
development, clone selection and process development (Hansen et al., 2015; 
Rouiller et al., 2013; Rouiller et al., 2016). HT miniaturised culturing 
technologies like the ambr 15 (Sartorius Stedium biotech,) and Biolector (m2p-
labs GmbH, 2018) present added benefits of sophisticated in-line monitoring of 
process parameters like pH and dissolved oxygen for multiple cultures (Long et 
al., 2014) (as discussed in Section 1.6). However, the capital cost incurred by 
the utilisation of these technologies is high, resulting in low adoption rates in 
small and medium sized enterprises. Additionally, these technologies 
(especially the ambr 15) lack flexibility towards the incorporation of closed box 
media additive screening technologies that the commercial product is 
envisioned to be. Shallow microplate and deep well plate culturing technologies 
present low cost, facile technologies for miniaturised parallel HT 
experimentation (Long et al., 2014). The ability of these technologies to be 
adapted for shaking culturing allows for a suitable miniaturisation of shake 
flasks and stirred tank bioreactors. The “System Duetz”, initially developed for 
microbial culturing, has been readily adapted for CHO cell culturing and allows 
for multi-well plate culturing at high speeds that promote efficient culture mixing 
and gas exchange (Barrett et al., 2010). The Duetz system is based on 




prevent evaporation and contamination (detailed explanation in Section 4.3.5) 
(Chaturvedi et al., 2014; Duetz, 2007). The platform is cost-effective, however, 
does not offer online monitoring as the other systems mentioned above (Long 
et al., 2014). The platform is readily adaptable to different plate types, culture 
volumes and shaking speeds. Traditional media and feed optimisation require 
intense component and mixture screening (Chaturvedi et al., 2014). Media 
optimisation techniques such as media blending, along with bioactive small 
molecule screens have employed DWP culturing along with “System Duetz” in 
previous industry studies (Brühlmann et al., 2017b; Rouiller et al., 2013). This 
indicates the successful application of this technology in industry. DOE 
technologies allow for testing for component interactions and can be readily 
tested in a multi-well plate based screening platform as evidenced in previous 
literature (Brühlmann et al., 2017b).  
We have to consider the potential commercialisation of the HT media additive 
screening platform that we aim to develop. It would not be ideal to develop a 
product that would have rigid requirements (such as having the sophisticated 
ambr 15 platform with in-line monitoring of pH). We would want a platform that 
can be easily adapted to the company’s already available culturing 
technologies. Microplate and DWP culturing present simple, standard solutions 
that would enable easy adoption into the available incubator technologies in 
industry. Thus, these technologies were mainly focused upon for the 
development of the media additive screening tool. While literature is available 
on culturing methodologies using microplates and shaken DWP cultures (Allen 
et al., 2008; Brühlmann et al., 2017b; Hansen et al., 2015; Rouiller et al., 2013), 
a multitude of factors influence the culturing efficacy in this miniaturised platform 
(Duetz, 2007; Duetz and Witholt, 2004). Thus, our studies focused upon 
optimisation of the multi-well plate culturing modalities.  
Another component of the HT screening platform would be the implementation 
of HT analytics. Growth and production titer were focused upon as the most 
crucial attributes that were required to evaluate SME efficacy. This chapter 
delves into the evaluation of available assays and instrumentation for the 
determination of cell growth, viability and titer.  
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Overall, this chapter describes the experimentation involved in the development 
of the HT screening platform. Two aspects of the platform are focused upon: HT 
culturing and HT analytics for growth and titer. Additional analytics (such as 
product quality) or implementation of fed-batch culturing at small scale can be 
thought of as future prospects to consider to further enhance the HT platform 
described in this chapter. 
 
4.2. Experimental Approach 
 
A systematic approach was adopted for the development of the HT screening 
platform. The ideal HT culturing platform would be one that (i) contained 
multiple parallel culturing (for example 96 wells) (ii) followed the same growth 
and production profile as a higher scale platform (for example shake flasks), (iii) 
was able to support long term cultures (for example a 7 to 8 day batch culture), 
(iv) was flexible (for example addition of feeds for fed-batch production 
culturing) and (v) had ample culture volume to allow for multiple analytics from 
the same culture well. All experimentation was performed using the Cobra 38 
CHO cell line. Firstly, the most simplistic HT platform readily available in the 
laboratory was evaluated: static microplate culturing. Analysis of that platform 
revealed it to be non-ideal for our purposes. Due to this, a survey of potential 
alternative culturing platforms was performed and 96 deep well plate culturing 
was evaluated as a HT platform for SME screening. Initial experimental 
evaluation was followed by optimisation and characterisation. In parallel, HT 
analytical technologies were evaluated for the culture attributes of interest: cell 
growth, viability and production titer. Herein, the criteria for selecting an ideal 
analytical assay would be based on (i) cost, (ii) throughput, (iii) assay time and 
(iv) ease of use. After the finalisation of the culturing and analytical platforms, 
different days of addition were evaluated to understand the impact of timing of 
addition of the SME on culture performance. Finally, chemical solubilisation 
vehicles were tested to account for and minimise any impact on cell culture 







 Evaluation of Cell Growth Measurement Technologies 4.3.1.
 
The ability to screen multiple SMEs in parallel required high-throughput 
analytics. Cell growth analytics formed a vital part of our HT platform, since it is 
important to determine cytotoxicity, growth suppression or growth improvement 
as a result of the SME addition. There are multiple fluorescence multi-well plate 
based assays commercially available to determine viable cell populations. We 
chose to employ the PrestoBlue assay (using the PrestoBlue™ Cell Viability 
Reagent (Thermo Fisher Scientific)) primarily due to its ease of use. Incubation 
times are quicker compared to similar cell viability assays (minimum 10 minutes 
vs. minimum 1 hour (alamarBlue) (Thermo Fisher Scientific,). It is highly 
sensitive in comparison to other metabolic cell viability assays, such as 
alamarBlue and MTT assay (Thermo Fisher Scientific, 2012), and can detect as 
low as 10 viable mammalian cells per well.  
Since a high variation in viable cell number was expected in one experimental 
setup, i.e. high control cell numbers vs. extremely low viable cell population due 
to small molecule toxicity vs. SMEs that improve cell growth, it was vital that our 
growth performance assessment methodology was sensitive across a larger cell 
concentration range. We tested a standard curve of cell concentrations ranging 
from 0.22 to 28×106 cells mL-1. Each concentration in the dilution series was 
double that of the previous one. The cell concentrations were also measured on 
the Vi-CELL XR (Beckman Coulter) (based on trypan blue exclusion), which 
served as the cell counting standard in this case. The standard curve is 











Figure 4.1 Standard curve profile of increasing cell populations using PrestoBlue 
assay in comparison to Vi-CELL XR. A viable cell concentration standard curve was 
created from 0.22 to 28×106 cells mL-1. 90 µL of sample for each cell concentration was 
transferred to 3 wells on a 96 well microplate. 20 µL of the PrestoBlue mix 
(PrestoBlue™ reagent to CD CHO media 1:1) was added to each well and the plate 
was incubated for 30 minutes at 37°C, away from light. 3 control wells containing CD 
CHO media were also included to account for background fluorescence. The sample 
fluorescence values were normalised to the media-only fluorescence. Samples were 
also run on the Vi-CELL XR for comparative purposes. PrestoBlue data is plotted on 
the right y-axis while the Vi-CELL XR data is plotted on the left y-axis. Presto blue data 
is represented as the mean and standard error of three experimental replicates, each 
with three technical repeats. The Vi-CELL data is represented as the mean and 




The PrestoBlue readings displayed consistent doubling in fluorescence values 
until the 7×106 cells mL-1 (Concentration 6). Post that cell concentration, there 
was saturation in fluorescence values observed. Conversely, the Vi-CELL XR 
displayed accurate doubling in cell concentration across all points tested. It 
would be possible to curb any inaccuracies in PrestoBlue readings above 7×106 
cells mL-1 using 3 possible actions: lowering incubation time, adding more 
PrestoBlue reagent or diluting the cells to be within the linear dynamic range of 
the PrestoBlue assay. Application of the first action point could lead to 
ambiguity and might require further optimisation of the ideal incubation time. It 












































could also translate to lower sensitivity at the lower end of the cell concentration 
curve due to the lower incubation time. Application of the second action point 
would result in an increased cost and would require further optimisation. Thus, 
for simplicity, the third approach was employed where necessary. 
 
	
Figure 4.2 Correlation of PrestoBlue Assay and Vi-CELL XR. The fluorescence 
values within the accurate dynamic range of the PrestoBlue assay as tested in Figure 
4.1 (between 0.22 and 7×106 cells mL-1) were plotted against the values recorded on 
the Vi-CELL XR. Linear regression line was fitted and R2 calculated. Mean values 
plotted for both measurement techniques with error bars representing standard error of 




From Figure 4.2, it was evident that within its accurate range, the PrestoBlue 
assay yielded a strong linear correlation with the Vi-CELL XR. The PrestoBlue 
assay is based on the metabolic activity of a living cell. The active reagent is 
a cell permeant, non-fluorescent dye, resazurin, which when comes in contact 
with the reducing environment of a living cell is converted to resorufin, a highly 
fluorescent compound that is red in colour (Thermo Fisher Scientific, 2012). The 
conversion to the reduced form is initiated mainly by mitochondrial enzyme 
activity, with resazurin accepting electrons from NADH, NAPDH and FADH (Xu 
et al., 2015). Thus, only viable cell population is measured that is directly 
proportional to the fluorescence intensity of the sample. In contrast, the Vi-
CELL XR is based on the membrane integrity of cells. Here, the active 
























ingredient, trypan blue can only enter cells with compromised membranes, i.e. 
dead cells. Thus, it is based on the exclusion of trypan blue and directly 
labels dead cells. Images are captured using a camera and cells that have 
visibly not taken up the dye are classed as living. It is evident that there is a 
huge mechanistic contrast between the two techniques. However, they were 
highly comparable. With the cost of assaying one well being 3.5 pence (Thermo 
Fisher Scientific,), PrestoBlue was selected as the main assay for growth 
performance assessment based on low cost, high sensitivity and quick 
turnaround. 
The major limitation of PrestoBlue is the inability to quantify viability percentage 
of the cell population tested. It was deemed that viability determination was not 
required for concentrations of chemicals that were ineffective in enhancing cell 
growth or titer. However, it was vital to determine if, at the effective dose (one 
that produced an improvement in growth or titer), there was detriment to 
viability. For small sample sizes, the Vi-CELL XR was employed, however, for a 
large set of samples, the Iprasense Norma (Iprasense) was utilised. The Norma 
works on the principle of light diffraction. Viable and dead cells have different 
light diffraction profiles. Samples are loaded on a flat slide with 48 chambers for 
increased throughput. Automated analysis is performed by illuminating each 
chamber, with a sensor recording the hologram intensity. A hologram 
reconstruction algorithm is employed to retrieve and reconstruct the hologram 
profile of each cell, which is then marked as live or dead based on the similarity 
to the standard live and dead profiles. This allows for the determination of viable 
cell densities, total cell densities and percentage viability per sample.  
A cost (56 pence per sample) and resource restraint prevented the Norma from 
being adopted for every screening experiment. However, it still served as a 
useful tool for selected experiments wherein absolute cell numbers were 
required and where viability of large numbers of cultures needed to be 
determined. As with the PrestoBlue assay, the cell number determination 
accuracy was compared with the Vi-CELL XR. Two slide thickness modes are 
available, 100 µm thickness slides that are more ideal for low cell numbers and 







Figure 4.3 Standard curve profile for the Iprasense Norma in comparison to the 
Vi-CELL XR. A standard curve ranging from 0.22 to 28×106 cells mL-1 (99% viability on 
the Vi-CELL XR) was tested on (A) 20 µm and (B) 100 µm slide thickness. Each 
concentration in the series is double the previous one. For the 20 µm thickness slides, 
3 µL of sample was loaded into each chamber. For the 100 µm thickness slides, 10 µL 
was loaded into each chamber. The slides were placed in the Norma reader and cell 
concentration and viability was computed using the HORUS software. The data for 
Norma readings is represented by the mean and standard error of three experimental 
replicates, each with three technical repeats. The Vi-CELL XR data is the mean and 




Figure 4.3 summarised the cell counting performance on both the slide 
thickness modes on the Norma and compared performance against the Vi-
CELL XR. It was evident that the Norma typically counted less cells in 
comparison to the Vi-CELL XR, irrespective of the plate thickness used. The 2 
different plate thickness modes are suggested for accurate reading across a 
large concentration range. The 20 µm thickness represents a slide chamber 
that is comparatively thinner than its counterpart and can only hold a 3 µL 
volume. A higher cell density can be loaded using these slides. Our data 
revealed that while the curve was linear and showed doubling for each 
concentration point across the range tested, viability readings were heavily 
skewed towards a total lower viability at the lower concentration range (dilutions 
1, 2 and 3) (data not attached). This indicated that the extremely low sample 
volume had a negative impact on the accurate differentiation of live and dead 
diffraction profiles at low cell concentrations. In addition, there was extremely 
poor distinction at the lowest 2 standard curve points. Thus, it was decided that 
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the accurate counting range for the 20 µm slides was from around 1.8×106 cells 
mL-1 (Concentration 4) onwards. A linear regression line was drawn for this 
range and an equation generated to show the linear relationship with the Vi-
CELL XR readings (Figure 4.4A). Like with PrestoBlue, there was a good linear 
correlation with the Vi-CELL XR, however, the values generated by the Norma 
were consistently lower. Interestingly, the size bounds for classification of a cell 
were highly similar. To compare readings across both methods, a correction 
factor of ×1.4 was taken into account for the Norma 20 µm slides (Figure 4.4A). 
The correction factor was stable across the concentration range and confirmed 
with experimentation performed by other laboratory group personnel. 
The 100 µm slides have a comparatively larger slide chamber and thus can 
hold a larger sample volume of 10 µL. This allows for a lower cell concentration 
to be determined accurately. This was evident from Figure 4.3B, wherein an 
accurate doubling in concentration was observed up to 7×106 cells mL-1 
(Concentration 6). Post this concentration, a plateauing of cell number and 
variable viability readings were observed. Like with the 20 µm slides, a linear 
regression plot was constructed to quantify the linear relationship with the Vi-
CELL XR (Figure 4.4B). 
It was observed that for the 100 µm slides, the Vi-CELL XR recorded double the 
cell density. This was consistent across the concentrations tested that fell within 
the accurate counting range. Thus, for any comparative analysis between the 
two measurement techniques, a correction factor of ×2 was adopted for the 100 















Figure 4.4 Linear regression analysis to investigate Norma and Vi-CELL XR 
count correlation. (A) represents the 20 µm thickness slides that had an accurate 
counting range from 1.8×106 cells mL-1 onwards. (B) shows the 100 µm thickness 
slides that had an accurate reading range from 0.22 to 7×106 cells mL-1. The viable cell 
densities recorded on the Norma (x-axis) were plotted against the Vi-CELL XR value 
(y-axis). Linear regression was fitted and R2 calculated (>0.99 in both cases). Mean 
values plotted for both measurement techniques with error bars representing standard 




 Evaluation Of Cell Viability Measurement Technologies 4.3.2.
 
As shown in the previous section, the Iprasense Norma can be employed to 
determine viable cell numbers in a high-throughput manner. While the 
PrestoBlue assay is available for viable cell population determination, its major 
drawback stems from its inability to evaluate culture viability as a whole. The 
Norma, though considerably more expensive than the PrestoBlue assay (56 
pence vs. 3.5 pence), overcomes this drawback. Thus, in cases where viability 
needed determination, the Norma was employed.  
A series of culture viabilities were trialled in both the slide sizes available and 
compared against the Vi-CELL XR (Figure 4.5). Both slides showed a strong 
linear correlation with the Vi-CELL XR. The trends followed were the same 
across all the methodologies tested, with each technique able to distinguish 
between high and low viable cultures. The 100 µm thickness slides (Figure 
4.5B) were relatively more sensitive at detecting extremely low viabilities than 





















Y = 1.363*X + 0.7643
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the 20 µm slides. Overall, both the slides were competent in differentiating 
between high and low viable culture populations. 
  
	
Figure 4.5 Viability comparison of the Iprasense Norma and the Vi-CELL XR. A 
series of differing viability samples beginning at about 100% viability and going down to 
20% (according to the Vi-CELL XR) were tested on the 20 and 100 µm slides on the 
Iprasense Norma. 3 µL of sample was added to the 20 µm thickness slides. 10 µL of 
sample was added to the 100 µm thickness slides. Viability was determined based on 
the light diffraction profile for each cell. Readings were taken on the Vi-CELL XR for 
comparison purposes. Viability on the Vi-CELL XR was determined using the trypan 
blue exclusion method. The data is represented as the mean and standard error of 




 Evaluation of Titer Measurement Technologies 4.3.3.
 
To enable screening of large numbers of singular and combinatorial SME 
deployment strategies for increased titer, HT methodologies for antibody titer 
measurement were necessary. We adopted the Valita™TITER assay 
(Valitacell) to quantify the antibody titer levels in our screens. The assay 
presents a quick, HT and cost-effective measuring methodology that spans a 
large dynamic range (1.25 to 80 mg L-1). Currently available titer measurement 
technologies are either low-throughput (Protein A high-performance liquid 
chromatography (HPLC)), have narrow dynamic ranges (Enzyme-linked 
immunosorbent assay (ELISAs)) or incur large costs (Biolayer interferometry) 
(Thompson et al., 2017). The Valita™TITER assay negates the aforementioned 
drawbacks and was thus perfectly suited for our purposes. The assay is 
viability	






































presented in a multi-well microplate format allowing for a larger throughput. The 
assay is based on fluorescence polarisation. A protein G based fluorescent 
probe displaying high specificity for the Fc region of mAbs is employed. The 
fluorescent probe (also termed fluorophore) is excited by polarised light. The 
fluorophore emits light depolarised to a degree that is proportional to the rate of 
molecular rotation (Moerke, 2009). To elaborate, attachment of the protein of 
interest to the fluorophore would lower the rate of molecular rotation, and result 
in less depolarisation of light in comparison to the free fluorophore. Thus, the 
extent of polarisation is directly proportional to the amount of protein of interest 
in solution. A standard curve was plotted to confirm linearity between 1.25 and 
80 mg L-1 (Figure 4.6). The curve was stable across different plates. A 
comparison against HPLC and biolayer interferometry presented in Thompson 
et al. (2017) confirmed a good correlation (R2 >0.99) for both measurement 




Figure 4.6 Linearity of the Valita™TITER assay across the 1.25 to 80 mg L-1 
antibody concentration range. A serial dilution series of known antibody 
concentrations of an IgG1 protein standard were run on the Valita™TITER assay. 
Culture media (CD CHO) only wells were included to account for background 
fluorescence. The media polarisation values were subtracted from sample polarisation 
values. The data represented is the mean and standard error of three experimental 




































 Microplate Culture 4.3.4.
 
The culture cultivation vessel is a crucial factor that influences cell growth 
(Duetz and Witholt, 2004). High-throughput culturing methodologies are 
essential to be able to screen multiple media components and supplements. 
Shake flask cultures can be classed as low-throughput and cost ineffective, 
while sophisticated mini-bioreactors (such as the ambr 15) can be expensive 
and difficult to operate manually. Since cost, resource and automation abilities 
were limited, 96 microplates presented the most straightforward approach for 
culturing cells in a HT manner. This was the first approach deployed to develop 
a scale down culture model to rapidly test small molecule culture enhancers. 
Plates would be cultivated in static conditions, lowering the number of factors to 
optimise since shaking speed and throw optimisations were negated. Culture 
volumes were limited to 90 µL of a 400 µL total fill volume in the 96 well plates 
to allow for headspace (based on personal communication on previous work 
performed in the David James’ laboratory at The University of Sheffield). 
Comparative 8-day batch culture experimentation (using the Cobra 38 cell line) 
was performed; with 30 mL shake flask cultures serving as a benchmark. 





Figure 4.7 Static 96 well microplate culture performance evaluated against 30 mL 
shake flask cultures. Cobra 38 cells were seeded at 0.2×106 cells mL-1. Cells were 
cultivated in 96 well microplates (90 µL) and 30 mL shake flask cultures in parallel to 
investigate microplate growth and production phenotype. Growth and production were 
monitored on multiple days as shown. Cell growth and viability were monitored using 
the Iprasense Norma and IgG1 titer measured using the Valita™TITER assay. Data 
represented is the mean and standard error of the mean (SEM) of three experimental 
replicates each with three technical repeats. 
	
	
























































































There were multiple observations based on the results shown in Figure 4.7. 
Firstly, static microplates were unable to support long-term cultures. This was 
evidenced by the drop in culture viabilities day 5 onwards while Erlenmeyer 
shake flask cultures dropped in viability only on day 7. Since cultures were 
static, there was no proper cycling of nutrients or gases, with cells settling at the 
bottom of the well (Jordan and Stettler, 2014) thus failing to provide cells a 
hospitable environment for growth and proliferation. Secondly, culture IVCD and 
titer were drastically lower than shake flasks across all measured time points. 
This was expected post the early drop in viability. However, biomass 
accumulation during the first 4 days where cell viability remained high, was still 
considerably poor in comparison to shake flask cultures. This proved that viable 
cell proliferation was limited. Again, this could be attributed to a multitude of 
factors such as lack of oxygen transfer, inefficient mixing of nutrients, settling of 
cells and potential contact inhibition. To directly compare, the final IVCD 
recorded on day 8 was 4.9 fold lower than the shake flask cultures. From 
production perspective, titer recorded was 3.6 fold lower in microplates than 
shake flask cultures that recorded titers in the range of 400 mg L-1 at the end of 
culture. SMEs like copper and sodium dichloroacetate have been proven to be 
late stage culture modulators (Buchsteiner et al., 2018; Yuk et al., 2015b). 
Thus, microplate culturing, which was unable to sustain long-term cultures, 
would be ineffective in isolating such late stage modulators. Additionally, edge 
effect is a well documented feature in microplate culture (Lundholt et al., 2003; 
Wagener and Plennevaux, 2014). This effect is characterised by differences in 
cell growth between the edge wells and the rest of the plate wells. This 
phenomenon occurs mainly due to thermal gradients leading to increased 
evaporation at the edges (Lundholt et al., 2003). This discrepancy is 
undesirable and can result in a lower throughput if edge wells are to be 
negated. These shortcomings coupled with the major deviation from larger 
scale culture growth and production phenotype eliminated shallow 96 well static 
microplates as a viable culturing option for the identification of bioactive small 






 Deep Well Plate Culture Optimisation 4.3.5.
 
It was evident that 96 well microplates presented an unsuitable culturing 
methodology for SME screening. The major limitation was the short culturing 
time in comparison to shake flasks. The disparity would be further exacerbated 
when compared to higher scale platforms such as stirred tank bioreactors. This 
would directly impact the scalable predictive capabilities of the platform. It was 
hypothesised that shifting plate incubation from static to shaking mode could 
alleviate some of the cellular growth bottlenecks. Shaking plate cultures are 
slowly becoming the norm in industry to support HT clone screening and 
process optimisation (Amanullah et al., 2010; Long et al., 2014). A shaking 
deep well plate approach (“System Duetz”) developed by Duetz et al. (2000) 
was initially developed for microbial cultures but has since been widely adopted 
into mammalian cell bioprocessing (Barrett et al., 2010; Hansen et al., 2015; 
Rouiller et al., 2013). The shift to shaking microwell cultures allowed for an 
improved oxygen transfer rate (Barrett et al., 2010; Duetz and Witholt, 2004). 
We applied and optimised the Duetz system in-house to improve growth profiles 
at the microscale level. The Duetz system we employed consisted of 2 
components: A clamp system to keep the DWP secured during shaking 
conditions, and a sandwich cover (stainless steel lid (with holes) with layers of 
filter and silicone) that allowed for (i) efficient gas exchange (ii) controlled 
evaporation (no edge effects observed) and (iii) prevention of cross 
contamination (Chaturvedi et al., 2014; Duetz, 2007; Jordan and Stettler, 2014). 
The type of plate and orbital shaking speeds employed can be varied, and thus 
these factors were focused upon for optimisation experiments. 
 
 Speed, Throw and Plate Type 4.3.5.1.
 
Incubator shaking speed, orbital diameter (or throw) and plate geometry have 
all been shown to impact cell growth performance in previous studies (Barrett et 
al., 2010; Duetz and Witholt, 2004; Long et al., 2014; Zhang et al., 2008). These 
factors mainly impact oxygen transfer rates and nutrient mixing. We aimed to 
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optimise culture conditions in DWPs so that growth profiles were comparable to 
shake flask cultures.  
There are 2 major 96 deep well plate types based on well shape: round or 
square. We initially trialled a number of commercially available square and 
round 96 DWPs (data not attached), however, there were a number of plates 
that could not support viable cell growth (this is likely due to leachables 
promoting cytotoxicity (Hill et al., 2018)). Our initial screens showed that only 1 
plate type was not cytotoxic or completely suppressing cell growth. These were 
the MasterBlock® Plates (square well, v bottom) (Greiner Bio-One). These 
plates were taken forward for more extensive optimisation experiments. The 
results of varying speeds and throw while utilising the MasterBlock® square 
plates are displayed below in Figure 4.8. The speeds were selected based on 
previous literature sources and personal communication (Duetz, 2007; Duetz 
and Witholt, 2004; Hansen et al., 2015; Rouiller et al., 2013; Rouiller et al., 
2016). 4 different seeding volumes and 2 seeding densities were employed to 
give a larger design space to evaluate and inform future experimentation to 
optimise seeding densities and working volumes. All readings were taken 3 
days post-seeding (no detriment to viability was observed across all conditions). 
Growth readings were only taken on a singular day so as to rapidly evaluate a 
number of conditions. The worst performing condition was the 350 rpm and 50 
mm throw combination (Figure 4.8D), wherein the best performing sub-
condition (i.e. culture volume and seeding density combination) only reached 
58% of the control flask culture growth. It was speculated that the high speeds 
combined with a larger orbital radius was too harsh on the cells; as high shear 
stress can stagnate mammalian cell proliferation (Jordan and Stettler, 2014). In 
contrast, the best performing condition was the 320 rpm and 25 mm throw 
combination (Figure 4.8A). Herein, the 0.2×106 seeded cells mL-1 across all 
volumes grew between 60 and 72% of the flask controls. Conversely, cultures 
seeded at 0.3×106 cells mL-1 (450 and 500 µL) matched the viable cell densities 
in flask cultures seeded at 0.2×106 cells mL-1. While those cultures did not 
match their flask counterparts that were also seeded at 0.3×106 cells mL-1, this 
was the first indication that growth performance in DWPs could match those of 




type: square) certainly seemed promising. However, it remained to be seen how 
these DWP cultures would fare against shake flask cultures in a full batch 
culture setup, with readings taken daily.  
 
 
Figure 4.8 Cell growth performance in MasterBlock® 96 square DWPs varied for 
shaking speed and orbital diameter (throw). 4 combinations of speed and throw 
were assessed. Cobra 38 cells were seeded at 0.2 or 0.3×106 cells mL-1 and cultured 
in the specified culture conditions for 3 days before cell growth was evaluated. Cell 
growth and viability was recorded using the Vi-CELL-XR. A 30 mL batch culture in an 
E125 flask was included as a control to compare performance. All cell densities 
presented as a fold change to the 30 mL flask control. The plates were cultured at their 
indicated speed and throw at 37°C, 5% CO2 and 85% humidity. The control flask 
cultures were incubated at 37°C, 5% CO2 and 85% humidity, with a speed and throw of 
140 rpm and 25 mm respectively. Red dotted line indicates the level of performance in 
0.2×106 cells mL-1 seeded shake flask cultures (which was set to 1 to base fold change 
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 Seeding Density and Volume 4.3.5.2.
 
Having determined the plate type, speed and throw conditions for the DWP 
platform, it was imperative to determine if seeding densities and volumes could 
be further optimised to achieve culture profiles similar to shake flasks. 
Additionally, since previous optimisation efforts focused only on day 3 culture 
sampling, it was vital to observe culture performance profiles over a longer time 
course. Thus, we assessed 2 seeding densities (0.2 and 0.3×106 cells mL-1) 
and 4 culture volumes (400 to 550 µL). The experimentation was performed at a 
shaking speed of 320 rpm and a throw of 25 mm using the Greiner 
MasterBlock® DWPs as recommended in the previous section. The cell growth 
performance when cells were seeded at 0.2×106 cells mL-1 at various culture 
volumes is depicted in Figure 4.9. The cells in the DWPs had a slower growth 
rate in comparison to shake flasks during the exponential culture phase. This 
was in agreement with our 3 day screens that indicated a slight reduction in 
growth in DWPs. However, moving from late exponential into stationary phase, 
DWP cultures (especially 450 µL) witnessed a highly similar cell density to 
shake flask cultures. However, IVCD was still lower throughout the culture 
duration period with all culture volumes recording around 90% IVCD of the 
control cultures on day 7. Interestingly, DWP cultures witnessed a slightly less 
drastic drop in culture viability on day 7 (450 µL: 83% viable, shake flask: 66% 
viable, Appendix B). This possibly had a bearing on the titer performance on 
day 7 (Figure 4.9C). While the flask cultures plateaued with regards to 
production on day 7, DWP production rates were still high resulting in identical 
titer values on day 7 for shake flasks and DWPs. Otherwise, across the other 
days tested (days 4-6), the DWP cultures recorded titers ranging from 65% to 
80% of the flask control titer values (Figure 4.9C).  
The growth and production trajectories followed by the different culture volumes 
were highly similar and it was concluded that any volume between 400 and 550 





Figure 4.9 Batch culture performance of cells seeded at 0.2×106 cells mL-1 in 
MasterBlock® 96 DWPs with varying seeding volumes. 4 culture volumes: 400 µL (
), 450 µL ( ), 500 µL ( ) and 550 µL ( ) were assessed and compared 
against 0.2×106 cells mL-1 seeded shake flasks ( ). (A) Viable cell density was 
measured using the Vi-CELL XR. (B) shows the progression of IVCD across the 
culture period (C) depicts the antibody titer calculated using the Valita™TITER assay. 
The data depicted is the mean and standard error of three experimental replicates 
each with three technical repeats. Day 7 IVCD and Titer not significantly different for 
any condition compared to the 0.2×106 cells mL-1 shake flask (one-way ANOVA, 
Dunnett’s multiple comparisons test). 
 











































































We also investigated if increasing the seeding density allowed the culture profile 
to reach the same level as the 0.2×106 cells mL-1 seeded shake flasks. Our 
earlier studies to optimise speed and throws revealed that at certain seeding 
volumes, 0.3×106 cells mL-1 seeded cells matched the viable cell concentrations 
of the 0.2×106 cells mL-1 seeded flasks on day 3 (Figure 4.8). While this was 
promising, we were wary of exceeding the growth performance of shake flasks 
across the batch culture period. Keeping the same experimentatal model as 
with previous experimentation, we trialled 4 different culture volumes seeded at 
0.3×106 cells mL-1 across a 7-day batch culture using the IgG producing Cobra 
38 cells. The resultant growth and product profiles are displayed in Figure 4.10.  
The target profile was the 0.2×106 cells mL-1 seeded shake flasks (shown with 
black circles), however a 0.3×106 cells mL-1 shake flask profile (shown with grey 
circles) was also included for comparison. While the 0.3×106 cells mL-1 seeded 
DWP cultures could not match the 0.3×106 cells mL-1 flask profiles, they were 
able to replicate the 0.2×106 cells mL-1 flask trajectory (Figure 4.10A). 
Interestingly, on days 4 and 5, the 400 µL cultures (white square symbol) 
surpassed the cell densities observed in the 0.2×106 cells mL-1 flask cultures.  
This resulted in total IVCD for the 400 µL cultures surpassing that of the 
0.2×106 cells mL-1 shake flasks (Figure 4.10B). The other cultures recorded a 
similar IVCD to that of the 0.2×106 cells mL-1 seeded shake flasks. Surprisingly, 
the production profiles indicated that all DWPs produced slightly lower titers 
than the target 0.2×106 cells mL-1 flasks from days 4 to 6. This resulted in lower 






Figure 4.10 Batch culture performance of cells seeded at 0.3×106 cells mL-1 in 
MasterBlock® 96 DWPs with varying seeding volumes. 4 culture volumes: 400 µL (
), 450 µL ( ), 500 µL ( ) and 550 µL ( ) were assessed and compared 
against 0.2×106 cells mL-1 ( ) and 0.3×106 cells mL-1 ( ) seeded shake flasks. 
(A) Viable cell density was measured using the Vi-CELL XR. (B) shows the 
progression of IVCD across the culture period (C) depicts the antibody titer calculated 
using the Valita™TITER assay. The data depicted is the mean and standard error of 
three experimental replicates each with three technical repeats. Day 7 IVCD and Titer 
not significantly different for any condition compared to the 0.2×106 cells mL-1 shake 
flask (one-way ANOVA, Dunnett’s multiple comparisons test). 
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qP analysis on day 5 (Figure 4.11) indicated that the high speed shaking DWP 
conditions did not particularly exert stress on the recombinant protein 
production pathways. qP values across all conditions were highly similar to the 
0.2×106 cells mL-1 seeded shake flasks (qP was not significantly different for 
any condition, one-way ANOVA, Dunnett’s test). From the experimentation 
results explained above, seeding density and volume were not vital factors that 
impacted cell growth and productivity in DWPs. In this case, it could be argued 
that any of the 4 volumes and 2 seeding density combination could depict a 
valid representation of shake flask culture and thus be employed for screening 
experiments to isolate SMEs. We decided to employ a 450 µL seeding volume 
and 0.2×106 cells mL-1 seeding density. This would allow us the flexibility to 
modify the setup if required, for example the addition of feeds increasing culture 
volume and cell growth rates. Day 5 was chosen as the point in culture for the 
collection of growth and productivity data for our SME screens. 
 
	
Figure 4.11 Specific productivity of all DWP cultures tested relative to 0.2×106 
cells mL-1 seeded shake flasks. Specific productivity was calculated at the day 5 time 
point of the batch cultures depicted in Figure 4.9 and 4.10. qP is expressed as a fold 
change to the 0.2×106 cells mL-1 seeded shake flask control (indicated by the red 
dotted line). Data represented is the mean and standard error of two experimental and 























































































 Delayed SME Addition Strategies 4.3.6.
 
The optimisation of the DWP platform allowed us to create a scale-down 
culturing modality that was validated against shake flask cultures. Another 
factor that can affect SME identification is the timing of addition of the small 
molecule. The most straightforward approach of adding the chemical at day 0 
was adopted for all initial screening. However, some chemicals have been 
shown to improve titer at the expense of growth. When these types of 
chemicals are added on day 0, a massive inflation in qP is observed, however, 
titer normally does not surpass control values. Since the overarching aim of this 
project is to enhance growth and/or titer over the no addition controls, it can be 
argued that later SME addition might serve as a better strategy for these qP 
enhancing molecules. This type of “biphasic” strategy is quite common in the 
biopharmaceutical industry (for example, hypothermic culture shifts) and often 
results in a bigger boost in titer compared to implementing the strategy at day 0 
(Yoon et al., 2006). Not stifling cells’ ability to proliferate in the early stages of 
culture, results in a larger biomass capable of producing the product of interest. 
When the chemical is added at the late stage, there are more cells that can be 
manipulated by the SME to improve their production capacity.  
Applying this rationale to our HT system, we investigated different days of 
addition for qP enhancing molecules. We chose to test chemical addition on 
day 3 and day 4 (mid to late exponential stage) and compare against the growth 
and titer achieved by chemical addition on day 0. The chemicals employed for 
this trial were well known qP enhancers that have been shown to improve qP in 
mammalian cells previously. The chemicals chosen were sodium butyrate 
(NaBu) (Chen et al., 2011), Trichostatin A (TSA) (Backliwal et al., 2008), MS 
275 (Backliwal et al., 2008), sodium phenylbutyrate (4PBA) (Johari et al., 2015) 
and 2 Thiopheneacetic acid (2TAA) (Allen et al., 2008). Most of these were 
histone deacetylase inhibitors wherein their mode of titer enhancement is 
indirectly linked to growth suppression (Bora-Tatar et al., 2009; Park et al., 
2016; Sung et al., 2004). As stated earlier, we had decided to record culture 
attributes on day 5 of a 7-day batch culture process in DWPs. With delaying the 
addition of chemical, we also had to check if day 5 was too early in the culture 
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process to quantify the benefit of the addition of the chemical. Thus, we also 
recorded culture attributes on day 6 to see if we witnessed larger gains at this 
time point, having the cells incubating with the chemical for an extra day. The 
results from this experimentation are displayed in Figure 4.12. 
Figure 4.12A depicts day 5 titer performance of the Cobra 38 cells incubated 
with various concentrations of different singular SMEs added on days 0, 3 or 4. 
There was a wide spread of titer improvements across all concentrations and 
days of addition tested. Unsurprisingly, day 4 addition of the chemical yielded 
the lowest titer gains on day 5 since incubation with the chemical was only a 
single day. Interestingly though, the highest concentrations of NaBu and 2TAA 
still yielded titer gains of 1.8 to 1.9 fold even though they were present in culture 
for only one day. Generally, day 3 addition returned higher improvements in titer 
performance over day 0 addition. For example, the highest absolute titer 
yielding TSA concentration at day 0 addition (0.35 µM) still generated titer 20% 
lower than the control culture titers. However, adding the chemical on day 3, 
yielded a titer boost of 45% for the best concentration (1 µM). Both 
concentrations of 4PBA returned 70% titer increase when added on day 3 
compared to non-increase when added on day 0. Similarly, the best performing 
2TAA concentration (0.4 mM) at the day 0 addition stage returned a titer yield of 
1.6 fold over the control, however the best titer boost using the day 3 addition 
strategy was a 3.2 fold increase (2 mM). NaBu addition on day 0 recorded that 
best titer increase of 2.2 fold (0.25 mM) while day 3 addition yielded a 2.6 fold 
increase (1 mM). Interestingly, there was no real benefit of adding MS 275 on 





Figure 4.12 Titer output summary for the delayed SME addition strategies tested. 
Cobra 38 cells were seeded at 0.2×106 cells mL-1 in 96 DWPs with a total culture 
volume of 450 µL. The 5 SMEs (at various concentrations) were added to culture on 
days 0, 3 or 4 (as indicated). Antibody titer was measured using the Valita™TITER 
assay. (A) depicts the antibody yields on day 5 in DWP cultures while (B) displays titer 
recorded on day 6. The data is represented as the mean and standard error of three 




The same experiment was repeated with the cultures incubated with the 
different chemicals for an extra day with titer being assayed on day 6 (Figure 
4.12B). While the absolute titer values did increase, the change in titer relative 
to the controls mostly remained constant for the day 0 and day 3 additions 
when compared to their fold changes on day 5. Day 4 addition of the chemical 
yielded larger benefit when assayed on day 6 in comparison to day 5, due to 
the obvious longer duration. However, generally the [day 4 addition/day 6 
assay] titer fold change could not surpass the [day 3 addition/day 5 assay] fold 















Day 5 Titer Analysis
D0 D3 D4
NaBu (mM) MS 275 (µM) TSA (µM) 4PBA (mM) 2TAA (mM)















Day 6 Titer Analysis





change. For example, [day 3 addition/day 5 assay] for 2TAA yielded a 
maximum of 3.2 fold increase in titer. Conversely, a [day 4 addition/day 6 
assay] yielded a 2.6 fold increase in titer for 2TAA. Similarly, for NaBu, [day 3 
addition/day 5 assay] yielded a larger titer boost than [day 4 addition/day 6 
assay] (2.6 vs 2.1 fold). From this data, we were able to conclude that there was 
lower merit of adding the SME in culture on day 4 in comparison to day 3. Day 3 
addition improved titers over the day 0 addition for most chemicals and this was 
evident on day 5. Thus, we decided to proceed with a two-tiered screening 
strategy. Chemicals that were shown to improve qP in the day 0 screens would 
be taken forward for delayed SME screening. For the delayed addition 
screening, the chemical would be added on day 3 with culture attributes 
assayed on day 5. 
 
 Appropriate Solubilisation Vehicle Concentration 4.3.7.
Determination 
 
A general literature survey of chemical enhancers revealed that some 
chemicals require a vehicle for solubilisation (Backliwal et al., 2008). Dimethyl 
sulfoxide (DMSO) and ethanol are general choices for help solubilise otherwise 
poorly water soluble chemical candidates to form a solution. With especially 
high concentrations of the solubilising vehicles impacting cell viability and 
functional pathways (Galvao et al., 2014), it was important to evaluate what 
concentrations can negatively impact CHO cell growth, viability and titer. This 
would give us a better indication of what volume percentage to employ in our 
SME candidate studies and minimise any functional impact of the vehicles on 
our screening outputs. 
Our selected chemicals that were not water soluble, were either soluble in 
DMSO or ethanol. We tested various concentrations of both solubilisation 
chemicals to test which concentrations did not impact culture attributes of 
interest i.e. IVCD, qP and/or titer. The chemicals were added on day 0 of batch 
culture in 96 DWPs and performance attributes were recorded on day 5. The 
results are displayed in Figure 4.13. DMSO had a higher impact on titer than on 




and consequently titer fell below 80% of the control cultures from 0.25% v/v 
onwards. Thus, the maximum acceptable DMSO concentration as a 
solubilisation vehicle was kept at 0.2% v/v, where no significant change in 
culture attributes was observed. The use of ethanol in culture (Figure 4.13B) 
did not impact cell growth till 0.5% v/v. Similar to DMSO, titer was more 
severely impacted by the use of ethanol. Titer dropped to about 80% of the 
control cultures at 0.3% v/v. Thus, the maximum ethanol percentage in SME 
cultures (that used ethanol as a vehicle control) was limited to 0.2% v/v where 
no significant change in growth or titer was observed.  
This experimentation model served to investigate the appropriate concentration 
in culture of 2 vehicle controls. A SME screen, where the SME being evaluated 




Figure 4.13 Impact of chemical solubilisation vehicle on DWP culture 
performance. Increasing concentrations of (A) DMSO and (B) Ethanol were added on 
day 0 of a 5-day batch culture in 96 deep well plates. Plates were seeded at 0.2×106 
cells mL-1 with a culture volume of 450 µL. Cell growth was established using the 
PrestoBlue assay and volumetric titer determined using the Valita™TITER assay. The 
data represented is the mean and standard error of three experimental replicates with 
three technical repeats. 














































This research chapter investigated the development of a HT screening platform 
to assess potential SMEs for improved CHO bioprocess. The screening 
platform would form the basis of a SME screening commercial tool, wherein 
singular enhancers and their rational combinations can be rapidly evaluated in a 
HT manner. All optimisation experiments were performed using the Cobra38 
cell line, the model cell line used for the SME screens in the following chapter. 
The HT platform development experiments were focused on 2 main aspects: (i) 
analytics and (ii) culturing methodology. 
From an analytics point of view, we were mainly concerned with measurements 
of 3 culture attributes: cell growth, viability and production titer. We evaluated 
the PrestoBlue assay and the Iprasense Norma as the two main HT growth 
analytical tools. Each analytical approach was compared against the Vi-CELL 
XR, the industry cell counting standard. Both PrestoBlue and Norma produced 
large accurate dynamic ranges. The PrestoBlue assay is based on reduction of 
the active ingredient to a highly fluorescent molecule in the presence of a viable 
cellular reducing environment. The assay is based on the output fluorescence 
being proportional to viable cell number and does not return absolute cell 
number or culture viability. This can be viewed as a disadvantage. However, we 
were mainly concerned with evaluating SME performance relative to a control, 
so absolute cell numbers were not necessary. The setup employed for the 
PrestoBlue assay reached VCD determination saturation post 7×106 cells mL-1, 
thus prompting dilutions with CD CHO (1:1) when concentrations approached 
those levels. Other fluorescent dyes based on membrane integrity (for example 
TO-PRO-3 (Bradford and Buller, 2009)) can be analysed using flow cytometry 
techniques and provide a measure of cell viability. However, flow cytometry is 
usually cost and time intensive, thus ruling out regular use of this approach. 
At the other end of the spectrum, a relatively new equipment, the Iprasense 
Norma determines cell viability based on light diffraction. We assessed the cell 
counting and viability determination capabilities of a series of samples and a 
strong positive correlation was observed against the Vi-CELL XR. Sample setup 




individual chambers for HT capabilities. An even distribution of sample is 
pipetted into each chamber, which in turn is analysed by light diffraction, 
creating holograms for each cell. Hologram patterns are unique for live and 
dead cells allowing for identification. It was impressive that accurate doubling of 
concentrations was observed on the standard curve series with sample 
volumes as low as 3 µL (20 µm plate thickness). However, cell numbers were 
consistently lower than the Vi-CELL XR. It could be postulated that the low 
sample volume played a role in the lower cell count. Surprisingly, when the 
sample volume was increased (10 µL; 100 µm plate thickness), the numbers 
recorded were consistently half that of the Vi-CELL XR. It could be possible that 
the increased slide thickness led to uneven distributions of cells resulting in 
lower cell counts. For consistency purposes with the Vi-CELL XR, we 
implemented correction factors for both slide types (20 µm: ×1.4, 100 µm: ×2). 
In terms of viability, the Vi-CELL XR and the Norma were evenly matched. The 
Norma would serve an ideal HT cell counter and viability analyser, however its 
high operating cost and late availability in our laboratory impeded its use as a 
sole HT cell growth analyser. In future projects the Norma could prove useful for 
daily culture monitoring (such as in fed-batch cultures), since the extremely low 
sample volumes would allow for multiple readings to be taken from the same 
well. In contrast, the PrestoBlue assay is more suited as an end-point assay 
where readings are only taken upon culture termination (like in the case of our 
platform). The simple, robust and cost-effective nature of the PrestoBlue assay 
made it attractive to employ for our purposes. To conclude, we employed the 
PrestoBlue assay as the main assay for cell growth analysis, with the Norma 
and the Vi-CELL XR employed in support whenever cell numbers and viability 
determination were deemed necessary.  
Volumetric titer was perhaps the most vital culture attribute that needed 
determination for our SME screens. We employed the Valita™TITER assay that 
was developed in-house to quantify Fc domain containing proteins in solution. 
Comparative analysis performed against the HPLC and biolayer interferometry 
showed a correlation R2 >0.99 (Thompson et al., 2017), with readings being 
stable across different plates. The large dynamic range coupled with quick 
assaying times gave it an edge over the other HT titer assay commonly 
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employed, ELISAs. Overall the assay was fit for purpose for our HT screens 
that utilised the Cobra 38 cell line, an IgG1 producer.  
Having evaluated and optimised the analytical methodologies for growth and 
titer, we focused our attention towards the development of a HT culturing 
platform. The main aim here was to be able to reproduce shake flask batch 
culture performance at a scaled down HT level. Initial analysis of 96 microplate 
static culturing technology revealed that cell proliferation was extremely limited 
with cultures stagnating at 2×106 cell mL-1. Viability also dropped prematurely in 
comparison to shake flasks indicating that long culture periods could not be 
supported. Oxygen transfer rates have been shown to be extremely limited in 
static plate cultures in comparison to shaking plates (Duetz and Witholt, 2004). 
This improper cycling of gases and nutrients could explain the poor culture 
performance in 96 static microplates. Culture volume was also limited to 90-100 
µL, which resulted in culture growth and titer performance often being assayed 
from different technical replicate wells. A different rate of evaporation between 
the plate centre and edges was also an impactful factor that could influence 
erroneous results. Thus, this culture mode was discounted as a potential HT 
culturing methodology.  
Shaking DWP culturing is slowly becoming the norm in bioprocess circles. 
Development of this culturing methodology had the potential to nullify 2 main 
problems of static shallow well culturing: poor cell growth and low culture 
volumes. Multiple studies have referenced the use of DWPs for different 
screening purposes; including for transient transfection (Hansen et al., 2015), 
recombinant cell line screening and selection (Rouiller et al., 2016), media 
blending experiments (Rouiller et al., 2013) and assessment of product quality 
modulators (Brühlmann et al., 2017b). These aforementioned studies formed 
the basis of our optimisation experiments. The availability of only a single 
incubator with varying speed and throws translated to an iterative approach and 
a smaller design space for speed and throw optimisation. Shaking speed, 
orbital diameter and plate geometry influence hydrodynamic behaviour in 
miniaturised shaking cultures (Barrett et al., 2010; Duetz, 2007; Duetz and 
Witholt, 2001; Duetz and Witholt, 2004). It is said that square well DWPs often 




same fill volume. This is often attributed to the turbulent flow pattern caused by 
the square well shape (Duetz, 2007). It could be argued that this flow pattern 
could also enhance nutrient mixing and keep cells in suspension. All these 
factors could be influential in presenting conditions for better cell growth. Our 
studies conformed to these observations made in past literature, with Greiner 
MasterBlock® 96 square well DWPs outperforming other plates (notably round 
well plates: see Appendix B). The “System Duetz” was employed to secure 
plates with vented lid covers, minimising evaporation and edge effect, while 
allowing for sufficient gas exchange. Shaking speeds and orbital diameter were 
also varied to estimate the conditions most suited for cell proliferation in the 
square DWPs. A speed of 320 rpm and orbital diameter of 25 mm was best 
suited for cell proliferation at various seeding densities and culture volumes. 
This initial optimisation experimentation already recorded culture densities 
higher than static culture plates, thus the benefits of shaking on cell growth 
were obvious. Additionally, shaking DWP cultures allowed for larger culture 
volumes; multiple attribute sampling from a single well was made possible.  
The next line of optimisation efforts was focused on seeding volume and 
seeding density. Fill volume influences headspace availability and networks 
with speed, throw and plate geometry in influencing gas transfer (Duetz, 2007). 
Interestingly, fill volume did not majorly influence cell growth in our studies. 
Admittedly, a narrow range of fill volumes was only tested (based on previous 
literature guidance (Jordan and Stettler, 2014; Rouiller et al., 2016)) and thus 
impact of largely different culture volumes was not visible. 2 seeding densities 
were tested based on the results shown in Figure 4.8A, which indicated 
0.3×106 cells mL-1 DWP cultures could match 0.2×106 cells mL-1 seeded flasks. 
Interestingly, evaluation over the 7 day batch culture period showed that 
0.2×106 cells mL-1 seeded DWPs were not far removed from 0.2×106 cells mL-1 
seeded shake flasks in terms of growth, IVCD and titer. Cellular qP was 
consistent with shake flasks when analysed on day 5 of culture. The 0.3×106 
cells mL-1 seeded DWPs matched 0.2×106 cells mL-1 seeded shake flasks over 
the 7 day batch culture period, with the 400 µL cultures slightly surpassing 
shake flask growth performance. Interestingly, titer was slightly lower, leading to 
slight reduction in qP as well. It could be debated whether seeding higher, 
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resulting in a larger biomass in the small well space, could negatively regulate 
antibody production pathways. More experimentation would be needed to 
accurately determine the impact.  
Seeding cells at 0.2×106 cells mL-1 in a culture volume of 450 µL was decided 
upon for all future screening experiments. This would allow for increase in 
culture volume (until 550 µL) by feed addition, for example. Seeding lower (0.2 
instead of 0.3×106 cells mL-1) would not limit the improvement capabilities in cell 
numbers over a longer culture period due to the addition of a chemical additive 
or feeds. 
The last variable in finalising the culture platform was the timing of addition of 
the SME. While day 0 addition was the most practically simple approach, any 
molecules that repressed cell growth concomitant with an increase in qP would 
be better suited for a delayed addition approach to amplify titer. This would 
allow for an initial biomass accumulation phase followed by a maximal 
production phase (Johari et al., 2015). Day 3 and day 4 additions were 
investigated with analytics performed on day 5 and day 6. It was evident that 
day 3 addition majorly improved titer performance (on days 5 and 6) for most 
qP enhancers. Functionality of molecules could have a bearing on the best 
timing of addition. Thus, it was important to have some degree of flexibility 
within the HT system to allow for the isolation of enhancers with differing timing 
of additions best suited to their mode of action. Thus, day 0 addition testing 
followed by a small subset being evaluated using a day 3 addition strategy was 
deemed a suitable addition to the HT platform. Both culture supplementation 
strategies would still be evaluated on day 5 since extending the culture by a day 
did not yield any new information (Figure 4.12).  
A visual summary of the final HT screening platform is displayed in Figure 4.14. 
Future studies could embed feed addition leading to longer culture duration. 
Addition of HT product quality analytics could also further enhance prediction 
capabilities at the microscale level (Yang et al., 2016). Additionally, the platform 
displays versatility in terms of applicability, the platform could be adapted for 
transient transfection and cell clone screening similar to those recorded in 
previous literature (Brühlmann et al., 2015; Brühlmann et al., 2017b; Hansen et 






Figure 4.14 Developed HT screening platform for the isolation of small molecule 
enhancers for improved CHO bioprocess. The developed platform consists of two 
components: HT Culturing technology and HT Analytics. 
	
	 	
•  “System Duetz”: low 
evaporation cover + clamp 
•  Greiner 96 square deep 
well plates 
•  Incubator speed: 320 rpm 
•  Incubator throw: 25 mm 
•  Seeding density: 0.2×106 
cell mL-1 
•  Seeding Voume: 450 µL 
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ABSTRACT:	 In	 this	 chapter,	we	describe	 the	 implementation	of	 the	developed	high-
throughput	screening	platform	described	 in	Chapter	4	 to	rapidly	screen	and	titrate	
various	 small	 molecule	 enhancers	 of	 growth,	 titer	 and	 qP.	 8	 functional	 categories	
(metal	 ions,	 metabolic	 modulators,	 fatty	 acids,	 chemical	 chaperones,	 HDAC	
inhibitors,	 DNA/histone	 methyltransferase	 inhibitors,	 cell	 cycle	 inhibitors	 and	
carboxylic	 acids)	were	 evaluated,	with	molecules	 being	 selected	based	on	prior	 art	




deacetylase	 inhibitors	 (maximum	 titer	 fold	 change:	 1.9)	were	 responsible	 for	 large	
increases	in	volumetric	titer.	A	sub-set	of	enhancers	that	actively	suppressed	growth,	
concomitant	 with	 an	 increase	 in	 cellular	 productivity	 were	 re-evaluated	 using	 a	
delayed	addition	strategy.	2TAA	recorded	the	highest	improvement	in	titer	(3.2	fold)	
when	 added	 on	 day	 3.	 A	 collection	 of	 successful	 enhancers	 was	 used	 to	 inform	
combinatorial	strategies	based	on	the	Design	of	Experiments	Methodology.	The	best	
combination	 of	 growth	 enhancers	 (2.1	 fold	 IVCD	 enhancement)	 and	 the	 best	
combination	 of	 titer	 enhancers	 (4.3	 fold	 titer	 enhancement)	 outweighed	 their	 best	
performing	 singular	 counterparts.	 Finally,	 selected	 combinations	 were	 tested	 in	




in	agreement	with	deep	well	plate	data.	The	data	presented	 in	 this	 chapter	 can	be	









While g L-1 protein titers are commonplace in the CHO host cell factory arena 
(Pybus et al., 2014), there is always an impetus to enhance upstream 
production outputs further. This need is further exacerbated due to the demand 
of novel complex molecules and the rise of biosimilars and biobetters (Walsh, 
2014). In short, high-throughput methodologies need to take centre-stage. In 
the previous chapter, we described the development of a high-throughput 
screening platform comprising HT culture techniques and analytics. 
There has been a steady increase in the use of SME entities in cell culture to 
boost protein production and cell growth. Functionally diverse, easy to titrate 
and comparatively cheap, these molecules present attractive utility 
opportunities. The use of these molecules is not entirely novel, with sodium 
butyrate being used as a protein production inducer since the 1990’s (Palermo 
et al., 1991). Since then, the repertoire of molecules available to modulate CHO 
function has only increased (Backliwal et al., 2008; Du et al., 2015; Ha et al., 
2014; Park et al., 2016). However, there is a lack of resources available to 
rapidly test these molecules in parallel to underpin their utility in CHO 
production environments. It cannot be denied that there are small molecule 
chemical libraries commercially available, however, these are majorly 
concerned with drug discovery and phenotypic profiling (Biolog, 2013; Selleck 
Chemicals, 2013; Sigma-Aldrich, 2018). These libraries are also not configured 
for optimal combinatorial screening. The lack of high throughput platform based 
focused libraries available for CHO cell bioprocessing presents a commercial 
opportunity.  
There are few previous studies that have undertaken large chemical library 
screening in recombinant protein producing CHO hosts.  The first one by Allen 
et al. (2008)  was able to identify novel enhancers for stable production in CHO 
cells. In this study, effects of 192 compounds on CHO cells (cultured in 96 well 
microplates (100 µL) for 4 days) were examined. Static, shallow well plate 
culturing implied that late stage culture performance could not be ascertained. 
Additionally, predictive capabilities when scaled from shallow plates to shake 




Our static microplate (90 µL) studies suggested that growth in this culture 
modality deviated from shake flask profiles (short culture period with low cell 
densities and volumetric yield) (Section 4.3.4). So poor scalability in this study 
was not unexpected. Chemicals in this study were selected based on their 
structure, for example, carboxylates, acetamides and hydroxamic acids. Many 
well known HDAC inhibitors exhibit similar structure to these compounds. 
Additionally, no combinations of chemicals were trialled, missing an opportunity 
to elevate performance. 
Another study by Meyer et al. (2017) screened 31,000 potential SMEs as 
enhancers for transient protein expression in HEK293 cells. 16 compounds 
were taken forward for further testing. Due to the vast number of compounds 
tested, only 1 concentration could be tested per chemical, presenting high 
probabilities of missing effective dose and eliminating promising candidates. 
Also, studies were performed using the transient expression mode, thus 
performance in stable production mode (routinely employed for large-scale 
production purposes) could not be established. 
Perhaps, another relevant study of chemical modulators in CHO cells would be 
one by Brühlmann et al. (2017b). Herein, 17 chemical modulators of 
glycosylation were assessed using DWP culturing technology. The main aim of 
their experimentation was to develop culture feeding strategies to maintain 
biosimilar product quality to the reference medicinal product. Multiple DOEs 
were performed in parallel, each with a subset of chemical modulators. Scale-
up predictive capabilities were assessed using TubeSpin shaking tubes. 
Interestingly, cellular growth and productivity were assayed for but data was not 
displayed. Only 2 concentrations were tested per chemical, although it was 
mentioned that prior studies were performed on some of the chemicals. Cross-
functional interactions between factors were ignored and no focus was given to 
the identification of novel modifiers. The number of compounds tested was 
comparatively small, and given that HT culturing and analytical technologies 
were employed, the design space could have easily been widened. 
The aforementioned screening studies depicted moderate success in isolating 
enhancers. However, many of them (especially the first 2) were practically not 
viable to implement as standard within a cell line and process development 
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process. We stipulate that a more function and mode of action led SME screen 
could yield greater benefit in various production scenarios. Instead of extremely 
large (>100 factors) SME screens, testing a more focused small number of 
chemicals would also mean more concentrations could be tested per chemical. 
Bearing these design criteria in mind, we chose 8 functional categories to 
rigorously evaluate. A total of 43 molecules were tested across all categories. 
This chapter details and discusses the chemical screens performed that would 
guide the creation of a commercial screening tool to assess the efficacy of small 
molecule enhancers in a high-throughput manner for CHO cell bioprocessing. 
Cell growth, titer and qP were chosen as important culture attributes to target. 
The HT culture and assessment techniques employed for this study are detailed 
in Chapter 4. This chapter also delves into combinatorial treatment strategies to 
observe if higher degree of improvement can be achieved through rational 
combinations of compounds. The addition of combinations of enhancers to the 
proposed screening tool can be viewed as advantageous, since no commercial 
HT screens at this scale investigate combinations. Of course, the various 
combinations would need to be tested across different cell lines and products to 
confirm validity as an additive to the screening tool (unfortunately this was 
beyond the time and resource window for this project). Small scale-up studies 
followed to investigate the validity of the HT study predictions.  
As mentioned earlier, this chapter would inform the design of a commercial 
screening tool to employ in the biopharmaceutical industry. Given that optimal 
concentrations and combinations are likely to be process dependent (cell line, 
product, base media) we aimed to develop a simple screening platform and 
process to enable bespoke media supplementation strategies as potential “out 
of the box” solutions. The product platform would be based on the HT platform 
described in Chapter 4. A 96 DWP coated with enhancers or combinations 
of enhancers in each well would be available for a user to test with their 
production system. The analytical data gathered from the screens and DOEs 
would help create novel media supplementation strategies that are completely 






5.2. Experimental Approach 
 
Before embarking on an extensive screening exercise to identify SMEs, it was 
imperative to devise a hierarchical approach to maximise information and 
probability of success. This approach is highlighted in Figure 5.1 and expanded 
upon in Figure 5.2. Firstly, we undertook a vast literature survey to identify prior 
successful SME deployment strategies and functions of the cell to target. 
Studies in mammalian cells (especially CHO) were prioritised and any previous 
work performed in the David James’ laboratory at The University of Sheffield 
was also taken into account. Functional targets were chosen based on their 
ability to improve cell growth and production processes. This amalgamated into 
the creation of a screening library wherein SMEs were grouped based on their 
broad function.  
SME screens were performed in a simple setup, with the chemical added on 
day 0 of a 5-day batch HT process. Minimum of 6 concentrations were tested 
per chemical. A one-factor-at-a-time (OFAT) approach was employed. HT 
measurements of growth and titer were recorded on day 5. Data from these 
screens informed which chemicals improve cellular productivity at the expense 
of growth. These chemicals would be better suited for a delayed addition 
strategy (as detailed in Section 4.3.6). A biphasic culture modality would thus 
be created allowing cells to proliferate (allowing sufficient biomass 
accumulation) before switching to protein production phase stimulated by the 
addition of the chemical. A small subset of chemicals was taken forward for 
delayed addition testing with the SME added to culture on day 3.  
Having completed the rigorous screening phase, we were able to elucidate 
clear enhancers of growth and titer/qP in our model cell line. With the aim of 
maximising these benefits, combinatorial designs were investigated to test for 
positive interactions (synergistic, additive or enhancing). 2 separate full factorial 
designs were employed to test for combinations while trying to maximise growth 
and qP respectively. A third combinatorial design with both enhancer groups 
aimed to display DOE designs as an informatic resource to manipulate culture 
performance for a desirable output.  
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Having performed all experimentation in 96 DWP batch conditions, we were 
interested to observe how selected chemicals and combinations performed in a 
more industrially relevant setting. Shaking Erlenmeyer fed-batch studies were 
performed over 12 days to ascertain scalability. Given time constraints, extra 
optimisation (for example: trialling different feed days, addition of SME at 
different stages of cell growth) was not performed to extract the best fed-batch 
performance. Thus, this part of the study should only be viewed as an exemplar 
case study and does not indicate best performing fed-batch conditions. 
 
	
Figure 5.1 Iterative approach taken to identify and test SMEs and their 
combinations. Decision-making approaches for each molecule are highlighted in 
subsequent sections. All experimentation performed in 96 DWP micro-scale cultures. 
The final experimentation approach involved scale-up to shake flask fed-batch culture 


























































Figure 5.2 Enhancer screening strategy for recombinant protein production. A 
summary of the experimental approach undertaken to determine bespoke media 
environments for enhanced growth and/or protein production performance of a 
biopharmaceutical production host. Stage 1: One-factor-at-a-time screening of various 
factors of interest that were selected from previous literature. Day 0 addition or 
exponential phase addition were trialled at multiple concentrations to determine best 
concentration and timing of addition. Stage 2: Selected growth and qP/titer enhancers 
taken forward for DOE based combinatorial designs. 1 effective concentation per 
chemical. Stage 3: Validation of the deep well plate predictions at a larger scale. Fed-




























1	 2	 3	 4	 5	 6	
A	 +	 ++	 +++	 ++++	 +++++	 ++++++	
B	 +	 ++	 +++	 ++++	 +++++	 ++++++	
C	 +	 ++	 +++	 ++++	 +++++	 ++++++	
D	 +	 ++	 +++	 ++++	 +++++	 ++++++	
E	 +	 ++	 +++	 ++++	 +++++	 ++++++	
F	 +	 ++	 +++	 ++++	 +++++	 ++++++	






•  OFAT screening 
•  Day 0 or day 3 
addition 





1	 −1	 −1	 −1	
2	 −1	 −1	 +1	
3	 −1	 +1	 −1	
4	 −1	 +1	 +1	
5	 +1	 −1	 −1	
6	 +1	 −1	 +1	
7	 +1	 +1	 −1	













•  Full Factorial 
designs 
•  Separate for growth 
and titer enhancers 




•  Scale-up to fed-
batch cultures to test 
validity of prediction 
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5.3.  Results 
 
 Informed Selection of Potential SMEs 5.3.1.
 
Detailed selection criteria were designed to inform the selection of SMEs from 
experimental data in literature sources and a priori knowledge. An effective 
SME is a molecule that:  
(i.) Has been trialled in mammalian cell types. 
(ii.) Is not toxic to CHO cells at its effective concentration i.e. cells remain 
viable (≥ 85%) for the duration of incubation. 
(iii.) Produces a titer or growth boost of at least 1.2 fold in prior literature (or is 
significance tested) or is predicted to produce a titer/growth 
enhancement based on function. 
(iv.) Is soluble in a solvent of choice. Ideally the solvent is water. If the 
molecule is insoluble in water, the solvent selected must not majorly 
impact cell culture performance negatively at its final volume percentage 
(v/v%). Suitable vehicles and their working volume percentage are as 
described in Section 4.3.7. 
(v.) Do not have any major regulatory concerns known. Some small 
molecules are being trialled for therapeutic use; any regulatory concerns 
raised during testing would have to be considered in a biopharmaceutical 
production scenario as well. 
(vi.) Generally safe to handle in a laboratory premise. 
(vii.) Potential for performance elevating interaction with other SMEs, i.e. act 
in conjunction with other SMEs to produce a growth or titer boost greater 
than that of the singular SME. 
Based on these set of rules, a broad literature survey was performed, leading to 
the development of an effector SME library. The potential effector molecules 
were divided into 8 distinct functional categories; the categories and rationale 
behind adoption is shown below. A further summary of all chemicals used in 




(i.) Metal ions: Components of media and generally co-factors for various 
metabolic processes in the cell. Supplementation into basal media has 
proved successful in prior studies. 
(ii.) Metabolic modulators: Chemicals that target various metabolic processes 
in the cell. Processes targeted include lactate and ammonia metabolism 
to reduce toxic-product build up. Other processes important to cell 
growth have also been targeted in mammalian lines with benefit to 
growth.  
(iii.) Fatty acids: Free fatty acids form media components and can assist in 
cell growth and survival. Fine-tuning their concentrations in media could 
be beneficial for improved growth/productivity. 
(iv.) Chemical chaperones: Employed in misfolding disease models to 
prevent aggregation and correct protein folding. Recent studies on 
application in CHO cells to relieve folding, assembly and secretion 
bottlenecks. 
(v.) HDAC inhibitors: Molecules that generally up regulate transcription 
through HDAC inhibition. 
(vi.) DNA/Histone methyltransferase inhibitors: Molecules that can relive 
transcriptional bottlenecks by inhibiting gene repressive 
methyltransferases. 
(vii.) Cell cycle inhibitors: Chemicals that enhance qP by arresting cells at a 
certain cell cycle phase while maintaining viability. 
(viii.) Carboxylic acids: structurally similar entities to common HDAC inhibitors. 
 
Stock concentrations were created, filter sterilised and stored at 4°C for short-
term storage and at −20°C for long-term storage. The subsequent sections 
highlight the effects of the OFAT SMEs on cellular growth and productivity. All 
experimentation was performed in 96 DWPs with culture attributes recorded on 
day 5. Cobra 38, a CHO-S transfectant stably producing an IgG1 molecule was 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Sections 5.3.2 to 5.3.9 describe the screens of 43 SME molecules in a stable 
producing CHO system. SME was added on day 0. 
 
 Metal Ion Supplementation 5.3.2.
 
5 metal ion compounds: copper sulphate (Cu), zinc sulphate (Zn), ferric 
ammonium citrate (FAC), manganese chloride (Mn) and sodium orthovanadate 
(V), were selected for supplementation experiments. Since these compounds 
are already components of general cellular growth media, it was interesting to 
observe if additional supplementation could fine-tune responses for added 
benefit. Metal ion supplementation results are shown in Figure 5.3. Cu 
supplementation at even its lowest concentration (0.5 µM) produced a growth 
stimulation of 1.4 fold over the control. Similar gains were seen at higher 
concentrations. Increase in total IVCD led to an increase in production titer. 
These results are consistent with previous studies performed with Cu (Qian et 
al., 2011; Yuk et al., 2014; Yuk et al., 2015b), wherein a reduction in lactate 
accumulation was observed concurrently. 
Zn and FAC produced concentration specific responses. Zn at 150 µM 
produced a 20% increase in total IVCD and 30% increase in overall titer. 
Interestingly, at 200 µM, no growth stimulation but a major titer stimulation was 
observed. This was interesting to observe since Zn is considered an insulino-
mimetic compound and was predicted to preferentially enhance cell growth 
(Wong et al., 2004). FAC (500 µM) improved IVCD by 1.6 fold and titer by 1.8 
fold. Mn supplementation did not produce any noteworthy improvements in 
growth or titer. This was not unexpected, since Mn is involved in the modulation 
of galactosylation (Grainger and James, 2013; Gramer et al., 2011), rather than 
protein production itself. It would be interesting to observe how the molecule 
impacted galactosylation in our production system, however the lack of HT 
glycosylation analytics at our disposal hindered this. Various concentrations of 
V induced slight titer boosts (ranging from 7 to 18%), however no improvements 







Figure 5.3. Culture responses due to metal ion supplementation. Cobra 38 cells 
were cultured in the presence of increasing concentrations of different metal ions. Cells 
were seeded at 0.2×106 cells mL-1 in a 96 DWP system and cultured for 5 days. 
Growth was measured using the Vi-CELL XR and/or PrestoBlue assay and titer 
recorded using the Valita™TITER assay. SMEs: (A) Copper Sulphate (Cu), (B) Zinc 
Sulphate (Zn), (C) Ferric Ammonium Citrate (FAC), (D) Manganese(II) Chloride (Mn) 
and (E) Sodium Orthovanadate (V). Data is shown as a fold change to the no addition 
control (red dashed line). Data shown is the mean and SEM of three biological 




 Metabolic Modulator Supplementation 5.3.3.
 
Modulating cell metabolism towards increased viable cell proliferation can yield 
benefits to the mammalian cell production processes (Altamirano et al., 2001; 
Kumar et al., 2007). Using small molecule modulators as a tool to achieve this, 

































































we trailed 5 different small molecule modulators. Dichloroacetic acid (DCA) is a 
well-known inhibitor of pyruvate dehydrogenase kinase, funnelling cellular 
metabolism towards the TCA cycle (Skelton et al., 2010). This reduces flux 
towards aerobic glycolysis, which is known to produce lactate, a toxic by-
product. We observed mild titer enhancement using DCA as a supplement 
(Figure 5.4A). This could be explained by its indirect effect on histone 
acetylation, which is known to play a role at the transcription level (Matsuhashi 
et al., 2015; Moussaieff et al., 2015). Interestingly, no stimulatory effect on cell 
growth was observed.  
 
 
Figure 5.4. Growth and titer responses to metabolic modulator supplementation. 
Cells were seeded at 0.2×106 cells mL-1 in a 96 DWP culture system. Growth and titer 
were measured on day 5. SMEs: (A) Dichloroacetic Acid (DCA), (B) Citric Acid, (C) SB 
216763 and (D) T0901317. Red dashed line indicates level of no addition/vehicle 
control.  Data represented as a fold change to the control. Mean ±SEM represented of 




We employed citric acid (the first TCA cycle substrate) to attempt to redirect 
cellular metabolism towards the TCA cycle instead of lactate production. 
Maximum titer production is associated with increased flux to the TCA cycle 



























































(Templeton et al., 2013). However, we were unable to demonstrate any utility of 
citric acid in improving cell growth/proliferation or titer. This was interesting 
since the iron compound of citrate (FAC: Figure 5.3) did yield improvements in 
cell growth and productivity across the same concentration range. This 
observation revealed that the iron component could play a crucial role towards 
the improvement in performance and that citrate could be fulfilling the role of an 
iron carrier and not impacting TCA cycling efficiency. Further experimentation 
would need to be performed to confirm this. It cannot be discounted that 
addition of citric acid in media could have deleterious effects on cell culture 
such as increased acidity and osmolarity masking any benefit to cell 
metabolism. 
Cancer cells are known to depend on lipid biogenesis to meet nutritional 
requirements while proliferating (Mukherjee et al., 2012). Based on this 
principle, we tried SB 216763 (Figure 5.4C) and T0901317 (Figure 5.4D) 
supplementation. Both molecules facilitate the upregulation of transcription 
factors (sterol regulatory element-binding proteins (SREBP)) involved in 
lipogenesis pathways (Hansmannel et al., 2006; Kim et al., 2004). Expression 
of fatty acid synthase (FAS), a key lipogenic gene was enhanced through the 
use of these chemicals in previous studies (Hansmannel et al., 2006; Kim et al., 
2004). However, only slight improvements in growth, titer or qP were observed 
in our production system. 
 
 Fatty Acid Supplementation 5.3.4.
 
Fatty acid biosynthesis, like previously mentioned, is important for cancer cell 
proliferation. While we did employ modulators of metabolism to promote TCA 
cycling to produce precursors for fatty acid synthesis, we were intrigued to 
investigate free fatty acid supplementation (Schmid et al., 1991). Free fatty 
acids do form part of commercially available cell culture media, so it was 
interesting to observe if additional supplementation yielded any benefit. Palmitic 
and linoleic acids form precursors for more complex fatty acids and we trialled 
various concentrations of these two molecules (Figure 5.5A and B). There 




It could be that CHO cells relied mostly on de novo lipid synthesis or that the 
levels of fatty acids in media were sufficient. We decided against testing other 




Figure 5.5 Fatty acid supplementation effects on culture attributes. Cells were 
seeded at 0.2×106 cells mL-1 in a 96 DWP culture system. Growth and titer were 
recorded on day 5. Chemicals employed: (A) Linoleic Acid and (B) Palmitic Acid. Data 
(IVCD: black bar, Titer: grey bar, qP: white bar) represented as a fold change over the 
ethanol vehicle (0.2%v/v) control. Data shown is mean ± SEM of two experimental and 




 Chemical Chaperone Supplementation 5.3.5.
 
Chemical chaperones are indirectly involved in improvements to protein folding 
and stabilisation. They are unlike their molecular chaperone counterparts that 
are directly involved in cellular processes that target protein folding and 
secretion (Cortez and Sim, 2014). Chemical chaperones have proved extremely 
effective in cases of DTE protein expression (Johari, 2015; Roth et al., 2012) 
and various misfolding diseases (Yam et al., 2007). Employing the same 









































rationale as the studies mentioned above, we trialled chemical chaperone 
molecules in our CHO-S expression system. Keeping in mind that the molecule 
expressed in our system is not particularly difficult-to-express (as seen with the 
high protein titers from our system (Figure 4.7)), we hypothesised that any 
effects seen in our system could be further amplified in a truly DTE protein 
system. The chemical chaperones tested were categorised into 2 sub-divisions: 
osmolytes (Figure 5.6A-G) and hydrophobic chaperones (Figure 5.6H-J). The 
osmolyte chaperones stabilise the protein molecule and promote folding. L-
proline recording a 1.4 fold increase in volumetric titer at 50 mM was the most 
effective osmolyte. Cell growth remained unaffected at that concentration. 
Interestingly, all CHO cells in use today require proline for their growth (Wurm, 
2013). Thus, it could be debated whether the increase in cellular production 
was a result of fulfilment of the nutritional requirement of the cell rather than a 
chaperone based improvement. Testing with different cell lines and different 
products would help test the validity of this narrative. 0.5% (v/v) Glycerol 
supplementation displayed a 20% titer increase. All other osmolytes only 
displayed stimulatory effects to cellular qP, with dimethyl sulfoxide (DMSO) 
recording the best qP sitmulation of 4.1 fold at 1.5% (v/v) without complete 
suppression of cell growth. Betaine (Johari et al., 2015; Roth et al., 2012), 
Trimethylamine N-oxide (TMAO) (Johari et al., 2015) and trehalose (Onitsuka et 
al., 2014) have previously been shown to improve volumetric titer and/or 
decrease aggregation, however they were ineffective in our expression system, 
strengthening the notion that SME efficacy is cell line and product specific.  
3 hydrophobic chaperones were also tested in our stable expression system. 4-
Phenylbutyric acid (4PBA) is perhaps the best-known chemical chaperone 
since it is approved for clinical use to treat urea cycle disorders (Kolb et al., 
2015). It was not highly effective with our cell line and product, with 1 mM 
producing a qP increase of 1.68 fold. 2 mM was cytotoxic to cells and thus was 
not taken into consideration for further testing. 6-Phenylhexanoic acid (6PHA) 
was reported as an analogue of 4PBA by Mimori et al. (2012), wherein it proved 
to be more effective than 4PBA in blocking aggregation and protecting against 
ER stress in human neuroblastoma cells. However, no such positive effects to 




bile acid, Tauroursodeoxycholic acid (TUDCA). Though operating through a 
similar mechanism as 4PBA, we observed drastically different results in 
comparison of 4PBA. TUDCA had no cytotoxic effects, improving titer by 1.6 
fold at the 2 mM concentration. All concentrations tested provided various 
ranges of titer improvements, with some degree of growth repression. The 
polarising effects of both supposedly functionally similar molecules has been 
reported before (De Almeida et al., 2007; Uppala et al., 2017) indicating that 














































































































































































































































































































































































































































































































































































































































































































 HDAC Inhibitor Supplementation 5.3.6.
 
Epigenetic modification (especially histone acetylation) is heavily associated 
with antibody production (Backliwal et al., 2008). HDAC inhibitors form the most 
well researched group of SMEs for the purposes of antibody production 
stimulation. Figure 5.7 shows the growth and titer responses to various small 
molecule HDAC inhibitors. Sodium butyrate (NaBu) is perhaps the most 
commonly used small molecule HDAC inhibitor. In our system, we observed 
titer enhancement up to 1.9 fold. Higher concentrations reported a large qP 
enhancement, with a suppression in growth. Previous studies have shown that 
NaBu induces apoptosis in cells (Lee and Lee, 2012). In our system, decreased 
viability was observed from 1.4 mM onwards. Further investigation would be 
necessary to investigate initiation of any apoptotic pathways. Sodium valproate 
(VPA) (Figure 5.7B) recorded a titer enhancement of 1.27 fold. This is in 
disagreement with previous literature, which conclude VPA to be a better/on par 
titer enhancer in comparison to NaBu (Backliwal et al., 2008). Scriptaid was 
tested as a novel HDAC inhibitor, that has been previously shown to be a 
general transcriptional enhancer in mammalian cells (Lee et al., 2008; Su et al., 
2000; Xu et al., 2013). It only displayed improvements in qP when trialled in our 
system. Trichostatin A (TSA) is another commonly used HDAC inhibitor. Similar 
to scriptaid, there were an increase in qP coupled with growth suppression. 
MS275, an HDAC1 to 4 inhibitor, proved to be an effective titer enhancer 
(Figure 5.7E). At 1 µM, titer was enhanced by 1.7 fold over the vehicle control. 
Also, growth suppression was not as severe as NaBu. 
All chemicals tested in this group improved qP concomitant with growth 
repression and it was hypothesised that this set of chemicals might yield bigger 
improvements when deployed at a later stage in the cell culture process. This 
would mean the cells would be allowed to proliferate for a certain time period 
before chemical addition, leading to more biomass available for increased qP, 






Figure 5.7. HDAC inhibitor supplementation responses over 5 days of DWP batch 
culture. SME added on day 0 of culture. Growth and titer recorded on day 5. SMEs: 
(A) Sodium butyrate (NaBu), (B) Sodium Valproate (VPA), (C) Scriptaid, (D) 
Trichostatin A (TSA) and (E) MS 275. IVCD, Titer and qP shown as a fold change 
relative to the no addition/DMSO control (red dashed line). Mean ± standard error 
represented of two experimental replicates (Scriptaid and TSA: three experimental 




 DNA/Histone Methyltransferase Inhibitor Supplementation 5.3.7.
 
DNA methylation correlates with a loss in recombinant gene expression in CHO 
cells (Yang et al., 2010).  Few research studies have investigated the use of 
methyltransferase inhibitors in mammalian cells for improvements in the 
recombinant protein production process. Backliwal et al. (2008) demonstrated 
the use of DNA methyltransferase inhibitors in CHO cell production systems; 
there was substantial benefit of adding these enhancers to culture (up to 1.8 

















































































fold improvement over the control) in both transient and stable modes. Using 
this as a precursor study, we adopted some methyltransferase inhibitors in our 
HT screens. 2 DNA methyltransferase inhibitors, RG108 (Figure 5.8E) and 
procaine (Figure 5.8C) were trialled. There was no substantial stimulation of qP 
or titer observed with either chemical additive. Procaine produced dose 
dependent growth repression leading to a qP increase above control level at the 
highest concentration (1.5 mM). RG108 is generally non-toxic in comparison to 
other demethylating agents (such as 5-azacytidine), since it does not complex 
with DNA, preventing strand breaks (Christman, 2002; Xu et al., 2013). While 
cell growth and viability were largely unaffected across all doses of RG108 
trialled in our cell line, no major stimulatory effect on titer was observed. 
Changing the concentration range could potentially provide more positive 
results for this molecule.  
Apart from DNA methyltransferase inhibitors, we also investigated the use of 
histone methyltransferase inhibitors. H3K27 (Histone 3, lysine position 27) 
methylation is associated with gene repression (Wang and Patel, 2013). 
UNC1999 inhibits enhancer of zeste homolog 2 (EZH2), a catalyst for H3K27 
methylation. UNC1999 proved to be an effective transgene expression 
enhancer (~1.4 fold improvement), in a study performed by Christensen (2016). 
In our system, there was no titer improvement observed when the molecule was 
added (Figure 5.8D). Similarly, other histone methyltransferases inhibitors 
tested: WDR5-0103 (Figure 5.8A) and RSC133 (Figure 5.8B) did not present 
any major benefit to antibody production, which were previously shown to be 





Figure 5.8. Culture responses to the supplementation of various 
methyltransferase inhibitors. SME added on day 0 of a 5-day batch production 
process in DWPs. Growth and titer recorded on day 5 and displayed as a normalisation 
to the control. SMEs used: histone methyltransferase inhibitors: (A) WDR5-0103, (B) 
RSC133 and (D) UNC1999; DNA methyltransferase inhibitors: (C) Procaine and (E) 





 Cell Cycle Inhibitor Supplementation 5.3.8.
	
Cell cycle (specifically G2/M) inhibitors were trialled using the DWP systems. It 
is known that cell cycle phases correlate with specific production of the 
recombinant protein (Dutton et al., 2006).  






































































Figure 5.9. Cell cycle inhibitor supplementation responses at various 
concentrations. G2/M phase inhibitors were added at day 0 of a 5-day screen in 
DWPs. Cobra 38 cells were seeded at 0.2×106 cells mL-1. Dose response curves 
shown are: (A) germanium dioxide (Ge), (B) D,L sulforaphane, (C) BI 2536, (D) RO-
3306 and (E) Lithium chloride (Li). Date represents mean ± SEM of two experimental 
replicates (Li represents means ± SEM of four experimental replicates), each with three 




Figure 5.9 summarises the dose responses of Cobra 38 cells to the addition of 
various singular cell cycle inhibitors in an OFAT setup. Growth inhibition was 
observed in a dose dependent manner, consistent with cell cycle phase 
inhibition. All cell cycle SMEs tested showed an improvement in qP at particular 
concentrations. Top concentrations of most cell cycle inhibitors (Germanium 
dioxide (Ge), BI 2536, Lithium chloride (Li) and RO-3306) majorly reduced cell 
growth (down to ~10% of the control) and viability. Due to the minimal growth 








































































and titers at these concentrations, noise during data acquisition can lead to an 
artificial inflation in qP. Thus, these concentrations were ignored for any further 
testing. Among the SMEs tested, Li ranked the best. Li recorded a 17% titer 
increase at 0.01 mM (the only cell cycle inhibitor in our screens to give a total 
volumetric titer boost) and qP improvements of 3.3 and 4.6 fold at concentration 
of 15 and 17.5 mM respectively. 
 
 Carboxylic Acid Supplementation 5.3.9.
 
Allen et al. (2008) reported the use of various carboxylic acids (or carboxylates) 
for the purposes of improving recombinant protein expression in CHO cells. 
These molecules were analogous in structure (i.e. contained a carboxyl group) 
to well-established HDAC inhibitors like sodium butyrate and valproic acid or the 
chemical chaperone 4PBA. The study elaborated on the use of novel carboxylic 
acids, including hydrocinnamic acid (HCA), 5-phenylvaleric acid (PVA) and 2-
thiopheneacetic acid (2TAA) to improve titer in a recombinant stable mAb 
reporter system and a stable type II receptor for interleukin 1 production system. 
Using this study as a precursor, we performed carboxylic acid supplementation 
studies in our 5-day DWP screens. 
Figure 5.10 depicts the cell culture responses when Cobra 38 cells were 
cultured in the presence of various singular carboxylic acids. PVA and HCA 
only recorded increases in qP, overall titer was not boosted unlike the study 
performed by Allen et al. (2008). PVA also severely impacted cell viability at 0.8 
mM onwards (data not attached). This indicates that responses to SMEs can be 
cell line and product dependent. All carboxylic acids recorded dose dependent 
growth inhibition consistent with well-established carboxylic acid SMEs such as 
4 PBA. 
2TAA produced a titer boost of 1.6 fold over the DMSO (0.2% v/v) control at 0.8 
mM, with increases in qP observed at higher concentrations. With 2TAA being 
the only SME from the initial screen to yield volumetric titer enhancement, we 
hypothesised that structural analogues of 2TAA could inform novel enhancer 
molecules for increasing volumetric titer. Figure 5.10 D-G shows culture 




based on structural similarity tests (Tanimoto similarity score>0.5) performed 
using the PubChem similarity search (Kim et al., 2016b) (analogue identification 
process described in more detail in Section 6.3.1). 2-Thiophenepropionic acid 
(TPA), 2-Thiophenebutyric acid (TBA) and 3-Thiopheneacetic acid (3TAA) 
recorded major enhancement in qP. However, TBA was detrimental to cell 
viability (data not attached). 3TAA matched the parent analogue efficacy 
(2TAA), recording a 1.6 titer improvement at 2.5 mM. It was interesting to note 
that 3TAA had a lower impact on cell growth (75% of the vehicle control) 
compared to 2TAA (54% of control) at their highest titer yielding concentrations. 
3TAA could be titrated to higher concentrations (up to 5.6 mM) without a 
detriment to cell viability in comparison to 2TAA, which recorded minimal cell 
growth and decreased viability at 1.6 mM. Another structural analogue tested, 
TPA proved to be an effective qP enhancer. Titer never fell lower than 75% of 
the control, while growth was reduced majorly. However, viability was reduced 
post 3.5 mM, making it imperative to modulate concentration of the chemical to 










































































































































































































































































































































































































































































































































































































































































































































































 Delayed Addition of SMEs 5.3.10.
 
Completion of SME testing using day 0 deployment served a dual purpose. 
Firstly, we were able to elucidate the range of concentrations that produced 
improvements in IVCD, Titer or qP and thus assess the efficacy of a particular 
molecule. Secondly, molecules that primarily boosted qP in the day 0 screens 
helped inform the next line of experimentation for delayed SME addition. 
Overall volumetric titer is dependent upon cell specific productivity (qP) and 
cellular biomass (IVCD). Our delayed addition hypothesis was based on the 
observation that most molecules that enhance qP, concomitantly suppress 
growth. This is depicted in Figure 5.11, wherein a negative correlation was 




Figure 5.11 Negative correlation between IVCD and qP for small molecule 
chemical enhancers. A single concentration per chemical enhancer depicted. r: 




As a result, there is a severe reduction in biomass that is capable of producing 
the protein product. To resolve this and maximise titer, we opted for a biphasic 
culture strategy for qP enhancers (Yoon et al., 2006). Cells would be allowed to 
proliferate in the absence of the chemical for a certain time period, before the 





















SME is added to culture. This would result in more biomass being available for 
production capacity enhancement by the chemical, leading to a bigger gain in 
volumetric titer. Certain concentrations of SMEs that were on the cusp of titer 
enhancement using the day 0 addition strategy would produce larger positive 
shifts in titer at the delayed addition stage. We chose day 3 as the time point for 
delayed addition of qP enhancers (based on experimentation discussed in 
Section 4.3.6); this time point coincided with mid-exponential stage of culture in 
DWPs, allowing the cells to proliferate before chemical addition. The chemicals 
and concentrations taken forward for this stage of screening were selected 
based on the following criteria, in addition to the obvious criteria of 
demonstrating a qP increase: 
(i.) SME supplementation at day 0 produced a growth reduction of not more 
than 90% (i.e. cellular IVCD should be at least 10% of the no addition/ 
vehicle control level). 
(ii.) Day 0 addition titer is at least 20% of the vehicle control at the day 5 
analysis point. 
(iii.) SME would potentially be better suited for later stage addition based its 
function, for example: cell cycle inhibitor, HDAC inhibitor. 
Based on these criteria, selected chemicals from 4 functional compound groups 
were tested in a day 3 addition setup in 96 DWPs. Selected chemicals are 
shown in Table 5.2. Growth and titer measurements were performed on day 5. 
  
Table 5.2 A summary of SMEs tested using the day 3 addition strategy. Chemicals 

























Cell cycle inhibitors did not show any major improvements when using the 
delayed addition setup (Figure 5.12A). This could indicate that cell cycle block 
at the G2/M phase did not improve specific productivity of the protein product. 
However, the range of concentrations tested at day 3 did not produce growth 
inhibition in some cases at all, indicating the design space of concentrations for 
this group was perhaps out of the effective range. We hypothesise a certain 
degree of growth inhibition would be required to stimulate cellular production.  
Chemical chaperones, conversely, achieved varying degrees of benefit using a 
delayed addition setup. Previously, day 0 addition of 4PBA showed no 
noteworthy improvements in overall titer, though major increases in qP were 
observed (Figure 5.6H). Day 3 addition of 4PBA (0.75 mM) resulted in a 71% 
boost in titer (4.2% for a day 0 addition at the same concentration). Though 
overall titer levels were improved by adding DMSO at day 3 instead of day 0, no 
concentration was able to surpass control production levels. The largest titer 
improvements recorded with TUDCA were highly similar to the day 0 addition 
titers.  
Amongst the HDAC inhibitors tested, NaBu performed the best in terms of titer 
improvement. Adding 1mM of NaBu on day 3 produced a 2.6 fold titer 
enhancement. In contrast, the best performing NaBu concentration at day 0 
addition produced a 1.9 fold improvement in titer (Figure 5.7A). TSA (1 µM) 
also recorded a titer boost of 1.4 fold using a day 3 addition strategy, wherein 
previously no titer boosts were observed using a day 0 addition strategy. There 
was no added benefit of a day 3 addition for MS 275 towards protein production 
compared to a day 0 addition. 
Carboxylates (Figure 5.12D) recorded the biggest improvement when the day 
of SME addition was changed for day 0 to day 3. 2TAA had previously recorded 
maximum titer boost of 1.6 fold (0.8 mM) using day 0 deployment. Using 
delayed addition propelled the maximum titer enhancement to 3.2 fold using 2 
mM. There was no detriment to viability when the molecule was added at day 3 
and assayed on day 5. It remains to be seen whether viability would be affected 
over a longer culture period. 2TAA analogue, 3TAA showed a 2.5 fold 
improvement in titer at 5.6 mM with no negative effect on viability (data not 




that the maximum titer enhancement through the use of that molecule had been 
achieved. TPA showed improvements up to 2.3 fold, however, similar to 3TAA 
there were only minor increases with increase in concentration from 3.5 to 4.8 
mM. This was an enhancement over the TPA day 0 addition strategy wherein 
no titer boost was observed. HCA recorded improvements ranging from 1.5 to 
1.9 fold. Viability remained unaffected while cell growth decreased with dose 






Figure 5.12 Culture attributes in response to supplementation of SMEs on day 3 
of a 5-day batch culture in 96 DWPs. IVCD, titer and qP depicted as a fold change to 
the no addition/vehicle control. 4 sub-categories of chemicals: (A) Cell Cycle Inhibitors, 
(B) Chemical Chaperones, (C) HDAC Inhibitors and (D) Carboxylic Acids were tested. 
Concentrations used were based on previous experimental results. Data is represented 
as mean and SEM of three experimental replicates with three technical replicates.  
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Figure 5.13 displays the maximum titer obtained per chemical (as a fold 
change over the control) at the 2 different timings of addition. It was evident that 
majority of qP enhancers had a larger positive impact on total volumetric titer 
when added during exponential growth phase (day 3) rather than at the start of 
culture. 2TAA, TPA and HCA witnessed at least a doubling in titer improvement 
through a shift in timing of deployment to day 3. SMEs (such as Li and MS 275) 
that did not witness any benefit of delaying deployment did not observe any 
drop in yield either. Overall, it could be concluded there was a large degree of 
merit in adding this set of enhancers during the exponential phase of the culture 
process rather than at the start. 
 
	
Figure 5.13. Effect of the day of addition of SME on volumetric titer. Addition of 
SME on 2 days compared: Day 0 (dotted bars) and Day 3 (diagonal striped bars). A 
single highest volumetric titer observed per chemical on each day of addition is shown. 





 Identifying the DOE Design Space 5.3.11.
 
Having established enhancers for growth and titer/qP, the next line of 
experimentation involved testing for any combinations to boost performance 
further. For ease of experimentation, we categorised the enhancers into either 























































DOE full factorial design techniques. Full factorial designs were selected due 
the lack of aliases for complete determination of significant factors and 
combinations. This meant only a select number of factors (SMEs) could be 
tested to ease experimental setup. Also, it is highly unlikely that significant 
interactions between 4 or more factors occur (Anderson and Whitcomb, 2016), 
thus testing all positive enhancers for growth/or titer was considered cost, 
resource and time ineffective.  
Stringent criteria were thus designed to determine which SMEs to take forward 
for combinatorial testing. Design rationale is outlined below: 
(i.) To prevent overburdening the cells and raising osmolarity levels beyond 
cellular tolerance limits (Takagi et al., 2000), it was decided to implement 
a biphasic DOE approach. Growth enhancer combinations were added 
on day 0 and titer/qP enhancers on day 3. This also allowed for larger 
titer effects to be recorded since cells had a proliferation period before 
switching to protein production stimulated by qP enhancer addition. This 
narrowed the design space for titer/qP enhancers to the molecules with 
previous data on day 3 addition available (see section 5.3.10). Separate 
DOEs for growth and qP specific enhancers were performed first before 
combining both. 
(ii.) Growth enhancer and effective concentration selection:  
• Improve growth (minimum of 20% enhancement over control). 
• No detriment to cell viability. 
• Maintain or improve titer. 
(iii.) qP/Titer enhancer and effective concentration selection (day 3 addition 
only): 
• Improve titer (minimum of 30% improvement). 
• No detriment to cell viability. 
• Growth repression (maximum of 50% reduction to control). 
• Only 1 molecule will be used if there are multiple structurally similar 




• Freedom to operate (2TAA is patented). 
This narrowed down the design space significantly to the following: 
(i.) Growth Enhancers: Cu, Zn, FAC 
(ii.) Titer/qP Enhancers: TUDCA, NaBu, MS 275, 3TAA 
3 types of positive interactions were of interest in the DOE studies (explained 
below through the use of 2 example arbitrary factors: A and B): 
(i.) Synergy: AB>A+B; wherein the effect of the combination is more than 
the sum of each component factor of the combination. 
(ii.) Additivity: AB=A+B; wherein the effect of the combination is equal to the 
sum of each component factor effect. 
(iii.) Enhancing: AB>max (A,B); wherein the effect of the combination is 
more than the most effective singular factor. 
 
 Combinatorial Design 1: Maximising Growth 5.3.12.
 
A 2-level factorial design was employed to determine interactions of growth 
enhancers. Cu (Factor A), Zn (Factor B) and FAC (Factor C) were each tested 
at 2 levels -1 and +1. -1 levels for each factor were set at 0 µM; +1 levels: Cu: 
0.5 µM, Zn: 150 µM, FAC: 500 µM. The enhancers were added on day 0 in 96 
DWPs. As with previous experimentation, cell culture attributes were recorded 
on day 5. Cell growth and viability were established using the ViCELL-XR; titer 
recorded using the Valita™TITER assay.  
Results of the combinatorial design are displayed in Figure 5.14. All outputs 
were displayed as separate graphs: (A) IVCD, (B) Titer, (C) qP and (D) Viability 
with the fold change (to the no addition control) of combinations ranked in 
ascending order. All conditions tested improved growth, indicating no 
combinations of chemicals had a severe negative interaction leading to 
complete nullification of each of their positive effects. Conversely, no 
combination completely outscored their individual component counterparts. 




compared to the no addition control. FAC (C) ranked a close second showing a 
1.9 fold improvement.  
While this design was concerned with maximising cellular IVCD, titer 
improvements were observed resulting from the increased biomass. Again, all 
combinations tested increased total volumetric titer. However, from the qP 
rankings it was evident that combinations AB, BC and ABC had larger 
improvements in titer relative to the increase observed in total IVCD.  This 
indicated that there were other mechanisms for improvement in total titer in 
addition to the increase in viable cell population. Viability remained above 96% 






Figure 5.14. Ranked performance for a 3 factor full factorial design. The 3 factors 
employed were Cu (coded as A), Zn (coded as B) and FAC (coded as C). 8 production 
runs were randomised. Experimentation was performed in 96 DWPs, cells were 
seeded at 0.2×106 cells mL-1 and enhancer (or combination) added on day 0.  Each 
factor or combination of factors was prepared on the day of experimentation to the 
desired concentration before addition to the plate. Plate was cultured in shaking 
conditions for 5 days. Cell growth and viability (D) were determined using the Vi-CELL 
XR; titer assayed using the Valita™TITER assay. (A) IVCD, (B) Titer and (C) qP 
represented as fold improvement over the no addition control. Data represented mean 
± SEM of three experimental replicates, with three technical replicates. 































































The cellular responses to the various combinations were further analysed using 
the DesignExpert® 10 software. Influential factors (shown in the half-normal plot 
Figure 5.15) that impacted the cellular response were employed to construct a 
model to predict said cellular response. Linear models were created for IVCD, 
Titer and qP. No aliasing of terms was observed, strengthening the accuracy of 
the model and the effect estimates of each term. The predictive models for each 
response are provided below. The responses are depicted as a fold change 
over the no addition control.  
 
 
Figure 5.15 Growth DOE: Half-Normal plots to identify significant factors and/or 
combinations. Effect of each factor calculated mathematically based on all production 
runs. All factor effects displayed on a half normal plot. A straight line was drawn 
through residual factors. Any factors deviating from the line were taken forward for 
significance testing and formed part of the predictive model. Half-Normal plots for (A) 
IVCD (B) Titer and (C) qP are displayed. Positive effectors are shown in orange 
whereas negative effectors are shown in blue. Three experimental replicate data was 






































































































































































!"#$ =  1.53+ 0.13! − 0.16! + 0.22! − 0.089!" − 0.083!" − 0.11!"
+ 0.057!"# 
Equation 5.1 
!"#$% = 1.85+ 0.2! + 0.14! + 0.53! + 0.077!" 
Equation 5.2 
!" = 1.22+ 0.055! + 0.22! + 0.20! + 0.11!" + 0.095!" 
Equation 5.3 
All models were significant (based on ANOVA statistics) with non-significant 
lack of fit. Most terms employed in the model had significant effects (see 
Appendix C). All singular factors were significant. A normality plot of the 
residuals confirmed that no model transform was required (Appendix C). Effect 
analysis of the factors indicated that the singular factors were most impactful on 
IVCD, with combinations not having the same level of effect. 
 
 Combinatorial Design 2: Maximising qP 5.3.13.
 
To investigate interactions between chemicals that improved qP and/or total 
titer, we employed a 4 factor full factorial design. Factors were as follows: (A) 
TUDCA, (B) NaBu, (C) 3TAA and (D) MS 275. The chemicals were tested at 2 
levels: -1 and +1. -1 level was set at 0 (mM or µM) for all factors and +1 levels 
were as follows: TUDCA: 2 mM, NaBu: 1 mM, 3TAA: 4 mM and MS 275: 3 µM. 
The chemical or cocktail of chemicals was added on day 3 of DWP culture, with 
culture attributes recorded on day 5. Ranking based fold change analysis is 
displayed in Figure 5.16. While all singular and combinatorial entities repressed 
cell growth (Figure 5.16A), culture population remained viable across all the 
tested conditions (above 90%, see Figure 5.16D).  
The rankings of titer (Figure 5.16B) indicated that various combinations were of 
interest. For example, AB in combination (3.5 fold) resulted in a bigger titer 
boost than the sum of A (1.32 fold) and B (2.45 fold). This indicated that AB was 
a synergistic interaction. All 4 chemicals in combination produced a titer 
improvement of 3 fold, outscoring the highest-ranking singular effector (B; 




termed as an enhancing interaction. The most effective titer enhancer 
combination was ABD. Adding factor D (2 fold) to AB was able to push the titer 
fold change from 3.5 (AB) to 4.3 fold (ABD). This again indicated a positive 
synergistic interaction between factors. It would be logical to conclude that 
certain combinations of chemical enhancers were able to generate greater titer 
enhancement when compared to singular molecule addition. Thus, 
combinatorial experiments provide valuable information that can elevate culture 
performance over singular additions. Several combinations also enhanced the 
cellular capacity to generate the protein product. The top performing qP 
enhancer combination (ABCD; 7.67 fold) improved qP more that twice over its 
nearest singular counterpart (B; 3.03 fold). A combination of ABD also had a 
major beneficial impact on qP, echoing its impact on titer. It was evident that 
there were several positive interactions between factors.  
Both the growth and qP/titer DOE experimentation served as a strong proof of 
concept of combinatorial screening. This gave impetus to include combinatorial 








Figure 5.16 Ranked responses for qP/Titer enhancer factorial design. The 4 
factors employed were TUDCA (coded as A), NaBu (coded as B), 3TAA (coded as C) 
and MS 275 (coded as D). 16 randomised production runs were performed. 
Experimentation was performed in DWPs (cells seeded at 0.2×106 cells mL-1) with 
enhancer added on day 3. Culture attributes were recorded on day 5. Cell growth and 
viability (D) assayed using the Vi-CELL XR/Iprasense Norma; titer was assayed using 
Valita™TITER. (A) IVCD, (B) Titer and (C) qP represented as fold improvement over 
the no addition/vehicle control. Data represented mean ± SEM of three experimental 
replicates, with three technical replicates.  



































































Figure 5.17. qP/Titer DOE: Half-Normal plot depicting factor effects and 
significance. A straight line was drawn through residual factors. Any factors deviating 
from the line were taken forward for significance testing and formed part of the 
predictive model. Half-Normal plots for (A) IVCD, (B) Titer and (C) qP are displayed. 
Positive effectors are shown in orange whereas negative effectors are shown in blue. 





As performed in the previous DOE, model fitting and analysis was performed in 
DesignExpert®. Significant effectors and combinations were identified through 
the half-normal plot with subsequent statistical significance testing (Figure 5.17 
and Appendix C) and used to create a linear model to predict IVCD, titer and 
qP. Viability was not modelled for since all combinations maintained high 
viability and it was not an attribute that needed improving above the control. 






























































































































































































!"#$ = 0.70− 0.024! − 0.081! − 0.16! − 0.043! − 0.029!" + 0.036!"
− 0.023!" 
Equation 5.4 
!"#$% = 2.51+ 0.37! + 0.61! − 0.01! + 0.22! + 0.064!" − 0.12!" + 0.054!"
− 0.093!" − 0.14!" − 0.23!" − 0.13!"# − 0.10!"# 
Equation 5.5 
!" = 4.06+ 0.79! + 1.33! + 0.88! + 0.55! + 0.18!" + 0.19!" − 0.20!" 
Equation 5.6 
 
Significant factors were revealed through ANOVAs and were used to base the 
model. All models were significant with a non-significant lack-of-fit (Appendix 
C). Normality analysis of residuals confirmed normality and that no transform 
was required (Appendix C). It was evident that most model terms had a 
negative impact on IVCD. In contrast, most combinations and singular entities 
had positive effects on titer and qP. The equations can be employed to 
determine levels of factors to achieve a desired IVCD, titer or qP. All models 
outputs would be a fold change over the control condition.  
 
 Combinatorial Design 3: Maximising Titer 5.3.14.
 
The first 2 factorial designs revealed combinations of interest for the elevation 
of growth and protein production performance separately. We were interested 
to determine if testing all the factors together yielded unique positive 
combinations that could not be predicted from performing the designs 
separately. Thus, a full factorial design comprising 7 factors was employed (128 
unique experimental runs). Experimentation was performed in 96 DWPs as 
previously. A secondary aim of the design was to investigate the potential of 
system control. The question to be addressed would be: Can we achieve 
desired cellular response phenotypes, for example, maximise titer while 
minimising biomass or maximise growth and titer through the use of chemical 
combinations? Growth enhancers (Factors E, F and G: Cu, Zn and FAC 




TUDCA, NaBu, 3TAA and MS 275) were added on day 3. The concentrations 
were as used previously (i.e. in the separate DOEs).  
A scatter plot (displayed in Figure 5.18) revealed that a high number of 
combinations improved IVCD and titer (top right quadrant) or titer specifically 
(top left quadrant). No extremely detrimental interactions were observed, with 
each combination maintaining an improvement over the control for titer. 
  
 
Figure 5.18 Scatter plot for each run of the 7 factor DOE. Each run is a unique 
factor or combination of factors (128 in total). Culture attributes recorded on day 5. 
Growth and viability assayed using the Iprasense Norma. Titer assayed using the 
Valita™TITER assay. Resulting IVCD and titer from each run are displayed. The plot 
can be divided into four quadrants. Top left: increased titer, decreased IVCD; Top right: 
increased titer, increased IVCD; Bottom left: decreased titer, decreased IVCD; Bottom 
right: decreased titer, increased IVCD. Dots marked in red indicate viability below 85%. 
Data depicted is the mean of two experimental and two technical replicates. Error bars 




This experimental model mainly served as a snapshot of the flexibility of the 
design space to suit a user’s requirements. For instance, 4 discrete culture 
phenotypes could be observed on the scatter plot:  












A: TUDCA    B: NaBu    C: 3TAA    D: MS275    E: Cu    F: Zn    G: FAC
maximise 
biomass 
maximise titer while maintaining biomass maximise 
titer
maintain/improve 






(i.) Maximising cellular biomass (blue circle): If the user would like to 
improve cellular IVCD, various combinations could present potential 
solutions. All combinations presented improved volumetric titer as well. 
(ii.) Maximising titer while maintaining biomass (orange box): If the user 
desires to exclusively increase titer without disturbance to other cellular 
processes impacting cell growth.  
(iii.) Maximise titer (green box): If the user would like to achieve the largest 
boost in volumetric titer through the use of various chemical 
combinations. 
(iv.) Maintain/improve titer while minimising biomass (purple oval): If the user 
would like to minimise downstream processing complexity while still 
maintaining a titer increase. Herein, cellular biomass would be minimised 
while cellular productivity improved, resulting in lower cell impurities to 
purify for downstream processing. These combinations would be 
valuable in situations where low cell numbers are desirable such as lines 
susceptible to host cell protein accumulation or to ease downstream 
processing.  
The spread of responses across the spectrum depict the flexibility of 
modulation. Chemicals would be added in tandem for a desired response, 
demonstrating the combinatorial power of bioactive small molecules to 
modulate cell function.  
At the top end of the spectrum for titer improvements, there were a number of 
combinations that improved titer, however with fold changes being extremely 
tight, there was no standout combination for the maximisation of titer (Figure 
5.19). However, this bestows flexibility on the user. For those who are reluctant 
to change their production system, can be parsimonious in their addition of 
chemical enhancers. For example, only a small reduction in titer is observed 
when going from 5 factors (ABCDE: 4.48 fold) to 3 (ABG: 3.76 fold). This factor 
redundancy is also shown in Figure 5.20. Herein, it can be concluded that 
combining 2 or more factors did have a beneficial impact on the volumetric titer 
gains in our system, however adding more than 4 factors together yielded 
diminishing returns. Interestingly, adding all 7 factors together still returned titer 




improvement effects of factors were muted. This instates the impetus towards 
parsimony and reducing complexity, similar titer improvement could be gained 
through the use of less number of factors (for example 4 vs. 5 in this case), thus 
reducing system complexity.  
 
 
Figure 5.19 Seven factor titer DOE: Top 40 titer boosting combinations. Top 40 of 
128 combinations depicted here. Control titer set to 1. All runs depicted as a fold 
change. Data depicted is the mean and standard error of two experimental and two 
technical replicates.  
	
	
Figure 5.20 Seven factor titer DOE: Impact of the number of factors on titer 
performance. Largest titer fold change yielding run for each number of factors is 
displayed. Data represented is the mean and standard error of two experimental 




As performed previously, the data was entered into Design-Expert®10 to model 














































































































































































Top 40 titer combinations
A: TUDCA    B: NaBu    C: 3TAA    D: MS 275    E: Cu    F: Zn    G: FAC

























significant (Figure 5.21) Significant models were created (with non-significant 
lack of fit). Non-normality of residuals was dealt with recommended power 
transforms. The predictive linear equation and information on the significance 
testing performed can be found in Appendix C. 
 
 
Figure 5.21 Half-Normal plots for the seven factor Titer DOE. Effect of each factor 
calculated mathematically based on 128 production runs. No aliasing was observed. 
Standardised effects of each factor and combination plotted on a half-normal plot. A 
straight line was drawn through residual factors. Any factors deviating from the line 
were taken forward for significance testing and formed part of the predictive model. 
Half-Normal plots for (A) IVCD (B) log10(Titer) and (C) 1/√qP are displayed. Power 
transforms were performed for Titer and qP to restore normality.  Positive effectors are 
shown in orange whereas negative effectors are shown in blue. Two experimental 




To summarise, the seven factor DOE design served to provide a glimpse of the 
power of combinatorial designs to decipher combinations of interest for a variety 




























































































































































































































































































































there was no standout combination that provided a massive improvement in 
comparison to other combinations. Conversely, a large number of combinations 
ranked higher than singular effectors.  
 
 Scale-Up Performance in Fed-Batch Culture 5.3.15.
 
Industrial production processes are often performed in fed-batch culture modes. 
In order to determine the capabilities of the HT platform to predictably isolate 
effective combinations of SMEs for scale-up culture, we trialled fed-batch 
production cultures (25 mL starting culture volume) that utilised a selection of 
SME combinations. It was hypothesised that correlation between 96 DWPs and 
shake flask fed-batch cultures in our experimental model would not be perfect. 
This was due to 3 reasons: (i) The HT screens were performed in batch culture, 
thus ignoring the effect of feeds on the process. It is highly likely that some 
enhancers like metal ions would form components of the feed so improvement 
effects could be muted, (ii) The feeding strategy of the feeds and enhancers 
was not completely optimised i.e. due to a time bound environment, only a 
single feeding strategy and single day of qP SME addition was employed and 
(iii) Since fed-batch processes yield high productivity conditions (due to 
replenishment of nutrients periodically), it is thought that the margin for 
improvement in fed-batch processes would be much lower than batch systems. 
The fed-batch experimentation can be divided into 3 categories. The first was 
growth enhancer supplementation. The best performing combination from the 
HT screens for growth (EG: Cu, FAC) was taken forward for fed-batch testing. 
The SME combination was added on day 0, with another condition also having 
an extra feed of the same combination at day 4. We aimed to discern if extra 
feeding of the growth enhancers is beneficial as the cells approach stationary 
phase. Figure 5.22A depicts the performance of the growth enhancers in fed-
batch culture. There were slight improvements in growth rate from day 3 
onwards in cultures that were supplemented with growth enhancers. The control 
and enhancer cultures reached maximum VCD on day 6. From there onwards 
the enhancer fed cultures were able to sustain the high cell number until day 




with all conditions cultured culminating on day 12. The IVCD calculations also 
revealed that there was a significant 13% increase in total IVCD (for both day 0 
only and day 0,4 fed cultures) on day 12 (Figure 5.23A) (P<0.05; one-way 
ANOVA, Dunnett’s test). There was no real benefit of adding an extra EG feed 
on day 4 compared to just the day 0 feed. While the margin of improvement 
was not similar to the ones shown in the 96 DWP 5 day batch mode, there was 
still credibility of the plate to predict enhancers of growth. As stated earlier, 
metal ions are commercial feed components and thus enhancer effects could 
be dampened. Titer recorded on day 10 (Figure 5.23B) showed slight reduction 
in the enhancer-supplemented cultures over the control (not significant; one-
way ANOVA, Dunnett’s test), suggesting that the mechanism of titer 
improvement in 96DWP batch mode did not translate to shake flask fed-batch 
mode. 
Secondly, the best performing titer (ABD: TUDCA, NaBu, MS 275) and qP 
(ABCD: TUDCA, NaBu, 3TAA, MS 275) enhancers from combinatorial design 2 
were tested in fed-batch mode (Figure 5.22C). The enhancers were added at 
mid to late exponential stage (day 5). Post addition, ABCD supplemented 
cultures had a reduction in growth rate, accompanied by decreasing viability 
over time (Figure 5.22D). This decline in viability was not observed in the 96 
DWP screens. We estimate that this was due to viability performance being only 
measured once at the start of DWP stationary phase, 2 days after the addition 
of chemicals. Conversely, ABD supplemented cultures followed a more 
standard viability trajectory. However, ABCD cultures were more productive 
overall, recording around 60% (2.9 g L-1; p<0.001, one-way ANOVA, Dunnett’s 
test) titer improvement over the respective control cultures. In comparison, ABD 
produced a 40% improvement (2.73 g L-1; p<0.01, one-way ANOVA, Dunnett’s 
test) (Figure 5.23B). Again, the cultures did not record the same level of 
improvement as in the DWPs. It is anticipated that since the shake flask fed-
batch control cultures recorded titer levels of around 1.85 to 2 g L-1, we might 
be reaching the limits of culture production capabilities and thus margins for 
improvement are lower. However, these were still major improvements in 
comparison to the control, syncing with the DWP data that predicted these 




Lastly, we evaluated whether any beneficial effects were observed by adding 
the IVCD enhancers and titer enhancers together (Figure 5.22E). While all 
conditions displayed a rescue of IVCD in comparison to just the titer enhancer 
conditions (Figure 5.23A), there was no major beneficial impact on titer in 







Figure 5.22 Fed-batch growth performance with various enhancer combinatorial 
strategies. Fed-batch culture studies were performed in shaking Erlenmeyer flasks for 
12 days. Cells were seeded at 0.2×106 cells mL-1. Samples were taken daily for cell 
density and viability analysis using the Vi-CELL-XR. (A) Cell growth and (B) viability 
performance in the presence of growth enhancers. The growth enhancers EG were 
added on day 0 ( ) or day 0 and 4 ( ). (C) Cell growth and (D) viability data for 
titer/qP enhancer combinations. 2 different combinations were tested ABD ( ) and 
ABCD ( ). SME added on day 5. (E) Growth and (F) viability data for IVCD and 
titer/qP enhancers in combination. Combinations tested were: day 0 addition of EG + 
day 5 addition of ABD ( ); day 0 addition of EG + day 5 addition of ABCD ( ); day 0 
and 4 addition of EG + day 5 addition of ABD ( ); day 0 and 4 addition of EG + day 5 
addition of ABCD ( ). Controls used: no addition ( ), ABD control (0.2% DMSO v/v) (
) and ABCD control (0.3% DMSO v/v) ( ). CHO CD EfficientFeed™B added on 
days 2, 4, 6 and 8 (light grey arrows). Black arrows indicate chemical enhancer cocktail 
addition. All data represented is the mean and standard error of two experimental 
replicates, with two technical replicates.  
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A: TUDCA (2 mM) B: NaBu (1 mM) C: 3TAA (4 mM) D: MS 275 (3 µM) E: Cu (0.5 µM) G: FAC (500 µM)
EG D0 EG D0,D4 
ABD D5
ABCD D5
EG D0 + ABD D5 EG D0 + ABCD D5
EG D0,4 + ABD D5
EG D0,4 + ABCD D5 no additon ctrl






Figure 5.23 IVCD and Titer outputs for all conditions tested in fed-batch 
production mode. (A) Absolute IVCD data plotted for each condition tested. 
Enhancers depicted in coded terms. IVCD level of no addition control depicted by the 
red dotted line. (B) Normalised titer values for all conditions tested. Values for each 
condition depicted as a fold change to their respective control (no addition, ABD control 
(0.2% DMSO v/v) or ABCD control (0.3% DMSO v/v). Data depicted is the mean ± 






The work depicted in this chapter, firstly served as an exemplar for the utility of 
the HT screening platform. We were able to identify SME chemicals that were 
successful in improving 1, 2 or 3 culture attributes (IVCD, titer, qP) in a stable 






































































































































































bypassed the problems faced in static culture as discussed earlier (Section 
4.3.4). This was ideal for testing SMEs since the cells could be incubated for a 
longer duration with the chemical of interest, to get an amplified signal or detect 
cytotoxicity. 
We were able to rigorously evaluate 8 functional groups of SMEs. Each group 
recorded varying success rates. We were able to thus present a suite of 
chemical enhancers that can be employed in cell culture for production 
performance elevation. The work presented here is envisioned to form the basis 
of a commercial HT screening tool. Thus, it is important to evaluate the efficacy 
of these enhancers in other model systems; i.e. different media and cell lines. 
Due to limitation on cell line and product resource availability, this comparison 
could not be performed. However, previous published work indicates that many 
molecules presented in our studies have shown improvements in other CHO 
systems (stable and transient). Looking at the data available from our study, 
perhaps the most telling group was the chemical chaperones. Tested in a 
standard protein production system that is known to reach g L-1 titers (personal 
communication and Section 5.3.15), this protein molecule can be classed as 
relatively easy-to-express. We observed positive effects with a cohort of 
chemical chaperones that are known to target protein misfolding and liaise with 
molecular chaperones that alleviate ER stress. Since these abnormalities are 
likely to be present at low levels in our easy-to-express protein system, the 
effects of chemical chaperones observed could be amplified in DTE systems. 
There has been a steady increase in the number of published articles and 
reviews exploring post-transcriptional bottlenecks in CHO cells, indicative that 
engineering the secretory pathways for better production performance is of 
interest (Hansen et al., 2017; Zhou et al., 2018). An example of chemical 
chaperone utility can be represented by a study performed by Johari et al. 
(2015). Their DTE model system witnessed increases of 1.7 fold in short term 
transient expression. In a shaking fed-batch production culture, the addition of 2 
chemical chaperones (4PBA and glycerol) and a molecular chaperone (cypB) 
led to ~3.5 fold improvements in total titer at the end of 12 days. Interestingly, 
4PBA and glycerol were not the most effective chaperones in our production 




their concentration are cell line and product dependent. This provides impetus 
for the creation of HT methods to isolate SMEs for different production 
processes, which is the overarching aim of this project. 
The molecules selected for the study had varying targets. Metal ions and 
metabolic modulators targeted efficient cycling of nutrients for improvements in 
biomass accumulation. The remainder of the groups targeted the synthetic 
protein production process. For example, HDAC inhibitors boosted general 
transcriptional activity whereas chemical chaperones impacted protein folding 
and stability. To summarise, a multitude of different functions can be targeted 
and modulated intelligently for a desired production fingerprint.  
Biphasic culture strategies also proved valuable in improving overall protein 
production. Enhancers like 4PBA and TSA did not provide titer improvements 
using a day 0 deployment strategy, but enhanced titer when deployed at mid-
exponential phase. This was analogous to some of the more common biphasic 
strategies employed in the biopharmaceutical industry such as temperature shift 
from 37 to 32°C (Yoon et al., 2006). Combining small molecule supplementation 
with strategies like temperature shift can be used to create desired biphasic 
processes as demonstrated by Coronel et al. (2016). 
Combinatorial designs further elevated enhancer effects on growth, titer and 
qP. Statistical analysis of the design model revealed multiple significant 
combinations that affected IVCD, titer or qP positively or negatively. However, 
from an engineering perspective, the design rules were simple, find the top 
producing or growing condition that did not negatively impact cell viability. The 
rationale behind adopting this strategy can be explained easily. A scenario 
where 2 factors produce the best IVCD, however their cumulative effect based 
on other “statistically identical” production runs is negative. Additionally, if their 
combination effect is lower that the sum of the individual factor effect, the 
interaction is classed as antagonistic. In our scenario, the most logical approach 
would be the selection of the best performing condition. Engineering firms use 
DOE design techniques for optimising factors that can’t be easily removed. 
Since our design operates on a plug and play concept, it is simple to remove 
factors and not all SMEs need to be employed. Thus, we adopted a simple 




that some literature sources investigate more diverse cross-functional 
combinations. For example, butyrate and pentanoate while increasing protein 
yields were shown to initiate apoptotic pathways (Camire et al., 2017). Addition 
of an antioxidant molecule (N-acetyl cysteine) to the chemical treated cultures 
enhanced IVCD and lowered apoptotic cell abundance. This study thus 
demonstrates that combining small molecules intelligently could diminish any 
off-target negative effects of certain SME use. This would be particularly useful 
in protein glycosylation modulation, wherein if any molecule negatively impacts 
protein glycoform profiles (but is beneficial to growth/titer), addition of a small 
molecule modulator could “correct” protein glycosylation profiles to meet 
regulatory standards (Brühlmann et al., 2017b; Brühlmann et al., 2017a; 
Grainger and James, 2013; Gramer et al., 2011). 
Trialling the predicted best combinations from DWP studies in a scaled-up, fed-
batch culture mode, suggested that performance in DWPs depicted the same 
trends at scale-up, however the extent of improvement did not concur between 
the 2 scales. This conclusion is not definitive since only 1 feeding strategy was 
evaluated so follow-up experimentation would be required to confirm this 
conclusion. However, it was evident that cellular viability selection criteria would 
need to be re-evaluated. The best performing qP condition from DWP studies, 
(ABCD; A: TUDCA, B: NaBu, C: 3TAA and D: MS 275) revealed a gradual 
decrease in viability when added to shake flask fed-batch culture. Even cultures 
incubated with the DWP predicted most productive condition, ABD, faltered in 
viability in advance of the control cultures. DWP screens could not predict this 
phenomenon since the incubation time was short. The most straightforward 
approach to remedy this would be to incubate the plate for longer or to create a 
fed-batch modality in DWPs. However, to keep with the quick and easy 
incubation setup, we decided to slightly update the design space selection 
strategy. This is explained below. 
The prospect of applying parsimony to the design space has always been 
discussed. Looking at our DWP qP combinatorial data, it was evident that 
combination AB had similar titer output to ABD and ABCD. However, growth 
inhibition was lower in comparison. It remains to be determined what its effect 




since growth arrest was low in DWPs, cells would react more favourably to AB 
supplementation, with culture viability remaining high. Thus, with cultures 
potentially lasting longer, bigger gains due to addition of the combination could 
be harnessed, making it a better combination than ABD and ABCD. Parsimony 
is also beneficial from a regulatory point of view since the number of factors to 
consider is lower. It is obvious that these hypotheses would need to be 
thoroughly tested to examine validity.  
The major limitation of our screening study was the lack of evaluation of product 
quality in the presence of SME molecules. Some small molecules can 
significantly alter the glycosylation state of the protein unfavourably (Hong et al., 
2014). Additionally, some small molecule modulators have been shown to 
modulate product quality favourably to obtain a desired glycosylation profile 
(Brühlmann et al., 2017a; Grainger and James, 2013) (detailed in Section 
2.2.5). Thus, addition of HT product quality assessment technologies to our HT 
analytics toolbox could assist in making more informed choices of SMEs with 
regards to product quality. Addition of small molecule glycosylation modulators 
would increase the diversity of the SME suite that we have already obtained. 
Overall, we were able to demonstrate the use of our developed HT screening 
platform to isolate enhancers of CHO production culture. Chemicals could easily 
be titrated, in order to determine their effective concentration. Small 
combinatorial designs informed the predicted best culture supplementation 
strategy. Scale-up performance was not ideal however the HT screens did 
correctly indicate combinations that enhanced culture performance. 
All the information presented in this chapter would assist in the creation of a 
commercial screening platform. We were able to assess the efficacy of a 
functionally diverse group of molecules. Ideally, singular enhancers or 
combinations of enhancers would be lyophilised on a 96 DWP. The contents of 
the plate would need to be determined through more cell line/product and basal 
media testing (resources that were not available for the purposes of this 
project). This would help determine chemicals and concentration ranges that 
are likely to be effective for a range of different cell types and production 
platforms. The user would add a pre-determined culture volume to the plate and 




determined on day 5 using the high-throughput assay techniques. Statistical 
modelling software would enable the creation of bespoke media environments 
tailored to the user’s production process. Statistical computational modelling 
would be in the form of small DOE based combinatorial testing. Extra caution 
would need to be applied when selecting growth-arresting enhancers. Cell 















in	a	CHO	cell	 system	 stably	producing	a	mAb	product.	 5	 thiophene	molecules	were	
evaluated	across	 a	wide	 range	 of	 concentrations	 in	 our	 high-throughput	 screening	
platform.	Growth	and	titer	were	measured	on	day	5	of	batch	deep	well	plate	culture.	
2	 Thiopheneacetic	 acid	 (2TAA)	 and	 3	 Thiopheneacetic	 acid	 (3TAA)	were	 shown	 to	
improve	volumetric	titer	by	1.6	fold.	Scaled-up	studies	in	shake	flasks	confirmed	that	
the	 enhancing	 efficiency	 of	 these	molecules	was	 conserved	 at	 a	 larger	 scale.	 2TAA	
supplemented	cultures	produced	a	2.4	increase	whereas	3TAA	supplemented	cultures	
produced	 a	 1.85	 fold	 increase	 in	 volumetric	 titer.	 There	 is	 very	 little	 evidence	 in	
literature	to	elucidate	mode	of	action	of	these	2	enhancer	molecules.	We	investigated	
mode	 of	 action	 through	 iterative	 functional	 and	mechanistic	 analyses.	 2	 and	3TAA	
were	shown	to	arrest	cells	in	the	G1	phase	of	the	cell	cycle,	a	trait	commonly	observed	
with	 the	 use	 of	 HDAC	 inhibitors	 such	 as	 sodium	 butyrate.	 Interestingly,	 2TAA	was	
shown	to	 induce	early	apoptosis	 in	CHO	cells	upon	treatment	at	 its	 titer	enhancing	
dose.	 Conversely,	 3TAA	 did	 not	 have	 any	 impact	 on	 the	 apoptotic	 state	 of	 the	 cell.	
Product	 gene	 mRNA	 analysis	 revealed	 than	 both	 2	 and	 3TAA	 acted	 partly	 at	 the	
mRNA	level.	Mass	spectrometric	analysis	conducted	showed	increased	abundances	of	













The mass spectrometry methods and analysis were performed by Eleanor 
Hanson (The University of Sheffield). Glycan release and analysis of the 
purified protein product was performed by Dr. Roisin O’Flaherty and Dr. Karen 




With g L-1 titer outputs becoming commonplace in the bioprocessing arena, it 
could be argued that focus should move towards downstream processing 
improvement. While improvements to downstream processes are crucial, 
upstream process improvement has consistently remained a core focal point for 
intense improvement. Chapter 5 focused on utilising the created HT screening 
platform to rapidly evaluate small molecule enhancer additives to improve cell 
growth and productivity. A by-product of this study was the ability to evaluate 
potential novel SME candidates.  
Carboxylic acids have been found to be global enhancers of protein production 
in CHO. Molecules like sodium butyrate, valeric acid, sodium phenylbutyrate 
and valproic acid have been employed in multiple studies to improve protein 
production in CHO cells (Backliwal et al., 2008; Coronel et al., 2016; Jiang and 
Sharfstein, 2008; Johari et al., 2015; Park et al., 2016; Sung et al., 2004). 
Studies by Allen et al. (2008) and Bora-Tatar et al. (2009) performed large 
carboxylic acids screens (in-vitro and in-silico respectively) to evaluate potential 
carboxylic acid molecule efficacy. The former study revealed an interesting set 
of molecules that were able to boost stable production performance in CHO 
cells. We employed that study to form the basis of our in-house search into 
novel carboxylates for recombinant protein production.  
We focused our efforts on thiophene carboxylate molecules (thiophenes: 
molecules that contain a sulphur group in the aromatic planar ring). There is 
hardly any evidence (apart from Allen et al. (2008) that employed 2 
thiopheneacetic acid) of the use of these molecules as enhancers for 




carboxylate HDAC inhibitors. They have previously been employed in polymer 
and semiconductor nanoparticle manufacture (Narizzano et al., 2005).  
The positive outcomes of various thiophene supplementations in our system 
motivated our efforts to investigate the molecular mode of action that is 
responsible for the protein production enhancement. Again, there is no literature 
evidence on mode of action (with the Allen paper failing to declare mechanism 
confidently). We consulted literature sources that contained detailed 
mechanistic analysis into the titer inducement prowess of SMEs to plan our 
mechanism exploratory strategy (detailed in Experimental approach) (Backliwal 
et al., 2008; Jiang and Sharfstein, 2008; Park et al., 2016).  
Given that the thiophene molecules contained the same structural backbone as 
common HDAC inhibitors (such butyrate and valproate), i.e. a carboxylate 
structure, we hypothesised that the molecules could act epigenetically. 
Epigenetic modifications, such as histone acetylation play an important role in 
regulating gene expression (Dahodwala and Sharfstein, 2014). A balance 
between histone acetyltransferase (writers) and histone deacetylases (erasers) 
normally governs histone acetylation. Acetylation of lysine residues on the 
histone molecule imparts a negative charge on the histone molecule, causing a 
decrease in interaction with the negatively charged DNA (Kim and Bae, 2011). 
This prevents tight multiple nucleosome packing, improving gene accessibility 
to transcriptional machinery, thus upregulating transcriptional activity (Jiang and 
Sharfstein, 2008; Kim and Bae, 2011). Thus, investigating transcriptional 
activity and histone modification activity in response to the thiophenes was of 
interest. Cellular health and cell cycle analytics also played an important role in 
our analysis of the molecules. Chemical enhancer molecules can instigate off-
target effects on cell viability (Lee and Lee, 2012). Additionally, initial screens 
depicted a repression in growth with the thiophene molecules, motivating efforts 
to investigate cell cycle arrest in greater detail. Lastly, it was important to 
evaluate product quality in the presence of the chemicals. It was necessary to 
determine any negative impacts on the protein product glycoform that could 
thwart product efficacy as a therapeutic. Protein glycosylation is often an 




incorrect glycosylation could hamper therapeutic efficacy and half-life (Hossler 
et al., 2009). 
 
6.2. Experimental Approach 
 
Our studies with the set of enhancer molecules listed in Allen et al. (2008) only 
yielded 2-Thiopheneacetic acid (or 2-Thienylacetic acid) (2TAA) (a molecule 
with a thiophene group) as an effective production stimulant. Since there is no 
mechanistic information regarding the molecule, we aimed to examine the 
molecule further. There are no studies in CHO cells elucidating the use of other 
thiophene molecules as production enhancers, so we took this as an 
opportunity to investigate mechanism and isolate novel enhancers for protein 
production.  
Firstly, we sought to employ computational structural similarity assessment to 
isolate structurally similar molecules to 2TAA. We were able to identify 4 
structurally similar molecules; these were subsequently tested in our HT 
system. Positive enhancers of productivity and/or qP were taken forward to test 
using delayed addition in our HT system (detailed in Section 5.3.10). Following 
the screens, we were able to identify 3TAA, a structural analogue to 2TAA as a 
protein production enhancer. Both these molecules were employed in scale-up 
batch culture shake flask studies to investigate their efficacy in a larger scale 
and over a longer incubation period. Only a single concentration per molecule 
(selected based on their HT day 0 addition screens) was tested in shake flasks, 
for ease of experimentation.  
The batch culture shake flask studies were performed in a 30 mL culture 
volume. Cobra 38, a CHO-S derived cell line that stably expresses an IgG1 
molecule was used in this study. The scale-up to 30 mL cultures allowed daily 
sampling for cell growth and titer analysis. Samples for other mechanistic 
studies (such as epigenetic, transcriptional and apoptosis analysis) were based 
on a single day sample collection for ease of experimentation. Most mechanistic 
and functional studies were performed on day 5 of a 9 to 10 day batch culture 




was chosen given that the largest increase in qP was observed at that time 
point. This was suggestive that cells were transitioning into peak production 
mode, wherein the effects of the SME on the protein production processes 
could be larger and more apparent. The chronology of experimentation was 
fluid. An iterative approach was employed, wherein results from previous 
experimentation was used to inform the next line of testing. Positive controls (in 
the form of well-known SME carboxylate molecule supplementation) were used 
to support some functional studies. 
Overall, this chapter serves as a standalone study investigating the mode of 
action of 2 thiophene carboxylate molecules that can be employed as protein 
production enhancers in CHO cells. The HT platform (described in chapter 4) 
assisted in the screening and identification of novel carboxylate SMEs. These 





 Identification and Assessment of 2TAA Analogs 6.3.1.
 
Our SME screens indicated 2TAA as an effective protein enhancer molecule 
(detailed in Section 5.3.9). This is only the second study (first being: Allen et al. 
(2008)) to date that has reported the use of a thiophene carboxylic acid 
molecule as a cell culture process enhancer. We aimed to identify more 
thiophene molecules as enhancers for CHO bioprocess. In-silico molecular 
docking studies have often been employed to predict molecule efficacy based 
on structure and function (Bora-Tatar et al., 2009). Since we could not assess 
functional efficacy in-silico (molecule substrate was not established), we chose 
to employ structural similarity testing and subsequently assess functional 
efficacy experimentally. We employed ChemMine tools (Backman et al., 2011) 
in combination with PubChem similarity search (Kim et al., 2016b) to isolate 
potential enhancer molecules based on their Tanimoto similarity score. 4 unique 
molecules with a structural similarity >0.5 (maximum of 1) were isolated (Figure 




Thiophenecarboxylic acid (2TCA) and 3-Thiopheneacetic acid (3TAA), all 
contained a thiophene group and a carboxylate group. The differences between 
the molecules stemmed from variation in hydrocarbon chain number. 
 
 
Figure 6.1 Structural Analogues of 2TAA. The molecules were selected based on 
their maximum common substructure (MCS) Tanimoto similarity (maximum similarity is 
1; cut-off >0.5) scores against the parent molecule 2TAA. Similarity was computed 
using the PubChem similarity plugin on the ChemMine Web tool. Structures depicted 





These molecules were then tested in our HT platform to assess their efficacy as 
protein production enhancers in CHO cells. The results are displayed in Figure 
6.2. The parent molecule 2TAA (tested from 0.2 to 2 mM) had recorded a 
maximum yield enhancement of 1.6 fold at 0.8 mM. The key culture 





Similarity index = 0.5833 
TPA TBA 
Similarity index = 0.5385 
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increase in qP and overall titer (concentration dependent) and (iii) no loss in 
viability at the highest titer yielding concentration. We aimed to investigate 
whether the analogues displayed similar performance in our HT screening 
platform. The same range of concentrations (as 2TAA) was initially tested for all 
analogue molecules.  
TPA (Figure 6.2B) did not show any major titer improvements when tested from 
0.2 to 2 mM. However, a gradual increase in qP with increasing concentrations 
was observed. This prompted us to further investigate a higher concentration 
range. Further enhancements in qP were observed with cell growth diminishing 
around the 4.8 mM concentration range, and viability dropping post 4 mM. TBA 
(Figure 6.2C) yielded the poorest performance amongst all the thiophene 
carboxylates tested. This was interesting since the molecule only had 1 extra 
carbon atom (1 hydrocarbon chain) in comparison to TPA. However, 
performance differed drastically, with cell growth diminishing and viability 
dropping at 0.8 mM. This molecule was thus excluded from any further 
experimentation. 2TCA (Figure 6.2D) displayed concentration dependent 
growth reduction, however, no positive effects to cellular qP were observed at 
any concentration. Testing higher concentrations did not yield any benefit 
either. Thus, this molecule was excluded from any further examination as well. 
Lastly, 3TAA (Figure 6.2E), recorded the best titer performance from the tested 
analogue molecules. The molecule is highly similar to 2TAA (the position of the 
aliphatic chain is displaced). Growth suppression was less severe compared to 
2TAA, thus a large range of concentrations could be tested. The optimum 
concentration (1.6 fold titer increase at 2.5 mM) was also higher than 2TAA. 
There is no literature evidence on the use of these molecules to improve 
biologics production. We decided to take forward 3TAA (as the best performing 
analogue for titer) along with the already reported 2TAA for scale-up batch 
studies in shake flasks. 3TAA, TPA along with 2TAA were also tested in our 
delayed addition setup to investigate whether titer could be further amplified 
when the qP enhancing thiophenes were added on day 3 (mid-exponential 

































































































































































































































































































































































































































































































































































































































































































 Production Performance of 2TAA and 3TAA in Batch Shake 6.3.2.
Flask Culture 
 
Our HT system allows for the discovery of novel chemical enhancer molecules 
as discussed in the previous section, however late stage culture performance 
and effect over a longer culture period cannot be elucidated. To ascertain that 
the culture elevating performance of 2TAA and its novel analogue enhancer 
3TAA were maintained at a larger scale and over a longer time period, we 
trialled both molecules in 30 mL shake flask batch cultures. Culture conditions 
were monitored daily and the cultures terminated when the viability of all culture 
conditions fell below 30%.  
Figure 6.3A depicts the growth profiles of the enhancer-supplemented cultures 
in comparison to the non-supplemented controls (no addition or 0.2% v/v 
DMSO (solubilisation vehicle for both 2 and 3TAA)). Cell growth was visibly 
reduced in both 2TAA and 3TAA supplemented cultures, however the cells 
remained viable (Figure 6.3B). The low number of cells in culture contributed 
towards the slow consumption of nutrients, resulting in the culture remaining 
viable for a longer period over the control cultures. Both the control conditions 
witnessed a drop in viability from day 7 onwards, with SME supplemented 
cultures remaining viable for at least an extra day. To compare the 2 molecules, 
3TAA had a lower impact on cell growth arrest in comparison to 2TAA. Their 
mean peak cell densities (both achieved on day 7) were 6.1±0.137×106 cells 
mL-1 and 8.87±0.461×106 cells mL-1 for 2TAA and 3TAA respectively. In 
contrast, control cultures peaked at around 12×106 cells mL-1 on day 5 (no 
addition: 12.1±0.642×106 cells mL-1; 0.2%v/v DSMO: 12.34±0.625 cells mL-1). 
The slower growing 2TAA cultures also recorded a slightly slower drop in 
viability in comparison to 3TAA cultures. IVCD is a measure of the accumulation 
of biomass throughout the culture period. Our studies showed that, 
unsurprisingly 2TAA and 3TAA cultures recorded lower IVCD than the control 
cultures. There was a 33% reduction in total IVCD for the 2TAA-supplemented 
cultures (p<0.01; one-way ANOVA, Dunnett’s test), with a 13% drop (not 






Figure 6.3 2TAA and 3TAA supplemented culture production performance in 
shake flask batch culture. Cobra 38 cells were seeded at 0.2×106 cell mL-1 in 30 mL 
shake flask cultures. The enhancer molecule was added on day 0 into the growth 
media (CD CHO). A 0.2% v/v DMSO control was included to account for any effects of 
the solvent on culture performance. Cell growth and viability readings were taken daily 
using the Vi-CELL XR and supernatant samples collected daily for analysis using the 
Valita™TITER assay. Cultures were maintained at 37°C for 10 days. (A) VCD, (B) 
Viability and (C) Titer shown for no addition control ( ), 0.2% v/v DMSO control (
), 0.8 mM 2TAA ( ) and 2.5 mM 3TAA ( ). Total IVCD accumulated over the 
10-day period is depicted in (D). Data depicted is the mean and standard error of three 




Supernatant samples collected on each day were used to quantify the antibody 
levels in culture across all tested conditions. A shift in titer profiles with the SME 
supplemented cultures was evident from day 4 onwards for 2TAA. 2TAA 
supplemented culture titers consistently ranked over that of the control cultures 
until culture culmination. In comparison, 3TAA cultures recorded titer levels 
above the control from day 6 onwards. At the end of a 10-day batch culture 
period, 2TAA supplemented cultures were able to produce a 2.4 fold increase in 

































































































antibody titer (p<0.001) whereas 3TAA produced a 1.85 fold titer increase 
(p<0.01) over the DMSO control.  
The concentration to test at the larger scale was informed through the HT 
screens. Thus, this study also embedded a secondary aim to understand scale-
up batch performance. The growth arrests were comparable, i.e. 2TAA was 
predicted to be a stronger growth inhibitor than 3TAA in the HT screens. The 
HT screens predicted both enhancers to produce the same titer boost at their 
respective effective dose. However, batch culture shake flask studies showed 
that 2TAA outperformed 3TAA with respect to titer improvement spanning the 
culture period.  
Overall, 2TAA was shown to be a stronger titer enhancer at the concentration 
tested. The major observation that decided the next line of experimentation was 
the growth arresting properties of both chemicals. Growth arrest is a common 
occurrence with many chemical enhancers such as butyrate and valproic acid 
(Chen et al., 2011; Park et al., 2016). G1 phase arrest is commonly linked to 
HDAC inhibition, as is the case with both butyrate and valproate (Yamaguchi et 
al., 2010). Since valproate and butyrate also contain a carboxylate structure, it 
was worth investigating the cell cycle state of the cells in 2 and 3TAA 
supplemented cultures. 
 
 Cell Cycle Analytics 6.3.3.
 
2TAA and 3TAA supplemented cultures were analysed for their cell cycle 
distribution by PI based flow cytometry. As explained in the previous section, 
G1 arrest is often an accompaniment to carboxylate HDAC inhibitor SME main 
function. The results of cell cycle analysis performed on day 4 of batch culture 
(as shown in Figure 6.3) are displayed in Figure 6.4. The 3 main phases of cell 
cycle: G1, S and G2 were analysed. Both 2 and 3TAA recorded an increased 
accumulation in the G1 phase. There was an 18% increase (p<0.001) in G1 
phase accumulation for 2TAA treated cells; while 3TAA cultures recorded a 
13% increase (p<0.01) over the DMSO control. 2TAA was slightly more 




viable cell accumulation in Figure 6.3A and D. There were slight decreases in 
both S and G2 phase accumulation as a result of the G1 increase for the 
chemical supplemented cultures. 
The results are in line with previous SME studies (of sodium butyrate and 
valeric acid) reporting an increase in G1 phase accumulation (Chen et al., 2011; 
Park et al., 2016). However, many SME led cell cycle arrest can culminate in 
apoptosis (Lee and Lee, 2012). Therefore, it was important to investigate the 
effect of 2 and 3TAA on cell health. 
 
 
Figure 6.4 Cell cycle phase analysis of Cobra 38 cells in the presence of 2TAA 
and 3TAA. 1×106 cells were taken from the shake flask cultures on day 4 of batch 
culture (SME added on day 0) and fixed. Cell cycle phases were analysed using flow 
cytometry techniques using PI staining. Cell cycle distribution is depicted as a 
percentage of the total cell population analysed. Data represented as mean percentage 
and standard error of three experimental replicates each with two technical repeats. A 
one-way ANOVA was performed on the G1 phase data of all conditions tested, with a 




 Apoptosis Analysis 6.3.4.
   
Cell cycle arrest can often come with one caveat, the induction of apoptosis. 





























and result in lower product return (Kim and Lee, 2000). Cultures supplemented 
with NaBu have recorded an induction of apoptosis from as early as 24 hours 
(Lee and Lee, 2012). Other studies investigated apoptosis induction 4 days 
after chemical addition (Backliwal et al., 2008; Camire et al., 2017). Since both 
2TAA and 3TAA were confirmed to be G1 phase inhibitors, it was vital to 
investigate if apoptotic induction accompanied it. The apoptotic profiles of the 
cells cultured with the chemical enhancers was analysed on day 5 post-addition 
using flow cytometry. The highest titer inducing concentrations for 2 and 3TAA 
(0.8 and 2.5 mM respectively) were analysed. A lower concentration of 2TAA 
(0.4 mM) was also included (one that grew around the same rate of 3TAA 
supplemented cultures) to more effectively compare apoptotic profiles with 
3TAA. Additionally, NaBu was included as a comparative control; 2 
concentrations with varying titer enhancement and growth suppression were 







Figure 6.5 Apoptosis analysis of Cobra 38 cells in the presence of various 
concentrations of SMEs. Cobra 38 cells were seeded at 0.2×106 cells mL-1 in 10 mL 
TubeSpin disposable bioreactors for 5 days. Chemical added on day 0. 1×106 total 
cells were collected on day 5 of culture and analysed using Annexin V (apoptosis 
indicator) and 7AAD (dead cell indicator) staining on the Attune Acoustic Focusing 
Cytometer. 10,000 total events were analysed. Annexin V +ve but 7AAD −ve, cells 
were classed as early apoptotic cells with intact membranes. Cell growth and titer were 
also measured on day 5 using the Vi-CELL XR and Valita™TITER assay respectively. 
(A) depicts the percentage of cells that were Annexin V +ve and 7AAD −ve out of all 
cell events recorded. (B) shows the early apoptotic percentages as a fold change over 
the respective control percentages (0.2% v/v DMSO control for 2TAA and 3TAA 
cultures; no addition control for NaBu cultures). Titer and IVCD fold change on day 5 
displayed for comparison. Data represented is the mean and standard error of three 
experimental replicates each with two technical replicates. No significant difference 































































































Figure 6.5A shows the percentage of the culture population displaying early 
apoptotic traits. 28.8% of cells cultured in the presence of 0.8 mM 2TAA were 
recorded to be undergoing early apoptosis. The other SME conditions trialled 
did not display any major deviations from the apoptotic profiles of their 
respective controls. Interestingly, there was a very slight increase in apoptotic 
fractions in the DMSO control compared to the no addition control. There were 
also slight increases in apoptotic fractions with increasing concentrations of 
2TAA and NaBu. This depicted the importance of titrating various 
concentrations to find the “sweet spot” in terms of titer enhancement and 
apoptosis onset. Interestingly, with our cell line and product, NaBu 
supplementation did not induce high levels of apoptosis or stunt cultures at its 
effective titer boosting concentration. This is in contrast with other studies on 
the topic (Backliwal et al., 2008; Lee and Lee, 2012). 
Figure 6.5B compares the relative levels of apoptotic cell population increase 
with relative titer enhancement and growth suppression. 0.8 mM 2TAA and 0.5 
mM NaBu supplemented cultures recorded similar growth reduction and titer 
enhancement over their respective controls. However, apoptotic induction for 
0.8 mM 2TAA cultures was about 1.5 fold higher than 0.5mM NaBu. This 
suggested that 0.8 mM 2TAA supplementation did elevate apoptotic cell 
population levels. This observation was not picked up on the Vi-CELL XR, 
however this was not unexpected considering the need for membrane 
permeability for determination of percentage viability on the machine. It was 
interesting to note that while titer levels for both 0.8 mM 2TAA and 0.5 mM 
NaBu at the day 5 data collection point were similar, 2TAA was revealed to be a 
stronger titer enhancer overall, at the end of the culture period (2TAA: ~ 2.5 fold 
vs. NaBu: 2 fold; data not shown). Conversely, 3TAA was the lowest ranked 
titer enhancer at the day 5 data point, however recorded similar titer levels to 
0.5 mM NaBu at the end of culture period. Both these observations were due to 
an extended culture period for 2 and 3TAA, caused by a slower crash in overall 
culture viability. This was surprising in the case of 2TAA since midpoint culture 






 Product Transcriptional Analysis 6.3.5.
 
Transcription is the first step for recombinant protein expression. Monitoring 
transcriptional activity based on product mRNA levels can reveal 2 important 
attributes of SME activity. Firstly, does the molecule act at the transcriptional 
level at all, i.e. is there an increase in mRNA levels of the recombinant protein 
product? Secondly, if transcription is increased, is it solely responsible for the 
increases in protein production or do pathways downstream of transcription also 
have an impact? Simply put, is the transcriptional increase equivalent to the 
cellular productivity increase? The cell cycle arrest at G1 along with the 
carboxylate structure seen in many HDAC inhibitor molecules, led us to 
hypothesise that both 2 and 3TAA could act at the transcription level; a 
characteristic of HDAC inhibitor SMEs. 
 
 
Figure 6.6 Heavy and light chain mRNA content analysis of cells cultured in the 
presence of 2TAA, 3TAA or NaBu. Total RNA was extracted on day 5 of shake flask 
batch culture, with the SME added on day 0. cDNA was created for each sample, 
which was in turn analysed using qPCR (SYBR green). Heavy and light chain primers 
were employed along with 2 reference gene primers. Fold change in mRNA expression 
was computed using the 2-ΔΔCt method based on the Ct values recorded for each 
condition. Relative mRNA expression represented for each SME to its respective 
control (0.2% v/v DMSO control for 2 and 3TAA; no addition control for NaBu). 
Supernatant samples were also collected on the day 5 collection point to compute titer 
and qP. Titer and qP also depicted as a fold change to their respective controls. Red 
line depicts the control level, i.e. set to 1. Data represented is the mean and standard 
error of three experimental replicates each with two technical replicates.  





































We investigated transcriptional activity at day 5 of the batch cultures shown in 
Figure 6.3. mRNA levels of the heavy and light chain of the IgG1 product were 
determined using qPCR. 0.5 mM NaBu was included as a positive control due 
to its role as a transcription enhancer through HDAC inhibition. The results are 
shown in Figure 6.6. Since cell number was accounted for when taking 
samples for RNA extraction, comparison to cell specific productivity served as a 
more appropriate indicator of the extent of the role of transcription in increasing 
protein titer. All the SME supplementation conditions tested recorded an 
increase in both heavy and light chain mRNA levels. This was in accordance 
with our hypothesis that 2TAA and 3TAA acted at the transcription level. 
Supplementation with 0.8 mM 2TAA recorded the largest increase in product 
mRNA levels. Given that those cultures recorded the highest qP, this was 
unsurprising.  There was a 1.44 fold increase (p<0.01) in light chain mRNA and 
a 1.51 fold increase (p<0.05) in heavy chain mRNA. This observation was in 
discord with the previous study by Allen et al. (2008), which reported minimal 
increase in mRNA levels with 2TAA supplementation. However, the 
enhancement in mRNA levels was much lower in comparison to the increase in 
qP (3.8 fold), suggestive that post-transcription events could also play a role in 
increasing qP. 2.5 mM 3TAA supplementation induced a light chain mRNA 
enhancement of 1.29 fold (p<0.05), whereas heavy chain mRNA was increased 
by 1.39 fold (p<0.05). Again, there was no replication of the levels of increase 
obtained at the cellular qP level, however the gap between the levels was lower 
in comparison to 2TAA. However, it cannot be discounted that events 
downstream of transcription also assist in the 3TAA facilitated qP increase. 
The positive control (0.5 mM NaBu), interestingly recorded a lower increase in 
mRNA levels in comparison to both 2 and 3TAA. There was a 1.2 fold increase 
in light chain mRNA levels and a 1.33 fold increase in heavy chain mRNA 
levels. Again, transcriptional activity increase did not account for all of the qP 
increase (3 fold). 
Overall, this line of experimentation confirmed that both 2 and 3TAA at least in 





 Histone Modification Analytics in Batch Culture Mode 6.3.6.
 
The confirmation of increased transcriptionally activity, reminiscent of HDAC 
inhibitors, led us to hypothesise that 2 and 3TAA could indeed act at the 
epigenetic level. A HDAC inhibitory mechanism was proposed as the mode of 
action. This was due to the structural similarity to established HDAC inhibitors 
like sodium butyrate and valproate, along with the HDAC inhibitor behavioural 
characteristics observed (transcriptional enhancement, cell cycle block at G1).  
To test this hypothesis, histones were extracted from the cells on day 5. Histone 
modification analytics were performed using mass spectrometry methods. Mass 
spectrometry sample preparation, loading and analysis was performed by 
Eleanor Hanson at The University of Sheffield. Different peptide fragments of 
histones 3 and 4 were analysed for acetylation and methylation modifications. 
Different proteoforms (unique modified version of a peptide) were detected 
using the MS2 scan. The relative abundance of each identified proteoform was 
calculated based on the area under the curve of the proteoform peak on the 





Figure 6.7 Acetylation modifications on histones 3 and 4 in the presence of 
thiophene SMEs. 10×106 cells were pelleted from shake flasks on day 5 of batch 
culture (SME was added on day 0). Histones were extracted, propionylated and 
analysed using the mass spectrometry techniques. MS1 spectra scans were labelled 
accordingly and area under each peak was calculated. Abundance was computed as a 
percentage for each proteoform relative to all proteoforms identified for that peptide. 
(A) Combined acetylation profiles for peptides analysed on histone 3. (B) Combined 
acetylation profiles for the single peptide analysed on histone 4. Relative abundances 
for proteoforms containing the same acetylation sites in each peptide were summated. 
Chemical concentrations used were: 0.8 mM 2TAA, 2.5 mM 3TAA and 0.5 mM NaBu. 
Glossary: K#: lysine at position #, ac: acetylation, me: methylation. Data represented is 




The acetylation state of histone 3 and 4 are depicted in Figure 6.7. 3 peptides 
were analysed on the histone 3 protein (Figure 6.7A): KSTGGKAPR (9th to 17th 




















Histone 3 Combined Acetylations






































amino acid from the N-terminus), KQLATKAAR (18th to 26th amino acid) and 
KSAPATGGVKKPHR (27th to 40th amino acid; letters represent one letter amino 
acid codes). All acetylated proteoforms tested recorded increased abundances for 
both 2 and 3TAA in comparison to the 0.2% v/v DMSO control. The level of 
enhancement varied between the 2 molecules, but generally 2TAA had higher 
abundance of acetylated lysine residues across histone 3. Double acetylated 
peptides, i.e. acetylated lysines at 2 positions on the peptide recorded the largest 
increase in abundance for both molecules. There was a 2.64 fold increase (p<0.05; 
Dunnett’s test) in K9 and K14 double acetylation for 2TAA treated cultures. On the 
second peptide, K18 and K23 double acetylation abundance increased by 2.13 
fold for 2TAA treated cells (p≤0.0001). Similar trends were observed for 3TAA 
treated cultures. K9 and K14 double acetylation recorded a 2.61 fold increase 
(p<0.05) with K18 and K23 double acetylation also recording a 1.54 fold increase 
(p<0.05). The unmodified peptide relative abundances in the presence of both 
molecules were decreased (data not shown). This is not unexpected based on the 
method we employed to quantify abundances. Since relative abundance is based 
on the percentage of the total abundances of all proteoforms analysed, the rise in 
different acetylated versions of the peptide, resulted in a relative decrease of the 
unmodified peptide form. 
NaBu treated cultures were included as positive controls for histone acetylation 
enhancement. On histone 3, consistent with the thiophene molecules, double 
acetylation recorded the highest enhancement in abundance compared to the no 
addition control (K18, K23: 1.88 fold (p<0.01) and K9, K14: 2.01 fold). Thus for 
histone 3, thiophene molecule supplementation followed the same trend as the 
established HDAC inhibitor molecule supplementation. 
On histone 4, there were a number of co-eluting proteoforms with acetylation 
modifications on different lysine positions for the peptide (GKGGKGLGKGGAKR) 
tested. For ease of understanding, relative abundances were summated based on 
4 categories: Unmodified (0ac), one lysine modified with acetylation (1ac), two 
lysines modified with acetylation (2ac), three lysines modified with acetylation 
(3ac), four lysines modified with acetylation (4ac). This data is displayed in Figure 
6.7B. Expectedly, the unmodified proteoforms displayed lower relative abundance 




Interestingly, there was a shift towards multiple acetylation modifications rather 
than singular acetylation marks. All 3 chemicals recorded lower 1ac marks, 
however, all other multiple acetylation marks were enriched. The highest gains 
were observed for the 4ac proteoforms. Cells cultured in the presence of 2TAA 
yielded a 4.03 fold increase (p<0.05) in 4ac residues over the DMSO control. 3TAA 
supplementation resulted in a 4.6 fold 4ac (p<0.01) abundance enhancement over 
the DMSO control. 3ac for both chemicals was enhanced around 2.2 fold 
(p<0.001) and 2ac enhanced around 1.5 fold (p<0.001).  
Similar trends were observed with the positive control, NaBu. Unmodified and 1ac 
abundances were lower than the no addition control. All other modifications 
witnessed increased abundances. 4ac modifications fold enhancement was slightly 
lower than the thiophene molecules (NaBu: 2.37 vs. 2TAA: 4.03 vs. 3TAA 4.6 fold) 
suggesting that 2 and 3TAA were more efficacious towards histone 4 HDACs in 
comparison, promoting acetylation on multiple lysine residues. Double and triple 
acetylation fold enhancements for NaBu were more comparable to the thiophene 
molecules (2ac: 1.47 (p<0.001) and 3ac: 1.94 fold (p<0.01)).  
The data from this experimental study informed that both 2 and 3TAA increased 
abundance of acetylated histones (full significance testing and separate proteoform 
data is available in Appendix D). Histone acetylation opens up the chromatin, 
increasing the probability of binding of transcription factors to initiate transcription. 
Thus, it is safe to conclude that the gene expression enhancement obtained 
through the use of 2 and 3TAA stems from its role at the epigenetic level. 
Comparison to the histone state in the presence of NaBu, yielded similar trends, 











 N-Glycan Analytics 6.3.7.
 
While investigating mechanism of action for titer enhancement was the main 
purpose for this study, evaluating any deleterious off-target effects on product 
quality was always imperative. It cannot be denied that SME use normally 
entails broad impacts; effects on product quality are not uncommon. Thus, IgG 
product glycosylation was analysed in the presence of 2TAA and 3TAA. 
Supernatant was collected from day 6 of batch culture and purified using protein 
A purification columns. Purified antibody samples (purity confirmed by SDS 
PAGE (see Appendix D)) were sent to NIBRT, Ireland and glycan release and 
subsequent analysis was performed by Dr. Roisin O’Flaherty and Dr. Karen P. 
Coss. 2-AB derivatised N-glycans were analysed by UPLC. 7 main N-glycan 
structures were analysed based on their chromatogram profiles depicted in 
Figure 6.8. The assignment of glycan peak (GP) to structure was performed in 
accordance with (Zhang et al., 2016). An additional control (human myeloma 






















Figure 6.8 N-Glycans on the IgG1 molecule that were analysed using UPLC. (A) 
Predominant N-glycans present in CHO-S IgG1 kappa. (B) Representative 
chromatograms of CHO-S IgG1 kappa biological replicates, with predominant N-glycan 
structures indicated. GP refers to glycan peak. Chromatograms for culture conditions 




















Graph	 of	 the	 average	 peak	 percentage	 areas	 of	 integrated	 chromatograms,	with	 SD	 of	 biological	 replicates.	 Blue	 represents	 untreated	 control;	 orange	 0.2%	
DMSO	control;	grey	2TAA	treated	and	yellow	3TAA	treated.	
Retention Time [min] 
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Figure 6.9 Average peak percentage areas of the different N-glycans analysed. 
Integrated chromatograms for each condition used to calculate peak area for each N-
glycan. Peak area for each glycan peak is represented as a percentage of the total 
peak area. All replicate peaks recorded a percentage coefficient of variation of 20% or 
lower, within the biological variance acceptance limit. Data represented is the mean ± 




The released N-glycan structure profiles for each condition are summarised in 
Figure 6.9. The average peak percentage area is displayed for each glycan 
structure. On the whole, there were no major deviations of the protein product 
glycoprofiles of the chemical treated cultures from the control cultures. It could 
be concluded that 2 and 3TAA did not alter glycosylation majorly for it to be a 




The use of carboxylic acids is a common media engineering strategy when 
targeting improvements in recombinant product yield. Multiple studies have 
reported the use of these molecules, most notably sodium butyrate, sodium 
phenylbutyrate and valeric acid (Backliwal et al., 2008; Jiang and Sharfstein, 
2008; Palermo et al., 1991; Park et al., 2016). These molecules mainly act by 































inhibiting histone deacetylases, promoting a more open chromatin that can be 
easily transcribed, leading to re-activation of silenced genes. However, the 
deployment of these molecules can include deleterious off-target effects such 
as the induction of apoptosis (Backliwal et al., 2008; Lee and Lee, 2012) or 
variation in glycoform profiles such as decreased sialic acid content (Santell et 
al., 1999; Sung et al., 2004; Yin et al., 2018). However, these molecules 
normally provide vast increases in protein product titers, are cheap and easy to 
deploy, so prove difficult to completely ignore. Thus, the search for more 
suitable SME options is vital.  
A large chemical library screening approach adopted by Allen et al. (2008), 
revealed novel carboxylate enhancers for protein production in CHO cells. This 
study revealed an effective thiophene carboxylate SME, 2TAA. However, 
mechanism of action was not clear from their experimentation. Screens with our 
in-house HT system and model CHO line and product confirmed its efficacy as 
a protein production enhancer. We investigated whether other thiophene 
molecules can be effective protein production enhancers. Instead of large 
cumbersome screening studies, we invested in small focused novel molecule 
screens based on structural similarity to 2TAA. Each analogue molecule had a 
unique culture performance profile; ranging from no impact (2TCA) and 
cytotoxic (TBA) to qP enhancing (TPA) to total titer improving (3TAA). It was 
interesting to note that similar structures resulted in drastically different 
phenotypic activity. It thus has to be noted that similar structure does not 
guarantee similar culture phenotype. It would be interesting to observe if each 
thiophene analogue has conserved activity when employed with different cell 
lines and products. The analogue screening revealed 3TAA as a previously 
unreported novel chemical enhancer molecule for improving CHO cell protein 
production. However, its mode of action as well as that of its parent molecule 
remained unknown. A series of carefully hypothesised experimentation enabled 
our understanding of the mode of action for both molecules. 
Culture performance in shake flasks revealed 2TAA as a stronger growth 
suppressor and titer enhancer. This could be a concentration dependent 
observation and perhaps a higher concentration of 3TAA could push titer further 




96 DWP level). Cell culture analysis also showed 2TAA to be a stronger G1 
phase inhibitor. Interestingly, cells displaying apoptotic phenotypes also 
increased in the 2TAA cultures, while 3TAA did not appear to induce apoptosis. 
Halving the concentration of 2TAA still displayed apoptosis induction. Further 
experimentation and analytics would be required to confirm whether 2TAA 
induced apoptosis at every concentration that improved titer and what pathways 
were initiated to increase the apoptotic fraction. Interestingly, cell viability 
recorded on the Vi-CELL XR indicated no detriment to viability till about day 9, 4 
days after the apoptotic analysis, which was detected on day 5. There could be 
2 theories to support this observation: (i) the discrepancy between the flow 
cytometry and VI-CELL-XR, that latter is not sensitive to apoptotic cells and 
requires compromised membranes for dead cell classification and/or (ii) the cell 
had a slow rate of conversion from early apoptotic to dead state, this could also 
explain the lack of a drastic viability drop and steady increase in protein 
production observed between days 5 and 9. Perhaps more detailed analysis 
and replicates would help elucidate the differentiation effectively. The variation 
between apoptosis experimental replicates deterred us from making any strong 
concluding statements. Based on the apoptotic analysis we had available, 
3TAA would outweigh 2TAA as the preferred enhancer despite the slightly 
lower titer return (2 vs 2.5 fold). Previous studies have shown the 
overexpression of bcl-2, addition of antioxidant chemicals or even reduction in 
culture temperature can combat carboxylic acid apoptotic activity while 
maintaining protein production enhancement activity (Camire et al., 2017; Chen 
et al., 2011; Kim and Lee, 2000). Perhaps the use of these strategies could be 
effective in controlling the supposed apoptosis induction by 2TAA. The inclusion 
of NaBu as a positive control for a G1 phase inhibiting carboxylic acid revealed 
no induction of apoptosis at its effective concentrations. This was interesting 
since this did not coincide with multiple studies that have reported on the 
induction of apoptosis in CHO and HEK293 in the presence of NaBu (Backliwal 
et al., 2008; Camire et al., 2017; Lee and Lee, 2012; Sung et al., 2004). 
Additionally, the lack of a sudden drop off in culture viability or production rates, 
suggests that NaBu indeed did not induce apoptosis at its effective 
concentration in our cell line. Then again, the effective dose for our cells was 




balance of apoptosis induction and production enhancement could vary 
between cell line and product.  
Transcriptional analytics confirmed that both thiophene molecules acted at least 
in part at the transcriptional level. 2TAA unsurprisingly had the largest 
enhancement given that the molecules ranked the highest for titer and qP 
enhancement at the day 5 data collection point. 3TAA and NaBu also showed 
increased mRNA levels for both the light and heavy chain of the protein 
product. There were multiple interesting observations from the qPCR analysis. 
Firstly, in none of the conditions, were the increases at product mRNA level 
able to account for 100% of the increase in cellular specific productivity. This is 
not uncommon, wherein analysis revealed that similar discrepancies were 
observed in HDAC inhibitor studies by Allen et al. (2008) and Wulhfard et al. 
(2010). This suggests that while all 3 molecules tested in our study enhance 
transcription of the product gene of interest, they also directly or indirectly 
impact other pathways in the cell. Since the positive control used in this study, 
NaBu has been shown to differentially express multiple genes (Fomina-Yadlin 
et al., 2015), it would be logical to assume that the SMEs could impact 
processes downstream to transcription i.e. translation, folding and secretion.  
Secondly, the cell cycle block induced by the thiophene molecules resulted in 
an increase in cell size (data not shown). This could indicate the availability of 
more cellular resources to potentiate protein-processing capacity. Additionally, 
the G1 phase is associated with increased ribosome biogenesis and 
upregulation of genes involved in translation (Kumar et al., 2007). Thus, an 
increased translational capacity could also be involved in the major qP 
enhancement associated with the use of 2 and 3TAA. This could constitute the 
basis of further experimentation in this area, perhaps proteomic analysis using 
mass spectrometry techniques could prove beneficial in understanding the 
translational capacity of the cell in the presence of the SMEs (Müller et al., 
2017; Schwanhäusser et al., 2009).  
Thirdly, heavy chain mRNA enhancement was slight stronger in comparison the 
light chain. It could be suggested that the opening up of the chromatin 
(suggestive from the histone acetylation data) indirectly alleviated 




gene transcription (heavy chain gene in our vector). This could explain the 
larger gains for the heavy chain mRNA transcription.  
As confirmed by our analysis using mass spectrometry, 2 and 3TAA both acted 
by promoting histone acetylation. This fits with the narrative of a HDAC inhibitor 
mode of action, with NaBu serving as a common exemplar. The abundance of 
acetylated lysine residues for majority of peptides analysed on histone 3 was 
increased in the presence of 2 and 3TAA. Interestingly, the thiophene 
molecules had no impact on the methylation state of the histone; this was 
consistent with the NaBu data as well. Thus, it could be concluded that both 2 
and 3TAA (like NaBu) acted specifically on the acetylation state of the histone. 
On histone 4, unmodified and single acetylated proteoform abundance went 
down in favour of double, triple and quadruple acetylated proteoforms. It was 
evident that the molecules promoted addition of acetylation modifications on the 
lysine residues, thus opening up chromatin, increasing transcription factor 
accessibility (Bora-Tatar et al., 2009) for initiation of transcription. This, linked 
with the transcriptional enhancement results, confirmed the action of the 
molecules as relievers of epigenetic gene silencing. Interestingly, NaBu has 
previously also been shown to induce transcription factor expression directly, 
and thus helped upregulate CMV promoter driven expression (Fomina-Yadlin et 
al., 2015). Thus, it cannot be discounted that apart from epigenetic de-silencing 
to provide a more transcriptionally active chromosome physically, the thiophene 
molecules could also directly increase recombinant expression through 
induction of transcription factors. An RNA-seq based analysis would probably 
provide the most comprehensive view on the impact these molecules on a gene 
expression level.  
Product quality is often a caveat that accompanies the use of SMEs. 2TAA and 
3TAA use did not deviate the protein product from its standard product quality 
profile majorly, allaying fears of unwanted glycosylation patterns. This could 
make these molecules more attractive for use in comparison to already 
available HDAC inhibitors like NaBu. NaBu has been shown to negatively 
impact galactosylation (Hong et al., 2014) and has been shown in some cases 
to decrease α 2,3 sialylation (Oh et al., 2005; Sung et al., 2004). With 2TAA and 




replicates for glycosylation analytics and perhaps comparison to the protein 
glycoforms of cultures in the presence of NaBu, would elevate and cement the 
analysis presented here. 
Given that these molecules act at the histone level, they could be used to 
inform novel chemotherapies for cancer. There is said to be a link between 
HDAC activity inhibition and tumour cell growth and survival (Kim and Bae, 
2011). HDACs 1 and 2 were found to be overexpressed in various cancers (Kim 
and Bae, 2011). Multiple HDAC inhibitor molecules have been approved for use 
or are at the clinical trial stage (Biswas and Rao, 2017). The specific HDACs 
impacted by 2TAA and 3TAA could be ascertained using HDAC activity assays. 
Additionally, molecule potency could be evaluated against cancer lines. 2TAA 
has been shown to initiate slow apoptosis in our CHO cell line; it could be 
effective in initiating apoptotic activity in cancer cells. This could be a potential 
utility avenue to investigate. 
To conclude, we were able to demonstrate the efficacy of our HT system in 
identifying previously untested SMEs for CHO cell bioprocess. We focused on 
thiophene carboxylic acid molecules and were able to isolate molecules with 
various degrees of impact on our stable bioproduction system. 2TAA and its 
structural analogue 3TAA maintained their enhancement activity in shake flask 
culture. We investigated the mechanism that mediated the titer improvement 
through various cell, product gene and epigenome specific pathways. We 
concluded that the molecules promoted gene transcription through their 
promotion of acetylated histone states. This associates them with an already 
growing repertoire of HDAC inhibitor molecules that are employed as inducers 
of protein expression. While some HDAC inhibitors aggravate apoptosis, while 
others struggle with correct glycosylation, 2 and 3TAA use can pose unique 
alternatives to battle these negative off-target impacts. Our studies indicate that 
3TAA did not promote apoptotic pathway initiation, whereas neither molecule 
supplementation resulted in a change in a major shift in glycoform profile. We 
admit that it could be premature to deem these molecules as versatile 
enhancers without conducting a larger study that evaluates their efficacy in 




is certainly promising and warrants increased interest in the investigation of 












This	 chapter	 presents	 a	 summary	 and	 general	 discussion	 of	 the	work	 presented	 in	
this	thesis.	As	with	any	piece	of	research,	there	are	a	number	of	avenues	that	can	be	







7.1. Summary and Conclusions 
 
This thesis describes the development of a HT screening tool to establish 
culture performance enhancers for CHO cell based bioprocess. The work 
contained in this thesis would enable the creation of a commercial screening 
tool for users to fine-tune their production media and improve cell proliferation 
and/or production performance. While we were able to demonstrate the efficacy 
of a multitude of bioactive small molecules in a stable CHO cell producer 
system, it would be naïve to assume efficacy in a wider CHO processing arena. 
This understanding underpins the commercial opportunity of this research 
study. Molecule efficacy has repeatedly been shown to be cell type and product 
dependent (Backliwal et al., 2008; Johari et al., 2015; Yuk et al., 2015b). Thus, 
a simple to use, HT and informative media additive testing resource presents 
much promise. Counterparts such as genetic engineering, and directed 
evolution present cumbersome, costly and time intensive methodologies for 
CHO cell production enhancement. In comparison, bioactive molecules are 
incredibly easy to adopt and versatile. 
The first step in creating a HT media additive screening tool was the 
development of HT culturing and analytical technologies (Chapter 4). The HT 
culturing platform developed was multi-well plate based. Shaken 96 DWP 
culturing allowed for better growth rates and longer culture duration in 
comparison to static cultures. Multiple studies reference the use of DWP 
technologies at various stages of cell line and process development (Hansen et 
al., 2015; Jordan and Stettler, 2014; Rouiller et al., 2016). This proves the 
popularity of the system in industry and academic circles. This was important 
since we want to present a commercial technology that can easily be adopted 
into the user’s established cell line and process development workflow. The 
technology, based on the “System Duetz” (Duetz, 2007; Enzyscreen BV,) 
provided a flexible, HT, cost effective and scalable (to batch shake flask culture) 
culturing methodology. The addition of HT analytics completed the HT 
screening platform. Cell growth measured using the PrestoBlue assay and 
volumetric titer measured using the Valita™TITER assay allowed for cost 




user’s available resources is key. Since both assays can be used on a single 
fluorescent plate reader, machinery costs are comparatively lower. However, if 
more sophisticated technologies such as the Iprasense Norma (Iprasense, 
Clapiers, France) or Guava® easyCyte (Merck, Darmstadt, Germany) are 
available for HT cell counting, these could be adopted into the platform. Overall, 
the HT screening platform developed allows for quick, simple and cost effective 
factor effect analysis. The ability to be easily adopted for robotic liquid handling 
and other automation methods is an added advantage of the platform. 
Additionally, the platform is robust and has shown adaptability to different cell 
lines and transient expression processes within our laboratory at The University 
of Sheffield. 
In order to determine SME efficacy in CHO cell bioprocessing, a suite of 43 
bioactive small molecules was evaluated in a stable CHO mAb producer system 
(Chapter 5). The screens were extensive in terms of functional targets and 
concentrations tested. A variety of molecules displayed improvements to the 
cell production process, enhancing cell growth, titer or both. Components that 
already formed part of the base media yielded improvements upon 
supplementation, suggestive of the potential of basal media component 
optimisation for cell growth and protein production benefit. The suite of 
molecules can be used for mainly 2 purposes: (i) maximising production and 
cell proliferation output in well established production systems and (ii) de-
bottlenecking inefficient production systems. The second purpose would 
particularly find use in DTE production systems (Johari et al., 2015), or cell lines 
prone to toxic metabolite build-up (Yuk et al., 2015b). Additionally, molecule 
functionality and effective concentration were largely dependent upon timing of 
addition. Majority of the qP enhancers tested were more efficacious when 
added at the mid-exponential stage rather than at the start of culture. This was 
partly due to their negative impact on cell proliferation. 
While singular addition of multiple molecules proved effective, combinatorial 
additions were able to elevate production levels further in our DWP culturing 
system. Strict criteria that governed design space suitability resulted in a small 
subset of molecules being tested for interactions with DOE techniques. The 




factors in a short amount of time. However, we demonstrated its suitability in a 
relatively small design space, wherein we had an indication of significant 
singular factors in advance. Thus, the DOEs employed in this case were 
essentially for understanding the potential of interactions to improve cellular 
production performance. We were able to demonstrate the benefit of employing 
enhancer combinations wherein a best performing combination of 3 enhancers 
yielded a 4.3 fold titer improvement over the respective control population in our 
model production system. Given our production system records high titers in 
comparison to other systems (especially systems that require a DTE protein 
product to be produced (Johari et al., 2015)), the titer improvement achieved 
here bears the potential for further enhancement. The 7 factor DOE that utilised 
all the chemical modulators in the DOE design space served as an exemplar of 
the power of combinatorial designs in achieving varied production and 
proliferation phenotypes. The choice solely rests with the user to select which 
combination to employ. Generally combining more than 4 factors gave 
diminishing returns or negative interactions and thus employing parsimony is 
attractive.  
Finally, our analysis on combinatorial treatment efficacy was trialled at a larger 
scale in shake flasks. The experimental model aimed to inform us on the 
scalability of our SME performance predictions. While the DWP platform was 
able to correctly predict enhancer combinations for improved production at 
scaled-up fed batch shake flask level, the extent of improvement did not concur. 
Our qP combinatorial strategy, while returning around a 60% improvement in 
titer in fed-batch shake flask studies did incur a loss in viability prematurely in 
comparison to the control cultures. Since DWP cultures only recorded culture 
attributes on a single day of short duration batch cultures, the loss in viability 
was not predicted at the smaller scale. This indicated that either a tweak in our 
DWP screening platform or our combination selection strategy was required. 
Perhaps adding feeds to the DWP system could provide us a more suitable, 
longer culture duration for testing enhancers that ultimately would be used in 
fed-batch production bioreactor studies. Alternatively, the guidelines on the 




this chapter would form the foundation of a commercial screening tool. The 
envisioned screening tool is described in Section 7.3.  
Finally, we employed our HT screening platform to test the efficacy of novel 
potential SME molecules (Chapter 6). We discovered that 2TAA, a thiophene 
carboxylic acid (Allen et al., 2008) was highly effective in our production system 
and give a 1.6 fold titer boost when added on day 0 of DWP culture, going up to 
3.2 fold when added during the mid-exponential culture phase. Structural 
analogues of the molecule have never been previously investigated for the 
purposes of biotherapeutic production. 3TAA, a structural analogue of 2TAA, 
demonstrated production titer improvement in our screens and titer 
improvements were maintained for both molecules in shake flask batch 
cultures. Analysis of the epigenetic state of the cell revealed both molecules 
promoted acetylation modification on multiple sites on histones 3 and 4. This 
was in agreement with an established HDAC inhibitor, sodium butyrate. 
Transcriptional activation of the product gene was confirmed through qPCR. 
Transcriptional silencing due to the histone deacetylation is a common 
occurrence. The tightly packed chromosomal structure physically impairs 
transcription (Jiang and Sharfstein, 2008; Kim and Bae, 2011). Thus, both 
molecules played a pivotal role in improving product gene transcription. From a 
product quality perspective, no major shifts in glycoprofiles were observed 
instilling confidence in the use of these molecules. Overall, the chapter 
presented the potential of the combined use of in-silico structure analytics and 
HT screening to identify novel SMEs for bioprocess. This strategy could be 
applied to other established SMEs to isolate novel structural analogues that 
improve bioprocess.  
 
7.2. Future Work Recommendations 
 
Like previously mentioned, this research study presents the conceptualisation 
of a potential commercial media additive screening technology. It is imperative 
that a number of reduction to practice steps would be required to fully validate 
and develop this technology for commercial use. Recommendations for future 




would focus mainly on the HT SME screening tool, future steps are also 
discussed to enhance the thiophene molecule mode of action analysis 
presented in Chapter 6. 
The major limitation of our HT screening platform (described in Chapter 4) is 
the lack of product quality analytics. With the competitive era of biosimilars and 
biobetters upon us and with product quality playing a role in determining 
product safety and efficacy, HT product quality analytics would be a valuable 
addition to the screening tool. HT purification (Phytips; PhyNexus, San Jose, 
CA), HT sample preparation and glycan release technologies (Stöckmann et al., 
2015) are increasingly being employed. Additionally, lectin microarrays 
(RayBiotech, Georgia, USA) or plate based lectin assays (GlycoImage; Galab 
Technologies, Hamburg, Germany) are available for HT analysis of glycan 
species. However, these are expensive, time intensive or low-throughput. 
Extensive research would be required to investigate commercial partners for 
glycoform analytics or development of a HT glycan assay in-house. 
Another functionality that could elevate the HT screening technology would be 
the addition of fed-batch culturing modalities. Fed-batch microwell DWP 
culturing has been described previously (Rouiller et al., 2016). Addition of 
feeds, and thus extending the culture could provide better predictability of shake 
flask fed-batch performance. Again, this hypothesis would need to be 
thoroughly validated. However, it should be noted that fed-batch modality adds 
another variable into the system, the effect of feeds. Most companies have their 
bespoke feed and feeding strategies and flexibility could rest with the user 
whether testing in fed-batch modalities is desired. Some preliminary fed-batch 
studies with a candidate clone, media and feeds would be ideal in determining if 
scale-up fed-batch predictability is improved by screening in a fed-batch DWP 
mode. 
The research contained in Chapter 5 described the extensive processes 
undertaken to identify potential enhancers for CHO cell bioproduction. It cannot 
be assumed that functional efficacy will predictably transfer across other cell 
lines and products. This rationale underpins the commercial opportunity of a 
screening tool. However, testing in a single media and cell type cannot be used 




and basal media would be necessary. This would help gauge a better 
understanding of molecules and concentrations that would be functionally 
efficacious across a number of production platforms. This would help narrow 
down the molecules that would form part of the finalised commercial platform. 
Additionally, small DOE studies accompanying the SME assessment in different 
lines and media would be ideal. Herein, we would be informed of the DOE 
strategy moving forward. If certain combinations always bear some degree of 
enhanced efficacy over their respective singular factor effects, these 
combinations would form part of the coated DWP product along with the 
singular enhancers. If combinations are extremely production system specific, 
then combinatorial designs could be an add-on bespoke service to the product, 
informed by the initial singular molecule screening performed in the user’s 
production process. 
Our DWP platform correctly predicted enhancers that improved cellular IVCD 
and production at a larger scale (in fed-batch shake flask mode). However, the 
extent of improvement over the control was much lower than the DWP 
predictions. One aspect to explain this discrepancy would be the un-optimised 
nature of the experimentation; feeding regimes were not optimised to maximise 
potential. Optimisation experiments mainly focusing on the timing of addition of 
the qP enhancer molecules would be beneficial. Second, fed-batch modality 
was not adopted in DWPs. Addition of feeds, if required, could remedy that as 
explained in the section above. Thirdly, fed-batch mode itself might present a 
smaller margin for improvement. Finally, it was observed that the most 
productive condition produced a steady drop in viability post addition of 
enhancers. The loss in viability potentially shortened the productive culture 
duration. This was not visible in DWP cultures. Perhaps, fed batch modality in 
DWPs could solve this issue. However, it also pointed towards a change in 
enhancer selection stringency. The extent of growth suppression in the short 
DWP cultures could be an indication of viability issues that could be associated 
with scaled-up fed-batch shake flask culture. Thus, perhaps selecting 
combinations that do not highly suppress growth could be better suited for 
scaled-up fed-batch production runs. More experimentation exploring this 




performed in an even larger scale such as bench top bioreactors. However, 
resource availability would play a major role in the realisation of such 
experimentation.  
As stated previously, addition of a protein glycosylation analytical tool to the 
screening platform would help assess SME impact on product quality. 
Additionally, it could help expand the repertoire of molecules. Small molecule 
modulators of glycosylation could be impactful in fine-tuning glycoprofiles to the 
desired standard. Molecules like manganese, uridine and galactose are 
common supplements added to media to improve mAb galactosylation (as 
discussed in Section 2.2.5) (Grainger and James, 2013; Gramer et al., 2011). 
Additionally, other studies have revealed that several modulators can be 
intelligently employed to modulate protein quality towards a desired glycoform 
(Brühlmann et al., 2017a; Brühlmann et al., 2017b). Thus, if we are able to 
expand our screening platform to include protein analytics, then small molecule 
modulators for glycosylation could be an impactful addition to our chemical 
suite. 
With regards to the thiophene study presented in Chapter 6, further analysis 
into their role in histone acetylation would be interesting. Kit-based HDAC 
activity assays are available to quantify impact on the different classes of 
HDACs. Additionally, a more sensitive detection of apoptosis induction through 
the use of the thiophenes would be beneficial. Due to equipment limitation at 
the time, that was not possible. As stated previously, an in-depth proteomic and 
transcriptomic analysis would provide most comprehensive analysis on impact 
of the molecules on cellular processes. Additionally, the discovery of thiophene 
molecules as novel enhancers for bioprocess could have a wider impact in 
other research circles. HDAC inhibitors find use in the treatment of various 
cancers (Kim and Bae, 2011), and the thiophene molecules could be re-
purposed for cancer therapy use. Potency against cancer cell models would 







7.3. Intended Product Use and Potential Impact 
 
As mentioned previously, the lack of commercial, standardised, easy to use, 
HT, media additive screening and optimisation technologies presents a 
commercial opportunity. The envisioned screening tool is a simple-to-use DWP 
(or multiple DWPs) delivered with a single or combination of SMEs pre-coated 
on each well. The addition of a pre-determined cell culture volume would 
essentially re-constitute the chemical enhancers in culture allowing for a 
chemical supplemented culture. A secondary plate model would be included to 
test for mid-exponential phase chemical addition. Herein, cells would be grown 
on an uncoated DWP; the chemical suite would be pre-coated on wells of a 
microplate. Following reconstitution of the chemical, the microplate contents 
would be added to the respective wells of the DWP at the mid-exponential 
phase of culture. The multiple chemical supplemented cultures would be 
incubated in shaking conditions for a stipulated culture duration period, 
following which culture attributes (cell growth and titer in our current 
specification) would be assessed. Software to analyse the culture performance 
to inform recommendations for the next line of experimentation would 
accompany the plate-based tool. The potential product would find use in both 
cell line development and process development stages of upstream processing. 
It could be used to augment clone selection and screening. Selection of clones 
is their most productive environment can assist in a more dynamic ranking of 
clones in comparison to screening in standard conditions (Legmann et al., 
2011). Clone selection under different media conditions, could inform of a highly 
productive clone that could have been eliminated in standard testing conditions 
(i.e. same production media). Our plate product could supplement the ambr 15 
screening that normally occurs during the latter stages of cell line development. 
However, the main use of the product would be post clone selection stages 
wherein only a couple of clones remain. Herein, the screening plate would help 
inform the development and optimisation of bespoke media environments 
relative to the user’s production system. Future experimental approaches can 
be gleaned from this quick and informative screening tool. Ultimately, the 
product would aid in obtaining desired growth and/or production profiles in CHO 
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Appendix Table A.1 Primer efficiencies for all primers utilised in the qPCR study. 
A slope of -3.322 equates to 100% efficiency. Primer efficiencies between 95 and 
105% were deemed acceptable. 
Primer Slope Efficiency Amplicon size 
Heavy chain (Primer 7) -3.31 100.56 198 
Light chain (Primer 1) -3.30 100.92 88 
Fkbp1a -3.34 99.09 95 








The cell pellet was re-suspended in 950 µL of a hypotonic lysis buffer (10 mM 
Tris-HCl pH 8, 1 mM KCl, 1.5 mM MgCl2 and 1mM DTT) and 5 µL of Protease 
Halt Cocktail (Thermo Fisher Scientific). After shaking the mix on ice for 30 
minutes, the extracted nucleus was pelleted. The nucleus was dissolved in 0.2 
M H2SO4 for 4 hours (on ice, shaken). Any nuclear debris was removed by 
centrifugation and histones precipitated overnight in a tube containing 132 µL of 
6.1 N Trichloroacetic acid. The histones were then washed twice in ice cold 




7 µg-10 µg of histones were mixed 1:1 with 100 mM ABC. A propionylation mix 
was created using propionic anhydride and isopropanol in a 1:3 ratio. 10 µL of 
the mix was added to the histone+ABC mix. pH was adjusted to 8 using 
ammonium hydroxide. The mix was incubated at 37°C for 15 minutes and dried 
down using a SpeedVac (Thermo Fisher Scientific). 10 µL of ABC was added 
and the process repeated once. 40 µL of 100 mM ABC containing 1.5 µg of 
Trypsin was added to the derivatised histones and left to incubate at 37°C 
overnight before quenching the reaction with 4 µL glacial acetic acid, on ice for 













m/z range was between 300-1100. MS1 resolution was set at 60,000; automatic 
gain control (ACG) target was 3×106 with a maximum fill time of 55 ms. A MS1 
scan was performed once every 10 MS2 scans. MS2 resolution was set at 











Appendix Figure B.1 Viable cell density on day 3 of a batch culture in a round 
well DWP. Different culture volumes and seeding densities trialed in a NUNC™ 96-well 
polypropylene DeepWell™ plate (Thermo Fisher Scientific). Incubator speed: 320 rpm, 
throw: 25 mm. VCD measured using the Vi-CELL XR. Data is mean and standard error 
of three technical replicates. 
	
	
Appendix Figure B.2 Viability profiles of the DWP batch cultures varied for 
seeding density and culture volume. (A) 0.2×106 cells mL-1 and (B) 0.3×106 cells 
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Appendix Figure C.1 Growth DOE: Normal plot of residuals to validate statistical 
assumptions. Residual normal plot for (A) IVCD, (B) Titer and (C) qP depicted. If the 
residuals fall roughly in a straight line, then the normality of residuals is confirmed and 
no power transform is required. No power transforms were deemed necessary for A, B 
or C. The colours of the residual dots indicate the actual output relative to the group i.e. 
the lowest ranking is blue while the highest ranking is red. Three replicate experimental 
datasets used to create this normality plot. 
	
Appendix Table C.1 Growth DOE: ANOVA table. Culture attributes modeled for: 
IVCD, Titer, qP. Significance of model and its terms presented. Model predictability 
seen as reasonable if difference between Pred R2 and Adj R2 is less than 0.2. Adeq 
precision presents signal-to-noise ratio, ratio of 4 or more is desirable. Lack of fit: Titer: 
F value: 0.98, p value: 0.4269, not significant. qP: F value: 0.60, p value: 0.5620, not 
significant. 






IVCD Model 2.87 < 0.0001 0.7096/0.8145 11.693 
 A-Cu 0.42 0.0011   
 B-Zn 0.59 0.0002   
 C-FAC 1.12 < 0.0001   
 AB 0.19 0.0164   
 AC 0.17 0.0234   
 BC 0.30 0.0038   
 ABC 0.077 0.1078   
Titer Model 8.30 < 0.0001 0.9307/0.9474 27.083 
 A-Cu 0.92 < 0.0001   
 B-Zn 0.50 < 0.0001   
 C-FAC 6.73 < 0.0001   
 AB 0.14 0.0148   
qP Model 2.72 < 0.0001 0.6721/0.7643 11.538 
 A-Cu 0.072 0.1650   






















































































Normal Plot of Residuals































































Normal Plot of Residuals































































Normal Plot of Residuals


















































 C-FAC 0.96 < 0.0001   
 AB 0.31 0.0078   






Appendix Figure C.2 qP/Titer DOE: Normal plot of residuals to validate statistical 
assumptions. (A) IVCD, (B) Titer and (C) qP. 
	
Appendix Table C.2 qP/Titer DOE: ANOVA table. Model lack of fit : IVCD: F value: 
0.24, p value 0.9808, not significant. Titer: F value: 1.03, p value 0.3910, not 
significant. qP: F value: 0.82, p value: 0.5890, not significant. 






IVCD Model 1.75 < 0.0001 0.8342/0.8647 20.103 
 A-TUDCA 0.029 0.0310   
 B-NaBu 0.31 < 0.0001   
 C-3TAA 1.20 < 0.0001   
 D-MS 275 0.088 0.0003   
 AC 0.039 0.0124   
 BC 0.062 0.0020   
 BD 0.025 0.0437   
Titer Model 33.28 < 0.0001 0.8944/0.9246 26.755 
 A-TUDCA 6.62 < 0.0001   
 B-NaBu 18.00 < 0.0001   
 C-3TAA 5.002E-003 0.7679   
 D-MS 275 2.34 < 0.0001   
 AB 0.19 0.0726   
 AC 0.75 0.0009   
 AD 0.14 0.1277   
 BC 0.42 0.0103   
 BD 0.96 0.0002   






















































































Normal Plot of Residuals






























Normal Plot of Residuals






























Normal Plot of Residuals
















 ABC 0.77 0.0007   
 ACD 0.48 0.0061   
qP Model 170.91 < 0.0001 0.9192/0.9341 34.453 
 A-TUDCA 29.69 < 0.0001   
 B-NaBu 84.67 < 0.0001   
 C-3TAA 36.80 < 0.0001   
 D-MS 275 14.69 < 0.0001   
 AB 1.52 0.0188   
 AC 1.71 0.0131   







Appendix Figure C.3 Seven factor titer DOE: Normal plot of residuals to validate 
statistical assumptions. (A) IVCD, (B) log10(Titer) and (C) 1/√qP. 
	
Appendix Table C.3 Seven factor titer DOE: ANOVA table. Model lack of fit: IVCD: F 
value: 0.94, p value: 0.6245, not significant. log10(Titer): F value: 1.08, p value: 0.3309, 
not significant. 1/√qP: F value: 1.13, p value: 0.2602, not significant. 








Final Equation in 
Coded Terms 
IVCD      IVCD= 
 Model 34.32 < 0.0001 0.7939/0.8228 31.408 +0.90 
 A-TUDCA 1.06 < 0.0001   -0.064×A 
 B-NaBu 5.43 < 0.0001   -0.15×B 
 C-3TAA 9.68 < 0.0001   -0.19×C 
 D-MS 275 0.80 < 0.0001   -0.056×D 
 E-Cu 0.69 < 0.0001   +0.052×E 
 F-Zn 0.66 < 0.0001   -0.051×F 






















































































Normal Plot of Residuals






























Normal Plot of Residuals






























Normal Plot of Residuals
















 AB 0.21 0.0066   +0.029×AB 
 AC 0.17 0.0146   -0.026×AC 
 AD 0.096 0.0667   -0.019×AD 
 AG 0.026 0.3344   -0.010×AG 
 BC 3.25 < 0.0001   +0.11×BC 
 BD 0.54 < 0.0001   +0.046×BD 
 BE 0.25 0.0034   -0.031×BE 
 BF 0.051 0.1798   +0.014×BF 
 BG 8.972E-003 0.5739   -5.933E-003×BG 
 CD 0.048 0.1923   -0.014×CD 
 CF 0.26 0.0025   +0.032×CF 
 CG 9.647E-004 0.8537   -1.946E-003×CG 
 DF 0.024 0.3599   +9.666E-003×DF 
 DG 3.755E-003 0.7159   +3.839E-003×DG 
 EF 0.29 0.0017   -0.033×EF 
 FG 0.61 < 0.0001   -0.049×FG 
 ACD 4.409E-003 0.6934   -4.159E-003×ACD 
 ACG 4.946E-003 0.6762   
+4.405E-
003×ACG 
 ADG 0.061 0.1424   -0.016×ADG 
 BCF 0.10 0.0598   -0.020×BCF 
 BCG 0.038 0.2473   -0.012×BCG 
 BEF 0.22 0.0059   +0.029×BEF 
 BFG 0.31 0.0011   +0.035×BFG 
 CDG 1.450E-004 0.9430   
-7.543E-
004×CDG 
 CFG 0.11 0.0486   +0.021×CFG 
 DFG 0.26 0.0027   +0.032×DFG 
 ACDG 0.27 0.0024   -0.032×ACDG 
      Log10(Titer)= 
Titer Model 3.66 < 0.0001 0.7718/0.7942 30.996 +0.40 
 A-TUDCA 0.18 < 0.0001   +0.027×A 
 B-NaBu 1.00 < 0.0001   +0.063×B 
 C-3TAA 0.060 < 0.0001   +0.015×C 
 D-MS 275 0.64 < 0.0001   +0.050×D 
 E-Cu 0.080 < 0.0001   +0.018×E 
 F-Zn 0.050 0.0003   -0.014×F 
 G-FAC 0.97 < 0.0001   +0.062×G 
 AC 0.090 < 0.0001   -0.019×AC 
 AD 0.048 0.0004   -0.014×AD 
 AG 0.047 0.0004   -0.014×AG 
 BC 0.018 0.0293   -8.302E-003×BC 
 BD 0.035 0.0021   -0.012×BD 
 BF 0.098 < 0.0001   -0.020×BF 
 BG 0.018 0.0277   -8.387E-003×BG 




 CF 0.054 0.0002   -0.015×CF 
 CG 0.025 0.0097   -9.872E-003×CG 
 DG 2.744E-003 0.3868   -3.281E-003×DG 
 FG 0.041 0.0010   +0.013×FG 
 ADG 0.037 0.0016   -0.012×ADG 
 BCD 0.037 0.0017   +0.012×BCD 
 BCF 0.030 0.0045   +0.011×BCF 
 BFG 0.047 0.0004   +0.014×BFG 
      1/Sqrt(qP)= 
qP Model 6.82 < 0.0001 0.8946/0.9078 43.204 +0.59 
 A-TUDCA 0.53 < 0.0001   -0.046×A 
 B-NaBu 2.07 < 0.0001   -0.090×B 
 C-3TAA 1.66 < 0.0001   -0.081×C 
 D-MS 275 0.86 < 0.0001   -0.058×D 
 E-Cu 0.013 0.0299   +7.104E-003×E 
 F-Zn 0.016 0.0148   -7.982E-003×F 
 G-FAC 0.10 < 0.0001   +0.020×G 
 AB 0.053 < 0.0001   +0.014×AB 
 AG 0.029 0.0011   +0.011×AG 
 BC 0.65 < 0.0001   +0.050×BC 
 BD 0.21 < 0.0001   +0.029×BD 
 BF 0.055 < 0.0001   +0.015×BF 
 BG 0.023 0.0041   +9.428E-003×BG 
 CD 0.018 0.0107   +8.365E-003×CD 
 CF 0.11 < 0.0001   +0.021×CF 
 CG 0.075 < 0.0001   +0.017×CG 
 DE 1.997E-006 0.9783   -8.852E-005×DE 
 DF 7.952E-003 0.0871   +5.586E-003×DF 
 DG 0.012 0.0328   +6.981E-003×DG 

























        		         
0.2% dmso vs. 
2TAA No ns 0.1201 		
No add control vs. 
2TAA Yes * 0.0209 
0.2% dmso vs. 
3TAA No ns 0.9999 		
No add control vs. 
3TAA No ns 0.6789 
0.2% dmso vs. No 
add control No ns 0.669 		
No add control vs. 
0.2% dmso No ns 0.669 
0.2% dmso vs. 
NaBu No ns 0.8824 		
No add control vs. 
NaBu No ns 0.2792 


















        		         
0.2% dmso vs. 
2TAA No ns 0.1668 		
No add control vs. 
2TAA No ns 0.7078 
0.2% dmso vs. 
3TAA Yes * 0.0193 		
No add control vs. 
3TAA No ns 0.1189 
0.2% dmso vs. No 
add control No ns 0.6419 		
No add control vs. 
0.2% dmso No ns 0.6419 
0.2% dmso vs. 
NaBu No ns 0.1248 		
No add control vs. 
NaBu No ns 0.5891 
		 		 		 		 		 		 		 		 		

















        		         
0.2% dmso vs. 
2TAA Yes * 0.0158 		
No add control vs. 
2TAA Yes * 0.0406 
0.2% dmso vs. 
3TAA Yes * 0.0173 		
No add control vs. 
3TAA Yes * 0.0446 
0.2% dmso vs. No 
add control No ns 0.9374 		
No add control vs. 
0.2% dmso No ns 0.9374 
0.2% dmso vs. 
NaBu Yes * 0.0223 		
No add control vs. 
NaBu No ns 0.0573 


















        		         
0.2% dmso vs. 
2TAA Yes ** 0.0045 		
No add control vs. 
2TAA Yes ** 0.0024 
0.2% dmso vs. 
3TAA No ns 0.7115 		
No add control vs. 
3TAA No ns 0.4555 
0.2% dmso vs. No 
add control No ns 0.98 		
No add control vs. 
0.2% dmso No ns 0.98 
0.2% dmso vs. 
NaBu Yes * 0.0159 		
No add control vs. 





















        		         
0.2% dmso vs. 
2TAA Yes **** 0.0001 		
No add control vs. 
2TAA Yes **** 0.0001 
0.2% dmso vs. 
3TAA Yes **** 0.0001 		
No add control vs. 
3TAA Yes **** 0.0001 
0.2% dmso vs. No 
add control No ns 0.0863 		
No add control vs. 
0.2% dmso No ns 0.0863 
0.2% dmso vs. 
NaBu Yes ** 0.0019 		
No add control vs. 
NaBu Yes **** 0.0001 
		 		 		 		 		 		 		 		 		

















        		         
0.2% dmso vs. 
2TAA Yes **** 0.0001 		
No add control vs. 
2TAA Yes **** 0.0001 
0.2% dmso vs. 
3TAA Yes * 0.0178 		
No add control vs. 
3TAA Yes ** 0.0082 
0.2% dmso vs. No 
add control No ns 0.9659 		
No add control vs. 
0.2% dmso No ns 0.9659 
0.2% dmso vs. 
NaBu Yes ** 0.0024 		
No add control vs. 
NaBu Yes ** 0.0012 


















        		         
0.2% dmso vs. 
2TAA No ns 0.764 		
No add control vs. 
2TAA No ns 0.4883 
0.2% dmso vs. 
3TAA No ns 0.9708 		
No add control vs. 
3TAA No ns 0.9999 
0.2% dmso vs. No 
add control No ns 0.9749 		
No add control vs. 
0.2% dmso No ns 0.9749 
0.2% dmso vs. 
NaBu No ns 0.4287 		
No add control vs. 
NaBu No ns 0.2332 


















        		         
0.2% dmso vs. 
2TAA No ns 0.3319 		
No add control vs. 
2TAA No ns 0.9738 
0.2% dmso vs. 
3TAA No ns 0.6203 		
No add control vs. 
3TAA No ns 0.9999 
0.2% dmso vs. No 
add control No ns 0.578 		
No add control vs. 
0.2% dmso No ns 0.578 
0.2% dmso vs. 
NaBu No ns 0.7922 		
No add control vs. 
NaBu No ns 0.9901 




























        		         
0.2% dmso vs. 
2TAA Yes ** 0.0064 		
No add control vs. 
2TAA Yes *** 0.0002 
0.2% dmso vs. 
3TAA No ns 0.0557 		
No add control vs. 
3TAA Yes *** 0.001 
0.2% dmso vs. No 
add control No ns 0.0769 		
No add control vs. 
0.2% dmso No ns 0.0769 
0.2% dmso vs. 
NaBu Yes * 0.042 		
No add control vs. 
NaBu Yes *** 0.0008 


















        		         
0.2% dmso vs. 
2TAA Yes *** 0.0002 		
No add control vs. 
2TAA Yes * 0.0146 
0.2% dmso vs. 
3TAA Yes *** 0.0001 		
No add control vs. 
3TAA Yes ** 0.0087 
0.2% dmso vs. No 
add control Yes * 0.0342 		
No add control vs. 
0.2% dmso Yes * 0.0342 
0.2% dmso vs. 
NaBu Yes *** 0.0004 		
No add control vs. 
NaBu Yes * 0.0398 


















        		         
0.2% dmso vs. 
2TAA Yes **** 0.0001 		
No add control vs. 
2TAA Yes **** 0.0001 
0.2% dmso vs. 
3TAA Yes *** 0.0001 		
No add control vs. 
3TAA Yes *** 0.0001 
0.2% dmso vs. No 
add control No ns 0.9993 		
No add control vs. 
0.2% dmso No ns 0.9993 
0.2% dmso vs. 
NaBu Yes *** 0.0002 		
No add control vs. 
NaBu Yes *** 0.0002 


















        		         
0.2% dmso vs. 
2TAA Yes *** 0.0003 		
No add control vs. 
2TAA Yes *** 0.0004 
0.2% dmso vs. 
3TAA Yes *** 0.0004 		
No add control vs. 
3TAA Yes *** 0.0007 
0.2% dmso vs. No 
add control No ns 0.9846 		
No add control vs. 
0.2% dmso No ns 0.9846 
0.2% dmso vs. 
NaBu Yes *** 0.0008 		
No add control vs. 
NaBu Yes ** 0.0014 






















0.2% dmso vs. 
2TAA Yes * 0.022 		
No add control vs. 
2TAA No ns 0.0616 
0.2% dmso vs. 
3TAA Yes ** 0.0078 		
No add control vs. 
3TAA Yes * 0.0214 
0.2% dmso vs. No 
add control No ns 0.9183 		
No add control vs. 
0.2% dmso No ns 0.9183 
0.2% dmso vs. 
NaBu Yes * 0.0395 		
No add control vs. 
NaBu No ns 0.1099 






Appendix Figure D.1 Histone 3 separated acetylated proteoforms for all peptides 

































































































Histone 3 Separated Acetylations














Appendix Figure D.3 Non-reduced SDS-PAGE gel depicting the purified IgG1 
samples. Prominent band seen at ~150 kDa (H2L2: complete antibody). Faint bands 
seen at ~125, ~100 and ~25 kDa, indicating slight degradation of the antibody in the 
storage solution. This gel was run ~2.5 weeks after purification and glycan analysis 
was completed so degradation is expected however was considered acceptable since 
the glycan analysis had already been performed. Lane 1-8: Control 1, 0.2% DMSO 1, 































































































































































Histone 4 separated acetylations






















Appendix Figure D.4 Reduced SDS-PAGE gel depicting the purified IgG1 
samples. Prominent bands seen at ~50 kDa (Heavy chain) and ~25 kDa (Light chain). 
Lane 1-8: Control 1, 0.2% DMSO 1, 2TAA 1, 3TAA 1, control 2, 0.2% DMSO 2, 2TAA 
2, 3TAA 2. 
	
Appendix Table D.3 N-glycan peak percentage areas from CHO-S IgG1 kappa 
integrated chromatograms. Peak percentage areas of glycan peaks (GP) of 
biological replicates, standard deviations (SD±) and percentage coefficient of variance 
(CV*100) are indicated. CV*100 below 20% is indicative of an acceptable level of 
biological variance. GP6 from 0.2% DMSO controls is 20%; the rest of the samples are 
below this value. 
 
GP1 GP2 GP3 GP4 GP5 GP6 GP7 
Untreated control_1 66.75 1.99 15.02 7.00 3.35 4.66 1.21 
Untreated control_2 66.46 1.71 14.92 6.62 3.64 5.28 1.37 
Untreated control_Ave 66.61 1.85 14.97 6.81 3.50 4.97 1.29 
SD± 0.21 0.20 0.07 0.27 0.21 0.44 0.11 
CV*100 0.31 10.70 0.47 3.95 5.87 8.82 8.77 
 0.2% DMSO control_1 61.98 2.51 15.05 6.57 4.26 7.95 1.68 
0.2% DMSO control_2 55.48 2.83 15.32 8.54 5.55 10.68 1.60 
0.2% DMSO control_Ave 58.73 2.67 15.19 7.56 4.91 9.32 1.64 
SD± 4.60 0.23 0.19 1.39 0.91 1.93 0.06 
CV*100 7.83 8.47 1.26 18.44 18.60 20.72 3.45 
 2TAA treated_1 61.19 3.19 18.51 10.28 3.78 2.18 0.88 
2TAA treated_2 60.58 3.29 17.29 11.08 4.24 2.63 0.89 
















SD± 0.43 0.07 0.86 0.57 0.33 0.32 0.01 
CV*100 0.71 2.18 4.82 5.30 8.11 13.23 0.80 
 3TAA treated_1 60.44 3.46 18.20 8.41 3.90 4.47 1.12 
3TAA treated_2 61.02 3.21 17.66 7.76 3.66 5.50 1.20 
3TAA treated_Ave 60.73 3.34 17.93 8.09 3.78 4.99 1.16 
SD± 0.41 0.18 0.38 0.46 0.17 0.73 0.06 
CV*100 0.68 5.30 2.13 5.68 4.49 14.61 4.88 
	
	
Appendix Figure D.5 Technical replicates of IgG1 kappa standard. Chromatogram 
overlay of replicates for reproducibility; graph of average peak percentage areas of 
biological with SD, and CV*100. All CV% are under 20%. 
	
Appendix Table D.4 Glycan peak significance testing for cultures in the presence 


















                  
0.2% dmso vs. No 
add control No ns 0.0608   
No add control vs. 
0.2% dmso No ns 0.0608 
0.2% dmso vs. 
2TAA No ns 0.7002   
No add control vs. 
2TAA No ns 0.1485 
0.2% dmso vs. 
3TAA No ns 0.7384 		
No add control vs. 
3TAA No ns 0.1387 


















        		         
0.2% dmso vs. No 
add control Yes * 0.0226 		
No add control vs. 
0.2% dmso Yes * 0.0226 
0.2% dmso vs. 
2TAA No ns 0.0724 		
No add control vs. 
2TAA Yes ** 0.0033 




GP1	 GP2	 GP3	 GP4	 GP5	 GP6	 GP7	
IgG1	kappa	Sigma_2	 46.26	 5.34	 20.50	 11.14	 4.57	 11.27	 0.92	
IgG1	kappa	Sigma_2	 45.36	 5.30	 20.61	 11.66	 4.63	 11.59	 0.86	
IgG1	kappa	Sigma_Ave	 45.81	 5.32	 20.56	 11.40	 4.60	 11.43	 0.89	
SD	 0.64	 0.03	 0.08	 0.37	 0.04	 0.23	 0.04	









































0.2% dmso vs. 
3TAA Yes * 0.0451 		
No add control vs. 
3TAA Yes ** 0.0026 


















        		         
0.2% dmso vs. No 
add control No ns 0.9411 		
No add control vs. 
0.2% dmso No ns 0.9411 
0.2% dmso vs. 
2TAA Yes * 0.0112 		
No add control vs. 
2TAA Yes ** 0.0085 
0.2% dmso vs. 
3TAA Yes * 0.0108 		
No add control vs. 
3TAA Yes ** 0.0082 


















        		         
0.2% dmso vs. No 
add control No ns 0.6972 		
No add control vs. 
0.2% dmso No ns 0.6972 
0.2% dmso vs. 
2TAA Yes * 0.0388 		
No add control vs. 
2TAA Yes * 0.0189 
0.2% dmso vs. 
3TAA No ns 0.8462 		
No add control vs. 
3TAA No ns 0.3681 


















        		         
0.2% dmso vs. No 
add control No ns 0.1055 		
No add control vs. 
0.2% dmso No ns 0.1055 
0.2% dmso vs. 
2TAA No ns 0.3036 		
No add control vs. 
2TAA No ns 0.6452 
0.2% dmso vs. 
3TAA No ns 0.1874 		
No add control vs. 
3TAA No ns 0.8928 


















        		         
0.2% dmso vs. No 
add control Yes * 0.0342 		
No add control vs. 
0.2% dmso Yes * 0.0342 
0.2% dmso vs. 
2TAA Yes ** 0.0067 		
No add control vs. 
2TAA No ns 0.1581 
0.2% dmso vs. 
3TAA Yes * 0.0345 		
No add control vs. 
3TAA No ns 0.9999 


















        		         
0.2% dmso vs. No 
add control Yes * 0.0165 		
No add control vs. 
0.2% dmso Yes * 0.0165 
0.2% dmso vs. 
2TAA Yes *** 0.0009 		
No add control vs. 
2TAA Yes ** 0.0098 
0.2% dmso vs. 
3TAA Yes ** 0.0053 		
No add control vs. 
3TAA No ns 0.2756 
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